---
document_datetime: 2023-09-21 18:42:23
document_pages: 42
document_pathfilename: www.ema.europa.eu/en/documents/scientific-discussion/zimulti-epar-scientific-discussion_en.pdf
document_name: zimulti-epar-scientific-discussion_en.pdf
version: success
processing_time: 20.1590748
conversion_datetime: 2025-12-31 04:12:57.204817
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised SCIENTIFIC/.notdefDISCUSSION/.notdef 1./.notdef Introduction/.notdef Obesity/.notdef is/.notdef a/.notdef chronic/.notdef and/.notdef highly/.notdef prevalent/.notdef illness/.notdef which/.notdef is/.notdef frequently/.notdef associated/.notdef with/.notdef numerous/.notdef and/.notdef sometimes/.notdef fatal/.notdef diseases./.notdef It/.notdef is/.notdef a/.notdef complex/.notdef disease/.notdef of/.notdef multifaceted/.notdef aetiology/.notdef (including/.notdef environmental/.notdef factors/.notdefand/.notdefgenetic/.notdefpredisposition),/.notdefwith/.notdefits/.notdefown/.notdefdisabling/.notdefcapacities,/.notdefpathophysiology/.notdefand/.notdefcomorbidities./.notdef Some/.notdef of/.notdef the/.notdef complications/.notdef of/.notdef obesity/.notdef include/.notdef type/.notdef 2/.notdef diabetes/.notdef mellitus,/.notdef dyslipidaemia,/.notdef cardiovascular/.notdef disease,/.notdefarthritis/.notdefand/.notdefcancer./.notdef Non-pharmacological/.notdef options/.notdef for/.notdef treatment/.notdef include/.notdef nutritional/.notdef education/.notdef and/.notdef modification/.notdef (usually/.notdef caloric/.notdef restriction),/.notdef behaviour/.notdef modification,/.notdef and/.notdef increased/.notdef exercise./.notdef In/.notdef severe/.notdef obesity,/.notdef very/.notdef low/.notdef caloric/.notdef diets/.notdef and/.notdef surgery/.notdef may/.notdef be/.notdef used./.notdef Pharmacological/.notdef options/.notdef are/.notdef only/.notdef considered/.notdef as/.notdef an/.notdef adjunct/.notdef to/.notdef dietary/.notdef measures./.notdefThere/.notdefare/.notdefa/.notdeffew/.notdefantiobesity/.notdefagents/.notdefavailable./.notdefThey/.notdefcan/.notdefbe/.notdefdivided/.notdefinto/.notdefcentrally/.notdefacting/.notdefanoretic/.notdef agents/.notdef and/.notdef drugs/.notdef that/.notdef inhibit/.notdef the/.notdef absorption/.notdef of/.notdef nutrients./.notdef There/.notdef are/.notdef numerous/.notdef symptomatic/.notdef treatments/.notdef of/.notdef the/.notdef metabolic/.notdef complications/.notdef of/.notdef obesity/.notdef (antihypertensive/.notdef drugs,/.notdef hypolipedemic/.notdef agents,/.notdef antidiabetic/.notdef drugs)./.notdef/.notdef Smoking/.notdef is/.notdef a/.notdef well-known/.notdef risk/.notdef factor/.notdef for/.notdef the/.notdef development/.notdef of/.notdef cardiovascular/.notdef disease,/.notdef chronic/.notdef obstructive/.notdef pulmonary/.notdef disease,/.notdef and/.notdef lung-cancer/.notdef and/.notdef therefore/.notdef represents/.notdef a/.notdef major/.notdef public/.notdef health/.notdef concern./.notdef Approximately/.notdef1.3/.notdefbillion/.notdefpeople/.notdefcurrently/.notdefsmoke/.notdefworldwide/.notdefand/.notdefsmoking/.notdefis/.notdefestimated/.notdefto/.notdefbe/.notdefresponsible/.notdef for/.notdef4.9/.notdefmillion/.notdefpremature/.notdefdeaths/.notdefeach/.notdefyear,/.notdefa/.notdeffigure/.notdefexpected/.notdefto/.notdefnearly/.notdefdouble/.notdefby/.notdef2020./.notdefMany/.notdefpeople/.notdefhave/.notdef difficulty/.notdefwith/.notdefquitting,/.notdefnicotine/.notdefdependency/.notdefbeing/.notdefstrong./.notdefIn/.notdefaddition/.notdefto/.notdefcounselling/.notdefprograms,/.notdefthere/.notdefare/.notdef several/.notdef options/.notdef for/.notdef pharmacotherapeutic/.notdef intervention:/.notdef nicotine/.notdef replacement/.notdef therapy/.notdef (NRT),/.notdef and/.notdef bupropion/.notdef (Zyban®)./.notdef The/.notdef latter,/.notdef originally/.notdef developed/.notdef as/.notdef antidepressant,/.notdef is/.notdef a/.notdef noradrenalin,/.notdef dopamine,/.notdef serotonin/.notdefre-uptake/.notdefinhibitor/.notdefand/.notdefa/.notdefnon-competitive/.notdefnicotine/.notdefreceptor/.notdefantagonist./.notdefBoth/.notdefare/.notdefmarketed/.notdefas/.notdefan/.notdef aid/.notdefto/.notdef smoking/.notdefcessation,/.notdefand/.notdefhave/.notdefan/.notdefefficacy/.notdefrate/.notdefof/.notdefapproximately/.notdef20-30%/.notdefabstinence/.notdefat/.notdefan/.notdefaverage/.notdefof/.notdef 3/.notdefmonths/.notdeftreatment./.notdef Rimonabant/.notdef is/.notdef a/.notdef selective/.notdef antagonist/.notdef of/.notdef cannabinoid/.notdef type/.notdef 1/.notdef (CB1)/.notdef receptor./.notdef Rimonabant/.notdef is/.notdef the/.notdef first/.notdef member/.notdef of/.notdef a/.notdef new/.notdef class/.notdef of/.notdef compounds/.notdef that/.notdef target/.notdef a/.notdef novel/.notdef physiological/.notdef system,/.notdef the/.notdef endocannabinoid/.notdef system/.notdef (ECS)./.notdef The/.notdef cannabinoid/.notdef system/.notdef has/.notdef been/.notdef shown/.notdef to/.notdef be/.notdef involved/.notdef in/.notdef the/.notdef central/.notdef regulation/.notdef of/.notdef food/.notdef intake/.notdefand/.notdefthe/.notdefcentral/.notdefnervous/.notdefsystem/.notdef(CNS)/.notdefreward/.notdefsystem./.notdefCB1/.notdefreceptors/.notdefwere/.notdeffirst/.notdeffound/.notdefin/.notdefthe/.notdefbrain,/.notdef and/.notdeflater/.notdefin/.notdefseveral/.notdefhuman/.notdeftissues,/.notdefincluding/.notdefadipocytes./.notdef/.notdef The/.notdef proposed/.notdef indications/.notdef for/.notdef rimonabant/.notdef were:/.notdef Management/.notdef of/.notdef multiple/.notdef cardiovascular/.notdef risk/.notdef factors,/.notdef weight/.notdefmanagement,/.notdeftype/.notdef2/.notdefdiabetes,/.notdefdyslipidaemia,/.notdefsmoking/.notdefcessation/.notdefand/.notdefmaintenance/.notdefof/.notdefabstinence./.notdef In/.notdef adults,/.notdef the/.notdef recommended/.notdef dosage/.notdef is/.notdef one/.notdef rimonabant/.notdef 20/.notdef mg/.notdef tablet/.notdef daily/.notdef to/.notdef be/.notdef taken/.notdef in/.notdef the/.notdef morning/.notdef before/.notdefbreakfast./.notdefRimonabant/.notdefhas/.notdefnot/.notdefbeen/.notdefstudied/.notdefin/.notdefpatients/.notdefless/.notdefthan/.notdef18/.notdefyears/.notdefold./.notdef This/.notdef application/.notdef was/.notdef a/.notdef complete/.notdef and/.notdef independent/.notdef application/.notdef concerning/.notdef a/.notdef new/.notdef active/.notdef substance/.notdef according/.notdefto/.notdefarticle/.notdef8.3/.notdef(i)/.notdefof/.notdefDirective/.notdef2001/83/EC./.notdef 2./.notdef Quality/.notdefaspects/.notdef Introduction/.notdef ZIMULTI/.notdefis/.notdefpresented/.notdefas/.notdeffilm-coated/.notdeftablets/.notdefcontaining/.notdef20mg/.notdefrimonabant/.notdefINN./.notdefThe/.notdefproduct/.notdefis/.notdefpackaged/.notdef in/.notdefPVC-aluminium/.notdefblisters/.notdefand/.notdefin/.notdefHPDE/.notdefbottles/.notdefclosed/.notdefwith/.notdefa/.notdefchild-resistant/.notdeftamper-proof/.notdefpolypropylene/.notdef screw/.notdefcap./.notdef

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised Active/.notdefSubstance/.notdef Rimonabant/.notdefis/.notdefa/.notdeffine/.notdefpowder,/.notdefwhite/.notdefto/.notdefpractically/.notdefwhite./.notdefTwo/.notdefdifferent/.notdefpolymorphic/.notdefforms/.notdef(1/.notdefand/.notdef2)/.notdefhave/.notdef been/.notdef identified/.notdef during/.notdef development./.notdef Form/.notdef 1/.notdef has/.notdef been/.notdef used/.notdef from/.notdef the/.notdef beginning/.notdef of/.notdef the/.notdef pharmaceutical/.notdef development/.notdefto/.notdef the/.notdef end/.notdef of/.notdef Phase/.notdef 3/.notdef clinical/.notdef studies./.notdef Form/.notdef 2,/.notdef identified/.notdef after/.notdef the/.notdef start/.notdef of/.notdef Phase/.notdef 3/.notdef studies,/.notdef was/.notdefselected/.notdeffor/.notdefproduct/.notdefdevelopment./.notdefThe/.notdeftwo/.notdefforms/.notdefhave/.notdefvery/.notdefsimilar/.notdefphysico-chemical/.notdefcharacteristics./.notdef As/.notdef rimonabant/.notdef is/.notdef practically/.notdef insoluble/.notdef in/.notdef water,/.notdef the/.notdef drug/.notdef substance/.notdef has/.notdef been/.notdef micronized/.notdef to/.notdef increase/.notdef particle/.notdefsurface/.notdefarea/.notdefand/.notdefthus,/.notdeffacilitate/.notdefdissolution,/.notdefand/.notdefto/.notdefensure/.notdefblend/.notdefhomogeneity/.notdefduring/.notdefdrug/.notdefproduct/.notdef manufacture./.notdef · Manufacture/.notdef The/.notdef quality/.notdef information/.notdef in/.notdef Module/.notdef 3/.notdef of/.notdef the/.notdef dossier/.notdef has/.notdef been/.notdef supplemented/.notdef by/.notdef detailed/.notdef confidential/.notdef information/.notdef on/.notdef the/.notdef synthesis/.notdef of/.notdef rimonabant/.notdef in/.notdef the/.notdef Restricted/.notdef Part/.notdef of/.notdef an/.notdef active/.notdef substance/.notdef master/.notdef file/.notdef (EDMF,/.notdefASMF/.notdef)./.notdef Acceptable/.notdef specifications/.notdef on/.notdef starting/.notdef materials,/.notdef intermediate,/.notdef solvent/.notdef and/.notdef reagents/.notdef have/.notdef been/.notdef presented/.notdef (in/.notdefthe/.notdefrestricted/.notdefpart)./.notdefThe/.notdefsubmitted/.notdefdata/.notdefare/.notdefconsidered/.notdefto/.notdefbe/.notdefacceptable./.notdef/.notdef Process/.notdef impurities/.notdef originating/.notdef from/.notdef each/.notdef of/.notdef the/.notdef starting/.notdef materials/.notdef and/.notdef from/.notdef synthesis/.notdef have/.notdef been/.notdef adequately/.notdef discussed./.notdef Organic/.notdef impurities/.notdef have/.notdef been/.notdef synthesised/.notdef and/.notdef characterised/.notdef by/.notdef spectroscopy./.notdef The/.notdef presence/.notdef or/.notdef absence/.notdef of/.notdef impurities/.notdef has/.notdef been/.notdef examined/.notdef by/.notdef spectroscopy/.notdef and/or/.notdef chromatography/.notdef in/.notdef all/.notdef batches,/.notdefincluding/.notdefthose/.notdefused/.notdefin/.notdeftoxicology/.notdefand/.notdefclinical/.notdefstudies./.notdef Crystallisation/.notdefstudies/.notdefconfirm/.notdefthat/.notdefpolymorphic/.notdefform/.notdef2/.notdefis/.notdefroutinely/.notdefproduced/.notdefby/.notdefthe/.notdefsynthesis./.notdef · Specification/.notdef The/.notdefspecification/.notdefincludes/.notdefrelevant/.notdeftests/.notdeffor/.notdefassay/.notdef(HPLC)/.notdefrelated/.notdefimpurities,/.notdefresidual/.notdefsolvents,/.notdefetc./.notdef In/.notdefaddition,/.notdefthe/.notdefparticle/.notdefsize/.notdefdistribution/.notdefis/.notdefalso/.notdefspecified/.notdef(laser/.notdefgranulometry)./.notdef The/.notdef final/.notdef specification/.notdef for/.notdef rimonabant/.notdef is/.notdef based/.notdef on/.notdef batch/.notdef analyses/.notdef for/.notdef three/.notdef consecutive/.notdef industrial/.notdef scale/.notdef batches,/.notdef several/.notdef toxicological/.notdef and/.notdef clinical/.notdef batches,/.notdef and/.notdef stability/.notdef data./.notdef The/.notdef analytical/.notdef methodology/.notdef has/.notdef been/.notdefvalidated/.notdefto/.notdefmeet/.notdefthe/.notdefrequirements/.notdefof/.notdefthe/.notdefICH/.notdefguideline/.notdefQ2B,/.notdefValidation/.notdefof/.notdefAnalytical/.notdefProcedures./.notdef/.notdef · Stability/.notdef Data/.notdeffrom/.notdefprimary/.notdefstability/.notdefstudies/.notdefin/.notdefthe/.notdefsolid/.notdefstate/.notdefdemonstrate/.notdefthat/.notdefunder/.notdefstress/.notdefcondition,/.notdefrimonabant/.notdef is/.notdef stable/.notdef to/.notdef high/.notdef temperature/.notdef and/or/.notdef humidity,/.notdef but/.notdef is/.notdef very/.notdef slightly/.notdef sensitive/.notdef to/.notdef intense/.notdef light./.notdef In/.notdef hydroalcoholic/.notdefmixture,/.notdefrimonabant/.notdefis/.notdefstable/.notdefat/.notdef80/.notdefºC,/.notdefbut/.notdefis/.notdefsensitive/.notdefto/.notdeflight/.notdefand/.notdefto/.notdefoxidants./.notdef/.notdef Three/.notdefpilot/.notdefscaled/.notdefbatches/.notdefof/.notdefform/.notdef2/.notdefhave/.notdefbeen/.notdefstored/.notdefin/.notdefthe/.notdefproposed/.notdefpackaging/.notdeffor/.notdefroutine/.notdefstorage/.notdeffor/.notdefat/.notdef least/.notdef12/.notdefmonths/.notdefat/.notdef30°C/65%/.notdefRH/.notdefand/.notdef6/.notdefmonths/.notdefat/.notdef40°C/75%/.notdefRH./.notdef/.notdef No/.notdefsignificant/.notdefchanges/.notdefin/.notdefthe/.notdefresults/.notdefof/.notdefthe/.notdefroutine/.notdeftests/.notdeffor/.notdefappearance,/.notdefwater/.notdefcontent,/.notdefrelated/.notdefsubstance,/.notdef assay/.notdefand/.notdefpolymorphic/.notdefform/.notdefwere/.notdefobserved/.notdeffor/.notdefany/.notdefof/.notdefthe/.notdefbatches/.notdeffor/.notdefthe/.notdefreported/.notdefduration/.notdefof/.notdefstorage/.notdefup/.notdef to/.notdef12/.notdefmonths/.notdefand/.notdef6/.notdefmonths/.notdefrespectively./.notdefThere/.notdefis/.notdefno/.notdefsignificant/.notdefformation/.notdefof/.notdefimpurities/.notdefThe/.notdefassay/.notdefresults/.notdef remain/.notdefwithin/.notdefspecification/.notdefand/.notdefX-Ray/.notdefstudies/.notdefindicate/.notdefthere/.notdefis/.notdefno/.notdefchange/.notdefof/.notdefthe/.notdefpolymorphic/.notdefform./.notdefThe/.notdef proposed/.notdefre-test/.notdefperiod/.notdefof/.notdef24/.notdefmonths/.notdefis/.notdefconsidered/.notdefto/.notdefbe/.notdefacceptable./.notdef/.notdef

<!-- image -->

/.notdef

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised Medicinal/.notdefProduct/.notdef · Pharmaceutical/.notdefDevelopment/.notdef The/.notdefdevelopment/.notdefof/.notdefthe/.notdeffinished/.notdefproduct/.notdefhas/.notdefbeen/.notdefwell/.notdefperformed/.notdefand/.notdefexplained/.notdefand/.notdefis/.notdefsatisfactory./.notdef/.notdef The/.notdefpermeability/.notdefof/.notdefthe/.notdefdrug/.notdefsubstance/.notdefhas/.notdefbeen/.notdefdetermined/.notdefin/.notdefCaco-2/.notdefcells/.notdefat/.notdefpH/.notdef6.5/.notdefand/.notdefis/.notdeffound/.notdefto/.notdefbe/.notdef high./.notdef Rimonabant/.notdef is/.notdef therefore/.notdef classified/.notdef as/.notdef a/.notdef Class/.notdef 2/.notdef substance/.notdef considering/.notdef solubility/.notdef and/.notdef permeability/.notdef properties,/.notdefaccording/.notdefto/.notdefthe/.notdefBiopharmaceutics/.notdefClassification/.notdefSystem/.notdef(BCS)./.notdef However,/.notdefconsidering/.notdefthe/.notdeflow/.notdefsolubility,/.notdefboth/.notdefparticle/.notdefsize/.notdefand/.notdefphysical/.notdefform/.notdefare/.notdefcontrolled./.notdef The/.notdef excipients/.notdefare/.notdefcommonly/.notdefused/.notdefin/.notdefmedicinal/.notdefproducts/.notdeffor/.notdeforal/.notdefuse./.notdefAlso/.notdefthe/.notdefpackagings/.notdefare/.notdefusual/.notdefand/.notdef suitable/.notdeffor/.notdefthe/.notdefproduct./.notdef The/.notdef phase/.notdef 2B/.notdef and/.notdef phase/.notdef 3/.notdef clinical/.notdef studies/.notdef were/.notdef performed/.notdef with/.notdef capsules/.notdef containing/.notdef Rimonabant/.notdef polymorphic/.notdefform/.notdef1,/.notdefwhereas/.notdefthe/.notdefcommercial/.notdefproduct/.notdefis/.notdefa/.notdeftablet/.notdefcontaining/.notdefrimonabant/.notdefpolymorphic/.notdefform/.notdef 2./.notdef These/.notdef differences/.notdef in/.notdef dosage/.notdef form/.notdef and/.notdef polymorphic/.notdef form/.notdef have/.notdef been/.notdef explained/.notdef and/.notdef justified/.notdef with/.notdef 'bridging'/.notdef bioequivalence/.notdef studies./.notdef The/.notdef bioequivalence/.notdef studies/.notdef demonstrated/.notdef that/.notdef there/.notdef is/.notdef bioequivalence/.notdef between/.notdef the/.notdef film-coated/.notdef tablets/.notdef intended/.notdef for/.notdef marketing/.notdef and/.notdef the/.notdef hard/.notdef capsules/.notdef used/.notdef in/.notdef Phase/.notdef 3/.notdef studies,/.notdef independent/.notdef of/.notdef polymorphic/.notdef form/.notdef or/.notdef solid/.notdef dosage/.notdef form/.notdef when/.notdef the/.notdef dissolution/.notdef profiles/.notdef in/.notdef pH/.notdef 6.2/.notdef are/.notdef similar./.notdef/.notdef In/.notdef addition,/.notdef during/.notdef further/.notdef development/.notdef the/.notdef colour/.notdef of/.notdef the/.notdef coating/.notdef changed/.notdef from/.notdef blue/.notdef (indigotoxin)/.notdef to/.notdef white/.notdef (titanium/.notdef dioxide)./.notdef The/.notdef tablets/.notdef cores/.notdef remained/.notdef identical/.notdef and,/.notdef except/.notdef for/.notdef the/.notdef dye,/.notdef the/.notdef coating/.notdef formulation/.notdef also/.notdef remained/.notdef the/.notdef same./.notdef These/.notdef differences/.notdef are/.notdef considered/.notdef to/.notdef be/.notdef minor/.notdef and/.notdef of/.notdef no/.notdef clinical/.notdef significance/.notdefin/.notdefthe/.notdefsatisfactory/.notdefperformance/.notdefof/.notdefthe/.notdefmarketed/.notdefproduct./.notdef · Manufacture/.notdefof/.notdefthe/.notdefProduct/.notdef A/.notdef standard/.notdef process/.notdef of/.notdef wet/.notdef granulation/.notdef is/.notdef used./.notdef This/.notdef has/.notdef been/.notdef validated/.notdef and/.notdef optimised/.notdef with/.notdef regard/.notdef to/.notdef a/.notdef number/.notdefof/.notdefvariables./.notdef · Product/.notdefSpecification/.notdef The/.notdef release/.notdef specification/.notdef includes/.notdef relevant/.notdef tests/.notdef with/.notdef validated/.notdef methods/.notdef and/.notdef limits/.notdef for/.notdef appearance/.notdef and/.notdef identification,/.notdef assay/.notdef (/.notdef HPLC/.notdef ),/.notdef uniformity/.notdef of/.notdef content,/.notdef degradation/.notdef products,/.notdef dissolution,/.notdef microbiological/.notdef purity/.notdefetc./.notdef The/.notdefshelflife/.notdefspecification/.notdefis/.notdefidentical/.notdefwith/.notdefregard/.notdefto/.notdefassay/.notdef(/.notdefno/.notdefchange/.notdef)./.notdef Batch/.notdefanalyses/.notdefconfirm/.notdefthe/.notdefsatisfactory/.notdefuniformity/.notdefof/.notdefthe/.notdefproduct/.notdefand/.notdefindicate/.notdefthe/.notdefmanufacturing/.notdefprocess/.notdef is/.notdefunder/.notdefcontrol./.notdef · Stability/.notdefof/.notdefthe/.notdefProduct/.notdef The/.notdeftablets/.notdefintended/.notdefto/.notdefbe/.notdefmarketed/.notdefhave/.notdefbeen/.notdefstudied/.notdefat/.notdef30°C/65/.notdef%/.notdefRH/.notdefand/.notdef40°C/75/.notdef%/.notdefRH./.notdefIn/.notdefaddition,/.notdef results/.notdef from/.notdef studies/.notdef on/.notdef prototype/.notdef formulations/.notdefnot/.notdef intended/.notdeffor/.notdef the/.notdef market/.notdef have/.notdef been/.notdef used/.notdef as/.notdefsupportive/.notdef data./.notdef/.notdef No/.notdefsignificant/.notdefchanges/.notdefin/.notdefthe/.notdefresults/.notdefof/.notdefthe/.notdefroutine/.notdeftests/.notdeffor/.notdefcharacters,/.notdefdissolution,/.notdefassay/.notdefand/.notdefdegradation/.notdef products/.notdefwere/.notdefobserved/.notdeffor/.notdefany/.notdefof/.notdefthe/.notdefbatches/.notdeffor/.notdefthe/.notdefreported/.notdefduration/.notdefof/.notdefstorage./.notdef The/.notdef tablets/.notdef were/.notdef also/.notdef evaluated/.notdef for/.notdef their/.notdef photostability/.notdef according/.notdef to/.notdef ICH/.notdef Q1B./.notdef The/.notdef results/.notdef of/.notdef this/.notdef study/.notdef conducted/.notdefunder/.notdefintense/.notdeflight/.notdefdemonstrate/.notdefthat/.notdefthe/.notdefproduct/.notdefis/.notdefstable:/.notdefNo/.notdefdegradation/.notdefproducts/.notdefare/.notdefformed,/.notdef

/.notdef

<!-- image -->

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised and/.notdefdissolution/.notdefis/.notdefunaffected./.notdefIn/.notdefgeneral/.notdefthe/.notdefresults/.notdefsupport/.notdefthe/.notdefshelf/.notdeflife/.notdefand/.notdefstorage/.notdefconditions/.notdefas/.notdefdefined/.notdef in/.notdefthe/.notdefSPC./.notdef Discussion/.notdefon/.notdefchemical,/.notdefpharmaceutical/.notdefand/.notdefbiological/.notdefaspects/.notdef In/.notdef general/.notdef satisfactory/.notdef documentation/.notdef has/.notdef been/.notdef provided/.notdef to/.notdef confirm/.notdef the/.notdef acceptable/.notdef quality/.notdef of/.notdef this/.notdef medicinal/.notdef product,/.notdef and/.notdef no/.notdef major/.notdef objections/.notdef have/.notdef been/.notdef raised/.notdef during/.notdef evaluation./.notdef The/.notdef drug/.notdef substance/.notdef is/.notdef adequately/.notdef characterized/.notdef and/.notdef the/.notdef specification/.notdef is/.notdef acceptable/.notdef in/.notdef view/.notdef of/.notdef the/.notdef route/.notdef of/.notdef synthesis/.notdef and/.notdef the/.notdef various/.notdefICH/.notdefguidelines./.notdefThe/.notdefsolid/.notdefdrug/.notdefsubstance/.notdefis/.notdefstable/.notdefwith/.notdefrespect/.notdefto/.notdefdegradation./.notdef Concerning/.notdef the/.notdef finished/.notdef product,/.notdef the/.notdef release/.notdef specification/.notdef and/.notdef in-process/.notdef controls/.notdef guarantee/.notdef consistent/.notdef control/.notdefof/.notdefthe/.notdefproduct/.notdefquality./.notdefThe/.notdefdrug/.notdefproduct/.notdefis/.notdefstable/.notdefwith/.notdefrespect/.notdefto/.notdefdegradation./.notdef/.notdef 3./.notdef Non-clinical/.notdefaspects/.notdef Introduction/.notdef Pivotal/.notdef toxicology/.notdefstudies/.notdefwere/.notdefperformed/.notdefaccording/.notdefto/.notdefGLP./.notdefExternal/.notdefreviews/.notdefof/.notdefhistopathological/.notdefdata/.notdef were/.notdef not/.notdef always/.notdef performed/.notdef according/.notdef to/.notdef GLP./.notdef The/.notdef safety/.notdef pharmacology/.notdef studies/.notdef (conducted/.notdef prior/.notdef to/.notdef guideline/.notdefpublication)/.notdefwere/.notdefnot/.notdefconducted/.notdefunder/.notdefformal/.notdefGLP/.notdefguidelines;/.notdefthe/.notdefsupplemental/.notdefstudies/.notdefon/.notdefvital/.notdef functions/.notdefwere/.notdefconducted/.notdefaccording/.notdefto/.notdefGLP/.notdefregulations./.notdef Pharmacology/.notdef Rimonabant/.notdefis/.notdefa/.notdefselective/.notdefCB1/.notdefantagonist./.notdef/.notdef At/.notdef present,/.notdef two/.notdef types/.notdef of/.notdef cannabinoid/.notdef receptors/.notdef have/.notdef been/.notdef characterized,/.notdef CB1/.notdef and/.notdef CB2./.notdef CB1/.notdef is/.notdef widely/.notdef distributed/.notdefin/.notdefthe/.notdefCNS/.notdefwith/.notdefhigh/.notdefconcentrations/.notdefin/.notdefthe/.notdefbasal/.notdefganglia,/.notdefhippocampus,/.notdefcerebellum,/.notdefand/.notdefparts/.notdef of/.notdef the/.notdef limbic/.notdef system./.notdef CB1/.notdef is/.notdef believed/.notdef to/.notdef modulate/.notdef the/.notdef'motivation/reward'/.notdefsystem/.notdefin/.notdefthe/.notdefbrain/.notdefand/.notdefto/.notdefbe/.notdef involved/.notdef in/.notdef the/.notdef regulation/.notdef of/.notdef appetite/.notdef and/.notdef drug/.notdef addiction./.notdef There/.notdef is/.notdef evidence/.notdef that/.notdef CB1/.notdef is/.notdef expressed/.notdef peripherally,/.notdefparticularly/.notdefon/.notdefadipocytes,/.notdefand/.notdefthat/.notdefthis/.notdefreceptor/.notdefsubtype/.notdefmay/.notdefbe/.notdefinvolved/.notdefin/.notdefthe/.notdefregulation/.notdef of/.notdeflipolysis./.notdefMuch/.notdefless/.notdefis/.notdefknown/.notdefabout/.notdefCB2;/.notdefthis/.notdefreceptor/.notdefsubtype/.notdefis/.notdefexpressed/.notdefin/.notdeflymphoid/.notdeftissues/.notdefbut/.notdefits/.notdef function/.notdefis/.notdefcurrently/.notdefunknown./.notdefInteraction/.notdefof/.notdefcannabinoids/.notdefwith/.notdefother/.notdefreceptor/.notdeftypes/.notdefthan/.notdefCB1/CB2/.notdefhave/.notdef also/.notdef been/.notdef reported/.notdefand/.notdefit/.notdef has/.notdef been/.notdef speculated/.notdefthat/.notdefsuch/.notdef'non-classical'/.notdefcannabinoid/.notdefreceptors/.notdefmay/.notdefplay/.notdefa/.notdef role/.notdeffor/.notdefthe/.notdefphysiological/.notdefeffects/.notdefof/.notdefendocannabinoids/.notdefand/.notdefother/.notdefcannabinoid/.notdefderivatives./.notdef · Primary/.notdefpharmacodynamics/.notdef/.notdef Binding/.notdef studies/.notdef demonstrated/.notdef that/.notdef rimonabant/.notdef is/.notdef a/.notdef potent/.notdef (pKi/.notdef 8.4)/.notdef and/.notdef selective/.notdef ligand/.notdef for/.notdef CB1/.notdef receptors./.notdef It/.notdef had/.notdef a/.notdef weak/.notdef affinity/.notdef to/.notdef Galanin2,/.notdef MC 5 ,/.notdef opioid κ ,/.notdef and/.notdef PCP/.notdef receptors./.notdef Similarly,/.notdef in/.notdef enzyme/.notdef interaction/.notdefexperiments/.notdefwith/.notdefa/.notdefvariety/.notdefof/.notdefenzymes,/.notdefrimonabant/.notdefwas/.notdeffound/.notdefto/.notdefactivate/.notdefCOX 1 /.notdefat/.notdef 10/.notdefµ M;/.notdefno/.notdef activation/.notdef was/.notdef seen/.notdef at/.notdef 1/.notdef µM./.notdef Functional/.notdef in/.notdef vitro/.notdef studies/.notdef confirmed/.notdef its/.notdef potent/.notdef (pA 2 /.notdef 7.98/.notdef -/.notdef 8.85)/.notdef and/.notdef selective/.notdefCB1/.notdefreceptor/.notdefantagonistic/.notdefactivity./.notdef/.notdef Intraperitoneal/.notdef administration/.notdef of/.notdef rimonabant/.notdef reversed/.notdef the/.notdef inhibition/.notdef of/.notdef the/.notdef isoniazid-induced/.notdef increase/.notdef in/.notdef cerebral/.notdef cGMP/.notdef levels/.notdef produced/.notdef by/.notdef cannabinoid/.notdef agonist/.notdef WIN55212-2/.notdef (ID 50 /.notdef value/.notdef of/.notdef 0.3/.notdef mg/kg),/.notdef without/.notdef affecting/.notdef basal/.notdef cGMP/.notdef levels./.notdef Turning/.notdef behaviour/.notdef in/.notdef mice/.notdef induced/.notdef by/.notdef unilateral/.notdef intrastriatal/.notdef injection/.notdef of/.notdef WIN55212-2/.notdef was/.notdef dose-dependently/.notdef antagonized/.notdef by/.notdef rimonabant/.notdef after/.notdef oral/.notdef or/.notdef intraperitoneal/.notdef administration/.notdef (ID50/.notdef values/.notdef of/.notdef 0.22/.notdef mg/kg/.notdef and/.notdef 0.12/.notdef mg/kg,/.notdef respectively)./.notdef WIN55212-2-induced/.notdef hypothermia/.notdefand/.notdefpsychomotor/.notdefeffects/.notdefin/.notdefmice/.notdefand/.notdefrats,/.notdefincluding/.notdefring-immobility/.notdefand/.notdef\"pop-corn\"/.notdefeffects/.notdef in/.notdef mice/.notdef and/.notdef barrel/.notdef rotation/.notdef in/.notdef rats,/.notdef were/.notdef potently/.notdef and/.notdef dose-dependently/.notdef antagonized/.notdef by/.notdef rimonabant/.notdef

/.notdef

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

Medicinal product no longer authorised (administered/.notdef either/.notdef i.p./.notdef or/.notdef p.o.;/.notdef with/.notdef ID 50 /.notdef values/.notdef ranging/.notdef from/.notdef 0.2/.notdef to/.notdef 1.7/.notdef mg/kg)./.notdef The/.notdef antagonism/.notdef of/.notdef WIN55212-2-induced/.notdefhypothermia/.notdefin/.notdefmice/.notdefby/.notdefrimonabant/.notdef(2.78/.notdefmg/kg,/.notdefp.o.)/.notdefwas/.notdeflong-lasting./.notdef In/.notdef models/.notdef for/.notdef obesity,/.notdef oral/.notdef administration/.notdef of/.notdef rimonabant/.notdef (1/.notdef and/.notdef 3/.notdef mg/kg)/.notdef caused/.notdef a/.notdef long-lasting/.notdef and/.notdef selective/.notdef inhibition/.notdef in/.notdef sucrose/.notdef drinking/.notdef (75/.notdef and/.notdef 70/.notdef %,/.notdef respectively)/.notdef and/.notdef eating/.notdef of/.notdef a/.notdef cane-sugar/.notdef enriched/.notdef (carbohydrate)/.notdefdiet./.notdefRepeated/.notdeforal/.notdefadministration/.notdefof/.notdefrimonabant/.notdef(3/.notdefmg/kg/day;/.notdeffor/.notdef12/.notdefdays)/.notdefalso/.notdefreduced/.notdef the/.notdef intake/.notdef of/.notdef the/.notdef preferred/.notdef high-fat/.notdef diet/.notdef (37/.notdef %)/.notdef and/.notdef the/.notdef total/.notdef energy/.notdef intake/.notdef in/.notdef obese/.notdef rats/.notdef (by/.notdef 30%)./.notdef A/.notdef marked/.notdef decrease/.notdef in/.notdef body/.notdef weight/.notdef gain/.notdef (93/.notdef %)/.notdef was/.notdef found/.notdef in/.notdef obese/.notdef rats/.notdef after/.notdef 3/.notdef mg/kg/day/.notdef of/.notdef rimonabant./.notdef Similar/.notdef(but/.notdefless/.notdefmarked)/.notdefeffects/.notdefwere/.notdeffound/.notdefin/.notdeflean/.notdefrats./.notdefThe/.notdefweight/.notdefreducing/.notdefeffect/.notdefof/.notdefrimonabant/.notdef(72/.notdef%/.notdef after/.notdef 10/.notdef mg/kg/day/.notdef for/.notdef 4/.notdef weeks/.notdef in/.notdef obese/.notdef rats)/.notdef was/.notdef partly/.notdef dependent/.notdef on/.notdef peripheral/.notdef metabolic/.notdef effects,/.notdef possibly/.notdef mediated/.notdef by/.notdef an/.notdef increase/.notdef in/.notdef adiponectin/.notdef secretion/.notdef from/.notdef the/.notdef adipocytes./.notdef Rimonabant/.notdef (10/.notdef mg/kg/day)/.notdef also/.notdef reduced/.notdef known/.notdef risk/.notdef factors/.notdef associated/.notdef with/.notdef obesity,/.notdef including/.notdef reduction/.notdef of/.notdef elevated/.notdef levels/.notdef of/.notdef serum/.notdef leptin/.notdef (81/.notdef %),/.notdef insulin/.notdef (78/.notdef %),/.notdef glucose/.notdef (67/.notdef %)/.notdef and/.notdef restoring/.notdef the/.notdef lipid/.notdef profiles/.notdef (triglycerides,/.notdefcholesterol,/.notdefHDLc/.notdef//.notdefLDLc/.notdefratio)./.notdef/.notdef /.notdef Rimonabant/.notdef reduced/.notdef nicotine/.notdef self-administration/.notdef at/.notdef 0.3/.notdef mg/kg/.notdef and/.notdef cue-induced/.notdef nicotine/.notdef seeking/.notdef at/.notdef 1/.notdef mg/kg/.notdef in/.notdef the/.notdef self-administration/.notdef paradigm/.notdef and/.notdef at/.notdef 3/.notdef mg/kg/.notdef in/.notdef the/.notdef conditioned/.notdef place/.notdef preference/.notdef test/.notdef in/.notdef several/.notdefanimal/.notdefmodels./.notdef /.notdef · Secondary/.notdefpharmacodynamics/.notdef /.notdef The/.notdefanxiolytic/.notdefand/.notdefantidepressant/.notdefeffects/.notdefof/.notdefrimonabant/.notdefwere/.notdefassessed/.notdefafter/.notdefa/.notdefsingle/.notdeforal/.notdefadministration/.notdefat/.notdef doses/.notdef ranging/.notdef from/.notdef 10/.notdef to/.notdef 100/.notdef mg/kg/.notdef in/.notdef male/.notdef mice,/.notdef using/.notdef a/.notdef battery/.notdef of/.notdef five/.notdef tests./.notdef Rimonabant/.notdef increased/.notdef significantly/.notdefthe/.notdefnumber/.notdefof/.notdefshocks/.notdef(0.3/.notdefmg/kg)/.notdefin/.notdefthe/.notdefpunished/.notdefdrinking/.notdeftest,/.notdefas/.notdefdid/.notdefdiazepam/.notdef(3/.notdefmg/kg)./.notdef Rimonabant/.notdefsignificantly/.notdefincreased/.notdefpercentage/.notdefof/.notdeftime/.notdefspent/.notdef into/.notdef open/.notdefarms/.notdefat/.notdef10/.notdefmg/kg/.notdefin/.notdef the/.notdef elevated/.notdef plus-maze/.notdef test/.notdef and/.notdef did/.notdef not/.notdef affect/.notdef the/.notdef number/.notdef of/.notdef entries/.notdef into/.notdef closed/.notdef arms;/.notdef diazepam/.notdef produced/.notdef a/.notdef similar/.notdef effect/.notdef at/.notdef 3/.notdef mg/kg./.notdef Rimonabant/.notdef significantly/.notdef decreased/.notdefimmobility/.notdeftime/.notdeffrom/.notdef3/.notdefmg/kg,/.notdefp.o./.notdefin/.notdefthe/.notdefforcedswimming/.notdef test;/.notdef fluoxetine/.notdef produced/.notdef a/.notdef similar/.notdef effect/.notdef at/.notdef 30/.notdef mg/kg./.notdef Finally,/.notdef rimonabant/.notdef slightly/.notdef enhanced/.notdef the/.notdefsexual/.notdefmotivation/.notdefof/.notdefsexually/.notdefnaïve/.notdefmale/.notdefrats/.notdefbut/.notdefdid/.notdefnot/.notdefglobally/.notdefmodify/.notdefthe/.notdefcopulatory/.notdefbehaviour/.notdefof/.notdef sexually/.notdefexperienced/.notdefmale/.notdefrats./.notdef /.notdef · Safety/.notdefpharmacology/.notdefprogramme/.notdef /.notdef Effects/.notdef on/.notdef the/.notdef CNS/.notdef (mouse,/.notdef single/.notdef oral/.notdef dose)/.notdef were/.notdef particularly/.notdef noted/.notdef at/.notdef dose/.notdef levels/.notdef GLYPH&lt;1&gt; /.notdef 30/.notdef mg/kg./.notdef Single/.notdef oral/.notdef administration/.notdef of/.notdef rimonabant/.notdef produced/.notdef an/.notdef increase/.notdef in/.notdef global/.notdef activity/.notdef followed/.notdef by/.notdef sedation/.notdef and/.notdef decreased/.notdefbody/.notdef weight./.notdef These/.notdef effects/.notdef were/.notdefmore/.notdefmarked/.notdefat/.notdef 100/.notdef mg/kg,/.notdef and/.notdef associated/.notdef at/.notdef this/.notdef dose/.notdef level/.notdef with/.notdef decreased/.notdef muscle/.notdef tone/.notdef and/.notdef impaired/.notdef motor/.notdef coordination./.notdef A/.notdef decrease/.notdef in/.notdef body/.notdef temperature/.notdef and/.notdef in/.notdef spontaneous/.notdefmotor/.notdefactivity/.notdefwas/.notdefalso/.notdefobserved/.notdefat/.notdef30/.notdefmg/kg./.notdef /.notdef Rimonabant/.notdef did/.notdef not/.notdef modify/.notdef the/.notdef threshold/.notdef dose/.notdef of/.notdef pentylenetetrazole/.notdef required/.notdef to/.notdef produce/.notdef clonic/.notdef convulsions,/.notdef but/.notdef showed/.notdef a/.notdef non-dose/.notdef related/.notdef propensity/.notdef to/.notdef potentiate/.notdef tonic/.notdef convulsive/.notdef activity/.notdef at/.notdef dose/.notdef levels/.notdef GLYPH&lt;1&gt; 10/.notdef mg/kg/.notdef in/.notdef mice/.notdef and/.notdef increased/.notdef mortality/.notdef from/.notdef 30/.notdef mg/kg./.notdef In/.notdef view/.notdef of/.notdef these/.notdef findings/.notdef and/.notdef of/.notdef the/.notdef convulsions/.notdefobserved/.notdefin/.notdefthe/.notdeftoxicology/.notdefstudies/.notdefwith/.notdefmice,/.notdefrats/.notdefand/.notdefmonkeys,/.notdefthe/.notdefapplicant/.notdefwas/.notdefrequested/.notdef to/.notdef study/.notdef more/.notdef in/.notdef depth/.notdef the/.notdef proconvulsive/.notdef activity/.notdef of/.notdef rimonabant./.notdef The/.notdef results/.notdef described/.notdef in/.notdef the/.notdef literature/.notdef and/.notdef obtained/.notdef by/.notdef the/.notdef applicant/.notdef indicated/.notdef a/.notdef proconvulsant/.notdef potential/.notdef for/.notdef rimonabant/.notdef in/.notdef animals/.notdef when/.notdef combined/.notdef with/.notdef physical/.notdef or/.notdef chemical/.notdef seizures/.notdef inducers,/.notdef or/.notdef with/.notdef stressful/.notdef conditions./.notdef Rimonabant/.notdef had/.notdef no/.notdef effect/.notdef on/.notdef neuronal/.notdef excitability/.notdef in/.notdef animals/.notdef when/.notdef administered/.notdef alone./.notdef According/.notdef to/.notdef literature/.notdef data,/.notdef this/.notdef proconvulsant/.notdefeffect/.notdefwas/.notdeflikely/.notdefto/.notdefbe/.notdefrelated/.notdefto/.notdefthe/.notdefblockade/.notdefof/.notdefan/.notdefexisting/.notdefendogenous/.notdefcannabinoid/.notdeftone./.notdef EEG-data/.notdefdid/.notdefnot/.notdefindicate/.notdefany/.notdefabnormality./.notdef/.notdef Other/.notdef safety/.notdef pharmacology/.notdef studies/.notdef suggested/.notdef that/.notdef at/.notdef the/.notdef dose-levels/.notdef tested,/.notdef rimonabant/.notdef did/.notdef not/.notdef produce/.notdef any/.notdef major/.notdef adverse/.notdef effects/.notdef on/.notdef the/.notdef cardiovascular,/.notdef respiratory,/.notdef renal/.notdef and/.notdef gastrointestinal/.notdef systems./.notdef Electrophysiology/.notdef findings/.notdef included/.notdef inhibition/.notdef of/.notdef the/.notdef I Kr /.notdef channel/.notdef in/.notdef CHO/.notdef cells/.notdef transfected/.notdef with/.notdef hERG/.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

Medicinal product no longer authorised (IC50 /.notdef=/.notdef 2.79/.notdefµ M)/.notdefand/.notdefa/.notdefprolongation/.notdefof/.notdefthe/.notdefaction/.notdefpotential/.notdefin/.notdefisolated/.notdefrabbit/.notdefPurkinje/.notdeffibres/.notdefat/.notdef3/.notdefµ M/.notdefand/.notdef higher./.notdefHowever,/.notdefno/.notdefQT/.notdefprolongation/.notdefor/.notdefother/.notdefECG/.notdefchanges/.notdefwere/.notdefseen/.notdefin/.notdefanaesthetised/.notdefdogs/.notdefafter/.notdefdoses/.notdef up/.notdefto/.notdef100/.notdefmg/kg,/.notdefi.d./.notdef/.notdef /.notdef · Pharmacodynamic/.notdefdrug/.notdefinteractions/.notdef /.notdef No/.notdefnon-clinical/.notdefstudies/.notdefon/.notdefpharmacodynamic/.notdefdrug/.notdefinteractions/.notdefwere/.notdefcarried/.notdefout./.notdef /.notdef /.notdef Pharmacokinetics/.notdef /.notdef The/.notdef metabolic/.notdef fate/.notdef and/.notdef disposition/.notdef of/.notdef rimonabant/.notdef were/.notdef assessed/.notdef in/.notdef five/.notdef animal/.notdef species,/.notdef i.e.,/.notdef mouse,/.notdef rat,/.notdef rabbit,/.notdef dog,/.notdef and/.notdef macaque./.notdef Rimonabant/.notdef was/.notdef rapidly/.notdef absorbed/.notdef following/.notdef oral/.notdef administration,/.notdef with/.notdef peak/.notdef concentrations/.notdef occurring/.notdef generally/.notdef within/.notdef 1/.notdef to/.notdef 3/.notdef h/.notdef after/.notdef dosing/.notdef in/.notdef rats,/.notdef dogs,/.notdef and/.notdef macaques./.notdef Oral/.notdef bioavailability/.notdefwas/.notdeflow/.notdefto/.notdefmoderate/.notdef(12%/.notdefin/.notdefmale/.notdefrats,/.notdef46%/.notdefin/.notdeffemale/.notdefrats,/.notdef18%/.notdefin/.notdefmale/.notdefmacaques);/.notdefthis/.notdef was/.notdef due/.notdef to/.notdef extensive/.notdef first/.notdef pass/.notdef metabolism./.notdef Rimonabant/.notdef exposure/.notdef increased/.notdef in/.notdef a/.notdef dose-related/.notdef manner/.notdef in/.notdef animals./.notdef A/.notdef sex/.notdef related/.notdef difference/.notdef in/.notdef rats/.notdef was/.notdef noted;/.notdef where/.notdef female/.notdef rats/.notdef had/.notdef higher/.notdef rimonabant/.notdef plasma/.notdef levels/.notdef than/.notdef males,/.notdef which/.notdef was/.notdef attributed/.notdef to/.notdef higher/.notdef metabolism/.notdef in/.notdef males./.notdef Steady/.notdef state/.notdef pharmacokinetics/.notdef generally/.notdefoccurred/.notdefwithin/.notdef1/.notdefweek/.notdefduring/.notdefonce-daily/.notdefdosing./.notdef /.notdef The/.notdef apparent/.notdefvolume/.notdefof/.notdef distribution/.notdefof/.notdef rimonabant/.notdeffollowing/.notdefintravenous/.notdefadministration/.notdefwas/.notdeflarger/.notdefthan/.notdef the/.notdeftotal/.notdefbody/.notdefwater/.notdef(0.7/.notdefL/kg)/.notdefin/.notdefrats/.notdef(11.5/.notdefL/kg)/.notdefand/.notdefmacaques/.notdef(24.4/.notdefL/kg)./.notdefExtensive/.notdeftissue/.notdefdistribution/.notdef of/.notdef radioactivity/.notdefwas/.notdefnoted/.notdefin/.notdefrats,/.notdefwith/.notdeftransfer/.notdefof/.notdefradioactivity/.notdefacross/.notdefthe/.notdefblood-brain/.notdefbarrier/.notdefand/.notdefalso/.notdefto/.notdef the/.notdef embryo/.notdef and/.notdef fetus/.notdef across/.notdef the/.notdef placenta./.notdef The/.notdef tissues/.notdef with/.notdef the/.notdef greatest/.notdef uptake/.notdef were/.notdef the/.notdef liver,/.notdef adrenals,/.notdef brown/.notdef fat,/.notdef kidneys,/.notdef lymph/.notdef nodes;/.notdef more/.notdef than/.notdef 3-/.notdef fold/.notdef accumulation/.notdef following/.notdef repeated/.notdef once-daily/.notdef doses/.notdef was/.notdef noted/.notdef in/.notdef the/.notdef thyroid,/.notdef spleen,/.notdef plasma,/.notdef thymus,/.notdef liver,/.notdef and/.notdef brain./.notdef There/.notdef was/.notdef no/.notdef uptake/.notdef or/.notdef retention/.notdef in/.notdef pigmented/.notdeftissue/.notdef(eye-melanin)/.notdefof/.notdefrats./.notdefRimonabant/.notdefwas/.notdefbound/.notdefvery/.notdefextensively/.notdef(up/.notdefto/.notdef100%)/.notdefto/.notdefanimal/.notdef and/.notdef human/.notdefplasma/.notdefproteins/.notdefin/.notdefvitro/.notdefand/.notdefdid/.notdefnot/.notdefdistribute/.notdefextensively/.notdefinto/.notdefred/.notdefblood/.notdefcells./.notdefThe/.notdefextensive/.notdef distribution/.notdef in/.notdef vivo/.notdef in/.notdef spite/.notdef of/.notdef the/.notdef high/.notdef plasma/.notdef protein/.notdef binding/.notdef indicated/.notdef a/.notdef higher/.notdef affinity/.notdef of/.notdef the/.notdef drugrelated/.notdefmaterial/.notdefto/.notdeftissues/.notdefcompared/.notdefto/.notdefplasma./.notdef /.notdef In/.notdef all/.notdef species,/.notdef the/.notdef metabolic/.notdef pathways/.notdef for/.notdef rimonabant/.notdef involved/.notdef amidohydrolysis,/.notdef multistep/.notdef oxidative/.notdef metabolism/.notdef on/.notdef the/.notdef piperidine/.notdef moiety,/.notdef and/.notdef further/.notdef glucuronidation/.notdef of/.notdef the/.notdef acid/.notdef and/.notdef hydroxy/.notdef phase/.notdef 1/.notdef metabolites./.notdefIn/.notdefplasma,/.notdefSR141715-metabolite/.notdefwas/.notdefthe/.notdefpredominant/.notdefmetabolite/.notdefin/.notdefhumans,/.notdefmice,/.notdefrats,/.notdefand/.notdef macaques./.notdef Since/.notdef the/.notdef formation/.notdef of/.notdef this/.notdef metabolite/.notdef was/.notdef accompanied/.notdef by/.notdef the/.notdef formation/.notdef of/.notdef Naminopiperidine/.notdef(NAP),/.notdefa/.notdefmetabolite/.notdefwith/.notdefgenotoxic/.notdefstructural/.notdefalert,/.notdeffurther/.notdefclarification/.notdefon/.notdefthe/.notdefformation/.notdef and/.notdef metabolism/.notdef of/.notdef this/.notdef compound/.notdef was/.notdef requested/.notdef by/.notdef the/.notdef CHMP/.notdef during/.notdef the/.notdef procedure./.notdef In/.notdef summary,/.notdef the/.notdef NAP-exposure/.notdefafter/.notdef a/.notdef therapeutic/.notdef dose/.notdef of/.notdef rimonabant/.notdef (20/.notdef mg/day)/.notdef was/.notdef estimated/.notdef to/.notdef be/.notdef about/.notdef 240/.notdef µ g/.notdef of/.notdef NAP/.notdefper/.notdefday;/.notdefthe/.notdefestimated/.notdefexposures/.notdefto/.notdefNAP/.notdefin/.notdefrats/.notdefand/.notdefmice/.notdefsuggested/.notdefthat/.notdefthere/.notdefwere/.notdeflarge/.notdefmargins/.notdefto/.notdef human/.notdefexposure/.notdefin/.notdefthe/.notdefcarcinogenicity/.notdefstudies/.notdef(about/.notdef140-5000/.notdefin/.notdefrats/.notdefand/.notdef150-780/.notdefin/.notdefmice,/.notdefdepending/.notdefon/.notdef gender/.notdefand/.notdefdose);/.notdefthere/.notdefwere/.notdefno/.notdefliver/.notdeftumours/.notdefin/.notdefthe/.notdefmouse/.notdefcarcinogenicity/.notdefstudy/.notdefor/.notdefin/.notdefmale/.notdefrats,/.notdefand/.notdefthe/.notdef liver/.notdef adenomas/.notdef found/.notdef in/.notdef female/.notdef rats/.notdef could/.notdef be/.notdef explained/.notdef by/.notdef other/.notdef mechanisms./.notdef These/.notdef findings/.notdef were/.notdef reassuring./.notdef The/.notdef applicant/.notdef committed/.notdef to/.notdef further/.notdef clarify/.notdef the/.notdef metabolic/.notdef fate/.notdef of/.notdef NAP/.notdef as/.notdef a/.notdef post-approval/.notdef follow-up/.notdefmeasure./.notdef Rimonabant/.notdefhad/.notdefa/.notdeflong/.notdef terminal/.notdefhalf-life/.notdefin/.notdef rats/.notdef(7.3/.notdefh)/.notdefand/.notdefmacaques/.notdef(20/.notdefh)/.notdefand/.notdefa/.notdefmedium/.notdefclearance/.notdefin/.notdef both/.notdef species/.notdef (~1/.notdef L/h/kg)./.notdef Rimonabant/.notdef and/.notdef its/.notdef metabolites/.notdef were/.notdef mainly/.notdef excreted/.notdef in/.notdef the/.notdef faeces/.notdef (&gt;70%/.notdef of/.notdef the/.notdef radioactive/.notdef dose)/.notdef via/.notdef bile,/.notdef with/.notdef only/.notdef a/.notdef small/.notdef amount/.notdef eliminated/.notdef in/.notdef urine/.notdef in/.notdef mice/.notdef (&lt;2%),/.notdef rats/.notdef (&lt;1%),/.notdef rabbits/.notdef (7%),/.notdef dogs/.notdef (&lt;1%),/.notdef and/.notdef macaques/.notdef (&lt;5%)/.notdef after/.notdef oral/.notdef dosing./.notdef Rimonabant/.notdef and/or/.notdef its/.notdef metabolite(s)/.notdef were/.notdefalso/.notdefexcreted/.notdefin/.notdefthe/.notdefmilk/.notdefof/.notdefthe/.notdefrats./.notdef /.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

CNS/.notdefeffects

Medicinal product no longer authorised Repeated/.notdef administration/.notdef of/.notdef rimonabant/.notdef resulted/.notdef in/.notdef an/.notdef increased/.notdef CYP2B/.notdef (and/.notdef to/.notdef a/.notdef lesser/.notdef extent/.notdef CYP1A,/.notdef 2C,/.notdef 2E/.notdef and/.notdef 3A)/.notdef activity/.notdef in/.notdef mice/.notdef and/.notdef rats,/.notdef but/.notdef not/.notdef in/.notdef macaques./.notdef In/.notdef vitro/.notdef studies/.notdef with/.notdef human/.notdef hepatocytes/.notdef did/.notdefnot/.notdefdemonstrate/.notdefinduction/.notdefof/.notdefCYPIA1,/.notdefIA2,/.notdefIIA,/.notdefIIIA./.notdef/.notdef Toxicology/.notdef · Single/.notdefdose/.notdeftoxicity/.notdef Acute/.notdeftoxicity/.notdefstudies/.notdefwere/.notdefperformed/.notdefin/.notdefboth/.notdefrats/.notdefand/.notdefmice/.notdefusing/.notdeforal/.notdefand/.notdefintraperitoneal/.notdefroutes./.notdefIn/.notdefmice/.notdef and/.notdefrats,/.notdefmortality/.notdefoccurred/.notdeffrom/.notdefday/.notdef4/.notdefor/.notdefday/.notdef2/.notdefafter/.notdeforal/.notdefor/.notdefintraperitoneal/.notdefadministration,/.notdefrespectively./.notdef By/.notdefthe/.notdeforal/.notdefroute,/.notdefthe/.notdefobserved/.notdefmaximum/.notdefnon-lethal/.notdefdoses/.notdefwere/.notdef1000/.notdefmg/kg/.notdefin/.notdefrats/.notdefand/.notdeffemale/.notdefmice/.notdefand/.notdef 500/.notdef mg/kg/.notdef in/.notdef male/.notdef mice./.notdef By/.notdef the/.notdef intraperitoneal/.notdef route,/.notdef the/.notdef observed/.notdef maximum/.notdef non-lethal/.notdef dose/.notdef was/.notdef 60/.notdef mg/kg/.notdef in/.notdef both/.notdef species./.notdef Both/.notdef mice/.notdef and/.notdef rats/.notdef showed/.notdef clinical/.notdef signs/.notdef evocative/.notdef of/.notdef health/.notdef deterioration/.notdef (decubitus,/.notdef prostration,/.notdef decreased/.notdef activity,/.notdef weakness,/.notdef piloerection,/.notdef soiled/.notdef urogenital/.notdef area,/.notdef nasal/.notdef discharge);/.notdefmice/.notdefhad/.notdefclonic/.notdefconvulsions/.notdefin/.notdefthe/.notdefhighest/.notdefdose/.notdefgroups./.notdef · Repeat/.notdefdose/.notdeftoxicity/.notdef Repeat-dose/.notdef toxicity/.notdef studies/.notdef were/.notdef conducted/.notdef orally/.notdef by/.notdef gavage/.notdef in/.notdef mice/.notdef up/.notdef to/.notdef 13/.notdef weeks/.notdef (maximum/.notdef dose/.notdef varying/.notdef from/.notdef 60/.notdef to/.notdef 500/.notdef mg/kg/day),/.notdef rats/.notdef up/.notdef to/.notdef 6/.notdef months/.notdef (maximum/.notdef dose/.notdef varying/.notdef from/.notdef 15/.notdef to/.notdef 500/.notdef mg/kg/day),/.notdef dogs/.notdef up/.notdef to/.notdef 3/.notdef months/.notdef (maximum/.notdef dose/.notdef varying/.notdef from/.notdef 15/.notdef to/.notdef 60/.notdef mg/kg/day)/.notdef and/.notdef cynomolgus/.notdef monkey/.notdef(macaque,/.notdef Macaca/.notdeffascicularis )/.notdefup/.notdefto/.notdef1/.notdefyear/.notdef(maximum/.notdefdose/.notdefvarying/.notdeffrom/.notdef12/.notdefto/.notdef45/.notdefmg/kg/day)./.notdef Following/.notdef rimonabant/.notdef administration,/.notdef adverse/.notdef clinical/.notdef signs,/.notdef which/.notdef varied/.notdef by/.notdef species,/.notdef were/.notdef observed/.notdef from/.notdef60/.notdefmg/kg/day/.notdefin/.notdefthe/.notdefmouse/.notdef(piloerection,/.notdefhunched/.notdefposture,/.notdeflethargy/.notdefwith/.notdefpartially/.notdefclosed/.notdefeyes,/.notdefcold/.notdef to/.notdef touch,/.notdef prostration,/.notdef convulsions),/.notdef from/.notdef 6/.notdef and/.notdef 40/.notdef mg/kg/day/.notdef in/.notdef the/.notdef female/.notdef and/.notdef male/.notdef rat,/.notdef respectively/.notdef (thinness,/.notdefdried/.notdefblood/.notdefon/.notdefthe/.notdefmuzzle,/.notdefreddening/.notdefand/or/.notdefswelling/.notdefaround/.notdefeyes/.notdefand/.notdefred/.notdefexudates/lacrimation/.notdef from/.notdef the/.notdef eyes,/.notdef soiled/.notdef urogenital/.notdef area,/.notdef piloerection,/.notdef dehydration,/.notdef hypotonia,/.notdef weakness,/.notdef loss/.notdef of/.notdef balance,/.notdef prostration,/.notdef hyperesthesia,/.notdef hyperexcitability/.notdef and/.notdef clonic/.notdef convulsions),/.notdef from/.notdef 1/.notdef mg/kg/day/.notdef in/.notdef the/.notdef rabbit/.notdef (decreased/.notdef defecation/.notdef and/.notdef urination),/.notdef from/.notdef 10/.notdef to/.notdef 15/.notdef mg/kg/day/.notdef in/.notdef the/.notdef dog/.notdef (ptyalism/.notdef from/.notdef 5/.notdef mg/kg/day/.notdef upwards;/.notdef tremors,/.notdef red/.notdef conjunctiva,/.notdef ataxia,/.notdef hypomotility,/.notdef aggressiveness/.notdef and/.notdef startling/.notdef movements)/.notdef and/.notdef from/.notdef 12/.notdef mg/kg/day/.notdef in/.notdef the/.notdef macaque/.notdef (decreased/.notdef activity,/.notdef weakness,/.notdef somnolence,/.notdef loss/.notdef of/.notdef balance,/.notdef ataxia,/.notdef prostration,/.notdefdecubitus,/.notdefcoma,/.notdeftremors/.notdefand/.notdefclonic/.notdefconvulsions)./.notdefRecovery/.notdeffrom/.notdefthe/.notdefadverse/.notdefeffects/.notdef(clinical/.notdef signs,/.notdef body/.notdef weight/.notdef changes/.notdef and/.notdef severely/.notdef decreased/.notdef food/.notdef consumption)/.notdef was/.notdef generally/.notdef observed/.notdef despite/.notdef continuation/.notdefof/.notdeftreatment./.notdef Mortality/.notdefoccurred/.notdefat/.notdefthe/.notdefhighest/.notdefdoses/.notdeftested/.notdefand/.notdefwithin/.notdefthe/.notdeffirst/.notdeffew/.notdefdays/.notdefor/.notdefweeks/.notdefof/.notdefdosing./.notdefIn/.notdefrats,/.notdefit/.notdef occurred/.notdefin/.notdef males/.notdef at/.notdef dose/.notdef levels/.notdef GLYPH&lt;1&gt; 120/.notdef mg/kg/day/.notdefor/.notdef GLYPH&lt;1&gt; 250/.notdef mg/kg/day/.notdefand/.notdefin/.notdeffemales/.notdeffrom/.notdef60/.notdefmg/kg/day./.notdef In/.notdef mice,/.notdef treatment-related/.notdefmortality/.notdefwas/.notdefseen/.notdeffrom/.notdef120/.notdefmg/kg/day./.notdefIn/.notdefrabbits,/.notdefmortality/.notdefoccurred/.notdeffrom/.notdef5/.notdef mg/kg/day./.notdefNo/.notdefdeaths/.notdefoccurred/.notdefin/.notdefthe/.notdef3-month/.notdefstudy/.notdefconducted/.notdefin/.notdefthe/.notdefdog/.notdefat/.notdefdoses/.notdefup/.notdefto/.notdef15/.notdefmg/kg/day./.notdefIn/.notdef the/.notdef 4-week/.notdef macaque/.notdef study,/.notdef 1/.notdef female/.notdef treated/.notdef at/.notdef 45/.notdef mg/kg/day/.notdef was/.notdef found/.notdef dead/.notdef on/.notdef day/.notdef 7;/.notdef the/.notdef remaining/.notdef macaques/.notdef treated/.notdef at/.notdef this/.notdef dose/.notdef level/.notdef were/.notdef euthanized/.notdef early/.notdef in/.notdef the/.notdef study/.notdef period/.notdef due/.notdef to/.notdef their/.notdef poor/.notdef general/.notdef health/.notdef condition./.notdefNo/.notdeftreatment-related/.notdefmortality/.notdefwas/.notdefobserved/.notdefin/.notdefthe/.notdef6-month/.notdefand/.notdef1-year/.notdefchronic/.notdefstudies/.notdef conducted/.notdefat/.notdefdose/.notdeflevels/.notdefup/.notdefto/.notdef16/.notdefmg/kg/day/.notdefor/.notdef12/.notdefmg/kg/day./.notdef \"Hyperexcitability\"/.notdef was/.notdef reported/.notdef in/.notdef rodents/.notdef from/.notdef 30/.notdef mg/kg/day:/.notdef hyperesthesia,/.notdef tactile/.notdef hyperesthesia/.notdef or/.notdef hypersensitivity/.notdef to/.notdef touch,/.notdef excessive/.notdef scratching,/.notdef hyperexcitability,/.notdef hyperactivity,/.notdef hypermotility,/.notdef aggressiveness/.notdef and/.notdef combative/.notdef behaviour./.notdef In/.notdef dogs,/.notdef at/.notdef 15/.notdef mg/kg/day,/.notdef aggressiveness/.notdef and/.notdef startling/.notdef movements/.notdefwere/.notdefnoted./.notdefConvulsions/.notdeflasting/.notdefa/.notdeffew/.notdefminutes/.notdefwere/.notdefseen/.notdefin/.notdefmice,/.notdefrats/.notdefand/.notdefmonkeys./.notdefIn/.notdefmice,/.notdef convulsions/.notdef were/.notdef observed/.notdef from/.notdef 60/.notdef mg/kg/day,/.notdef in/.notdef rats/.notdef from/.notdef 6/.notdef mg/kg/day/.notdef in/.notdef females/.notdef and/.notdef from/.notdef 40/.notdef mg/kg/day/.notdef in/.notdef males,/.notdef in/.notdef macaques/.notdef from/.notdef 12/.notdef mg/kg/day./.notdef Rimonabant/.notdef exhibited/.notdef a/.notdef non/.notdef dose-related/.notdef

/.notdef

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised propensity/.notdef to/.notdef potentiate/.notdef pentylenetetrazole-induced/.notdef tonic/.notdef convulsions/.notdef in/.notdef mice/.notdef at/.notdef dose/.notdef levels/.notdef GLYPH&lt;1&gt; 10/.notdef mg/kg./.notdef Thus,/.notdefrimonabant/.notdefmay/.notdefhave/.notdefsome/.notdefpotential/.notdefto/.notdefproduce/.notdefadverse/.notdefneurological/.notdefeffects;/.notdefconvulsions/.notdefoccurred/.notdef at/.notdef systemic/.notdef exposures/.notdef below/.notdef (male/.notdef rat),/.notdef similar/.notdef (female/.notdef rat)/.notdef or/.notdef 2-3/.notdef fold/.notdef (mouse,/.notdef monkey)/.notdef human/.notdef therapeutic/.notdefsystemic/.notdefexposure./.notdef In/.notdef CD-1/.notdef mice/.notdef treatment/.notdef with/.notdef rimonabant/.notdef was/.notdef dose-dependently/.notdef associated/.notdef with/.notdef neuropil/.notdef vacuolation,/.notdef most/.notdef notably/.notdef in/.notdef cortical/.notdef areas,/.notdef the/.notdef hippocampus/.notdef and/.notdef septal/.notdef nuclei./.notdef This/.notdef was/.notdef not/.notdef observed/.notdef in/.notdef rats/.notdef or/.notdef cynomolgus/.notdef monkeys,/.notdef and/.notdef in/.notdef dogs/.notdef the/.notdef finding/.notdef was/.notdef not/.notdef clear./.notdef In/.notdef mice,/.notdef neuropil/.notdef vacuolation/.notdef was/.notdef accompanied/.notdef by/.notdef dose-related/.notdef increased/.notdef glial/.notdef fibrillary/.notdef acidic/.notdef protein/.notdef (GFAP)/.notdef immunoreactivity/.notdef (i.e./.notdef reactive/.notdef astrocytes/.notdef indicative/.notdef of/.notdef neuronal/.notdef damage)/.notdef immunostaining./.notdef Applicant/.notdef was/.notdef requested/.notdef by/.notdef the/.notdef CHMP/.notdefto/.notdeffurther/.notdefclarify/.notdefthis/.notdefissue/.notdefduring/.notdefthe/.notdefprocedure;/.notdefhowever,/.notdefthe/.notdeffinding/.notdefremained/.notdefunexplained./.notdefYet,/.notdef the/.notdef lack/.notdef of/.notdef any/.notdef other/.notdef signs/.notdef indicating/.notdef a/.notdef neuropathological/.notdef process/.notdef in/.notdef rats,/.notdef dogs/.notdef and/.notdef monkeys,/.notdef despite/.notdef a/.notdef reasonable/.notdefeffort/.notdefto/.notdefinvestigate/.notdefthis,/.notdeflargely/.notdefdiminished/.notdefthe/.notdefconcern/.notdefregarding/.notdefthe/.notdefGFAP/.notdefsignal/.notdefin/.notdefmice./.notdef/.notdef Skin/.notdefabnormalities/.notdef An/.notdef increased/.notdefincidence/.notdefof/.notdefdepilated/.notdefskin/.notdefareas,/.notdefvariously/.notdefrecorded/.notdefas/.notdefhair/.notdefloss/.notdefor/.notdefalopecia,/.notdefwas/.notdefobserved/.notdef in/.notdef treated/.notdef rats./.notdef In/.notdef the/.notdef one-year/.notdef cynomolgus/.notdef monkey/.notdef study/.notdef an/.notdef increased/.notdef incidence/.notdef of/.notdef hair/.notdef loss/.notdef was/.notdef observed/.notdefin/.notdefthe/.notdefhigh/.notdefdose/.notdefmales./.notdef/.notdef Bone/.notdefmarrow/.notdefand/.notdefhaematology /.notdef In/.notdef rats,/.notdef an/.notdef increase/.notdef in/.notdef the/.notdef incidence/.notdef of/.notdef fatty/.notdef involution/.notdef of/.notdef the/.notdef bone/.notdef marrow/.notdef was/.notdef observed/.notdef from/.notdef 10/.notdef mg/kg/day/.notdefin/.notdefthe/.notdef4-week/.notdefstudies./.notdefIn/.notdefmacaques,/.notdef\"acute/.notdefchanges\"/.notdefdescribed/.notdefas/.notdefoedema/.notdefof/.notdefthe/.notdefbone/.notdefmarrow/.notdef were/.notdefobserved/.notdefin/.notdefmost/.notdefof/.notdefthe/.notdefanimals/.notdefgiven/.notdef15/.notdefand/.notdef45/.notdefmg/kg/day./.notdefIn/.notdefdogs,/.notdefa/.notdefslight/.notdefincrease/.notdefin/.notdefthe/.notdefdegree/.notdef of/.notdef fatty/.notdef involution/.notdef was/.notdef observed/.notdef at/.notdef dose/.notdef levels/.notdef close/.notdef to/.notdef the/.notdef maximum/.notdef tolerated/.notdef dose./.notdef No/.notdef changes/.notdef were/.notdef observed/.notdefin/.notdefthe/.notdefbone/.notdefmarrow/.notdefin/.notdefthe/.notdef6-month/.notdefstudy/.notdefin/.notdefrats/.notdefup/.notdefto/.notdef40/.notdefmg/kg/day,/.notdef6-month/.notdefand/.notdef1-year/.notdefstudies/.notdef in/.notdefmacaques/.notdefup/.notdefto/.notdef16/.notdefor/.notdef12/.notdefmg/kg/day,/.notdefrespectively./.notdef/.notdef Immunotoxicity Despite/.notdef the/.notdef lack/.notdef of/.notdef functional/.notdef changes/.notdef in/.notdef the/.notdef immune/.notdef system/.notdef in/.notdef a/.notdef 4-week/.notdef immunotoxicity/.notdef study/.notdef in/.notdef rats/.notdef and/.notdef in/.notdef the/.notdef 6-month/.notdef and/.notdef 1-year/.notdef toxicity/.notdef studies/.notdef in/.notdef monkeys,/.notdef slight/.notdef haematological/.notdef changes,/.notdef including/.notdef leucopenia/.notdef and/.notdef lymphopenia/.notdef in/.notdef monkeys/.notdef were/.notdef noted/.notdef in/.notdef various/.notdef toxicity/.notdef studies/.notdef at/.notdef clinically/.notdef relevant/.notdef doses./.notdef At/.notdef high/.notdef doses,/.notdef associated/.notdef with/.notdef health/.notdef deterioration,/.notdef other/.notdef effects/.notdef such/.notdef as/.notdef thymus/.notdef atrophy/.notdef and/.notdef decreased/.notdefspleen/.notdefweight/.notdefwere/.notdefalso/.notdefnoted./.notdef/.notdef Liver /.notdef An/.notdef increase/.notdef in/.notdef liver/.notdef weight/.notdef and/.notdef size,/.notdef hypertrophy/.notdef of/.notdef centrilobular/.notdef hepatocytes/.notdef with/.notdef ground-glass/.notdef appearance/.notdef of/.notdef the/.notdef cytoplasm/.notdef and/.notdef hyperplasia/.notdef of/.notdef the/.notdef smooth/.notdef endoplasmic/.notdef reticulum/.notdef of/.notdef hepatocytes/.notdef at/.notdef electron/.notdef microscopy/.notdef were/.notdef observed/.notdef across/.notdef rodent/.notdef studies/.notdef (rats/.notdef and/.notdef mice)./.notdef These/.notdef types/.notdef of/.notdef changes/.notdef are/.notdef generally/.notdef considered/.notdef to/.notdef be/.notdef indicative/.notdef of/.notdef liver/.notdef enzyme/.notdef induction./.notdef Micro-/.notdef and/.notdef macrovesicular/.notdef hepatocyte/.notdef steatosis/.notdefwas/.notdef also/.notdef observed./.notdef Focal/.notdef hepatocellular/.notdefnecrosis/.notdefoccurred/.notdefslightly/.notdefmore/.notdeffrequently/.notdefin/.notdefmale/.notdefrats/.notdef of/.notdefthe/.notdef40/.notdefmg/kg/.notdefdosage/.notdefgroup./.notdef/.notdef Genital/.notdeftract/.notdef In/.notdef male/.notdef mice/.notdef and/.notdef rats/.notdef testis,/.notdef prostate,/.notdef seminal/.notdef vesicles/.notdef and/.notdef epidydimides/.notdef were/.notdef affected,/.notdef which/.notdef was/.notdef probably/.notdef related/.notdef to/.notdef the/.notdef effects/.notdef of/.notdef rimonabant/.notdef on/.notdef prolactin/.notdef and/.notdef testosterone/.notdef levels,/.notdef as/.notdef discussed/.notdef under/.notdef reproductive/.notdef toxicity/.notdef below./.notdef In/.notdef female/.notdef rats,/.notdef a/.notdef reversible/.notdef increase/.notdef in/.notdef ovarian/.notdef (dose-related)/.notdef and/.notdef uterine/.notdef relative/.notdef weights/.notdef were/.notdef observed/.notdef in/.notdef females/.notdef at/.notdef the/.notdef end/.notdef of/.notdef the/.notdef 6-month/.notdef study/.notdef from/.notdef 10/.notdef mg/kg/day/.notdef or/.notdef at/.notdef 40/.notdef mg/kg/day,/.notdefrespectively./.notdef Other/.notdefhormonal/.notdefchanges An/.notdef increase/.notdef in/.notdef plasma/.notdef ACTH/.notdef concentrations/.notdef in/.notdef the/.notdef six-month/.notdef rat/.notdef study/.notdef at/.notdef 40/.notdef mg/kg/day/.notdef in/.notdef females/.notdef was/.notdef seen;/.notdefalso/.notdefrelative/.notdefweight/.notdefof/.notdefadrenals/.notdefand/.notdefcorticosterone/.notdefserum/.notdeflevels/.notdefwere/.notdefincreased./.notdef/.notdef

/.notdef

/.notdef

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Medicinal product no longer authorised · Genotoxicity/.notdef The/.notdef genotoxicity/.notdef of/.notdef rimonabant/.notdef was/.notdef evaluated/.notdef in/.notdef vitro/.notdef in/.notdef an/.notdef Ames/.notdef test,/.notdef DNA/.notdef repair/.notdef test,/.notdef and/.notdef in/.notdef a/.notdef gene/.notdef mutation/.notdef assay/.notdef on/.notdef mouse/.notdef lymphoma/.notdef cells,/.notdef and/.notdef the/.notdef clastogenic/.notdef potential/.notdef in/.notdef human/.notdef lymphocytes/.notdef and/.notdef in/.notdef vivo/.notdef rat/.notdef micronucleus/.notdeftest./.notdef All/.notdef of/.notdef these/.notdef studies/.notdef gave/.notdef negative/.notdef results/.notdef with/.notdef the/.notdef exception/.notdef of/.notdef the/.notdef first/.notdef gene/.notdef mutation/.notdefassay/.notdefin/.notdefmouse/.notdeflymphoma/.notdefcells./.notdefIn/.notdefthat/.notdefstudy,/.notdefa/.notdefweak/.notdefincrease/.notdefin/.notdefmutation/.notdeffrequency/.notdefand/.notdefsmall/.notdef colonies/.notdef(reflecting/.notdefchromosomal/.notdefaberration)/.notdefwas/.notdefobserved/.notdefin/.notdefthe/.notdefpresence/.notdefof/.notdefmetabolic/.notdefactivation/.notdefat/.notdef30/.notdef µM./.notdefThis/.notdefmutagenic/.notdefeffect/.notdefwas/.notdefconsidered/.notdefas/.notdefnot/.notdefbiologically/.notdefrelevant./.notdef/.notdef /.notdef · Carcinogenicity/.notdef The/.notdef oncogenic/.notdef potential/.notdef of/.notdef rimonabant/.notdef was/.notdef assessed/.notdefin/.notdef mice/.notdef and/.notdef rats./.notdef No/.notdef treatment-related/.notdef proliferative/.notdef findings/.notdef were/.notdef observed/.notdef in/.notdef the/.notdef mouse/.notdef with/.notdef doses/.notdef up/.notdef to/.notdef 60/.notdef mg/kg/day/.notdef (maximum/.notdef tested/.notdef dose),/.notdef or/.notdef in/.notdef the/.notdef male/.notdefrat/.notdef up/.notdef to/.notdef 240/.notdef mg/kg/day./.notdef In/.notdef female/.notdef rat/.notdef treatment-related/.notdefneoplastic/.notdeffindings/.notdefwere/.notdefobserved/.notdeffrom/.notdef20/.notdef mg/kg/day/.notdef(mid-dose/.notdefgroup)/.notdefin/.notdef the/.notdef liver/.notdef (increases/.notdefin/.notdef incidences/.notdefof/.notdef hepatocellular/.notdefadenomas)/.notdefand/.notdefin/.notdefthe/.notdef female/.notdef genital/.notdef tract/.notdef (increases/.notdef in/.notdef incidence/.notdef of/.notdef endometrial/.notdef polyps/.notdef and/.notdef endometrial/.notdef carcinomas/.notdef in/.notdef the/.notdef uterus/.notdefand/.notdefsquamous/.notdefcell/.notdefcarcinomas/.notdefin/.notdefthe/.notdefcervix/.notdefand/.notdefuterus)./.notdefThe/.notdefgenital/.notdeftract/.notdefchanges/.notdefwere/.notdefmost/.notdeflikely/.notdef related/.notdef to/.notdef the/.notdef decreased/.notdef prolactin/.notdef levels/.notdef in/.notdef these/.notdef animals./.notdef The/.notdef increased/.notdef incidences/.notdef of/.notdef hepatocellular/.notdef hypertrophy,/.notdef foci/.notdef of/.notdef cellular/.notdef alteration/.notdef and/.notdef benign/.notdef liver/.notdef tumours/.notdef in/.notdef rats/.notdef were/.notdef considered/.notdef to/.notdef be/.notdef adaptive/.notdef changes/.notdef secondary/.notdef to/.notdef detoxification/.notdef and/.notdef metabolism/.notdef and/.notdef excretion/.notdef of/.notdef rimonabant./.notdef With/.notdef respect/.notdef to/.notdef the/.notdef occurrence/.notdef of/.notdef liver/.notdef adenomas,/.notdef there/.notdef was/.notdef no/.notdef safety/.notdef margin/.notdef for/.notdef human/.notdef therapeutic/.notdef exposure./.notdef Adenomas/.notdef might/.notdef have/.notdef been/.notdef a/.notdef consequence/.notdef of/.notdef enzyme/.notdef induction/.notdef and/.notdef the/.notdef subsequent/.notdef liver/.notdef hypertrophy/.notdef as/.notdef well,/.notdef and/.notdef were/.notdefregarded/.notdefas/.notdefrodent-specific./.notdefSeveral/.notdefother/.notdeftumour/.notdefand/.notdefnon-tumour/.notdeffindings/.notdefsupported/.notdefthe/.notdefprobability/.notdef of/.notdefa/.notdefhormonal/.notdefimbalance./.notdef/.notdef /.notdef · Reproduction/.notdefToxicity/.notdef The/.notdef effect/.notdef of/.notdef rimonabant/.notdef on/.notdef fertility/.notdef and/.notdefearly/.notdefembryonic/.notdefdevelopment/.notdefwas/.notdefassessed/.notdefin/.notdefmale/.notdefand/.notdeffemale/.notdef rats/.notdef and/.notdef in/.notdef female/.notdef rabbits./.notdef In/.notdef male/.notdef rats,/.notdef fertility/.notdef was/.notdef not/.notdef affected/.notdef up/.notdef to/.notdef 50/.notdef mg/kg/day./.notdef At/.notdef higher/.notdef doses,/.notdef there/.notdef was/.notdef a/.notdef decrease/.notdef in/.notdef the/.notdef weight/.notdef of/.notdef the/.notdef testis,/.notdef prostate,/.notdef seminal/.notdef vesicles/.notdef and/.notdef epididymal/.notdef fat/.notdef pad/.notdef and/.notdef a/.notdef decrease/.notdef in/.notdef the/.notdef motility/.notdef of/.notdef the/.notdef spermatozoa./.notdef These/.notdef changes/.notdef on/.notdef the/.notdef male/.notdef reproduction/.notdef system/.notdef were/.notdef attributed/.notdef to/.notdef reversible/.notdef decreases/.notdef in/.notdef testosterone/.notdef and/.notdef prolactin/.notdef concentrations/.notdef in/.notdef serum,/.notdef since/.notdef both/.notdef hormones/.notdef play/.notdef a/.notdef major/.notdef role/.notdef on/.notdef spermatogenesis./.notdef These/.notdef changes/.notdef fully/.notdef or/.notdef partially/.notdef recovered/.notdef despite/.notdef continuation/.notdef of/.notdef dosing/.notdef by/.notdef day/.notdef 91,/.notdef and/.notdef were/.notdef completely/.notdef reversed/.notdef 2/.notdef weeks/.notdef or/.notdef 4/.notdef months/.notdef after/.notdef cessation/.notdef of/.notdef treatment./.notdef In/.notdef rabbits/.notdef no/.notdef adverse/.notdef effects/.notdef on/.notdef the/.notdef female/.notdef reproductive/.notdef system/.notdef were/.notdef seen./.notdef In/.notdef female/.notdef rats/.notdef (dosing/.notdef for/.notdef 2/.notdef weeks/.notdef prior/.notdef to/.notdef mating),/.notdef rimonabant/.notdef decreased/.notdef the/.notdef number/.notdef of/.notdef corpora/.notdef lutea/.notdef and/.notdef fertility/.notdef index,/.notdefand/.notdefcaused/.notdefabnormal/.notdefoestrous/.notdefcyclicity./.notdefThe/.notdefeffects/.notdefon/.notdeffemale/.notdeffertility/.notdefwere/.notdefattributed/.notdefto/.notdefdecrease/.notdef in/.notdefprolactin/.notdefconcentration/.notdefin/.notdefserum/.notdefdue/.notdefto/.notdefrimonabant/.notdeftreatment./.notdef/.notdef In/.notdefpre/postnatal/.notdefstudies,/.notdefthere/.notdefwas/.notdefno/.notdefevidence/.notdefof/.notdefrimonabant-induced/.notdefdevelopmental/.notdeftoxicity/.notdefat/.notdefdoses/.notdefup/.notdef to/.notdef 20/.notdef mg/kg/day/.notdef in/.notdef rats/.notdef and/.notdef up/.notdef to/.notdef 5/.notdef mg/kg/day/.notdef in/.notdef rabbits./.notdef In/.notdef rats,/.notdef increases/.notdef in/.notdef litter/.notdef loss/.notdef were/.notdef seen/.notdef at/.notdef 10/.notdef mg/kg/day/.notdefand/.notdefan/.notdefincreased/.notdefnumber/.notdefof/.notdefpups/.notdeffound/.notdefdead/.notdefbefore/.notdefweaning/.notdefwas/.notdefseen/.notdefat/.notdefmaternal/.notdefdoses/.notdefof/.notdef3/.notdef and/.notdef 10/.notdef mg/kg/day./.notdefIn/.notdefthe/.notdefdevelopmental/.notdeftoxicity/.notdefstudies/.notdefin/.notdefrabbits,/.notdefmaternal/.notdeftoxicity/.notdefwas/.notdefseen/.notdefat/.notdefdoses/.notdef5/.notdef and/.notdef 10mg/kg/day;/.notdef developmental/.notdef toxicity/.notdef was/.notdef seen/.notdef at/.notdef 10/.notdef mg/kg/day/.notdef as/.notdef decreased/.notdef litter/.notdef size,/.notdef increased/.notdef post-implantation/.notdefloss,/.notdefdecreased/.notdeffoetal/.notdefbody/.notdef weight,/.notdef and/.notdef increased/.notdefmalformations/.notdef(anencephaly,/.notdefmicroophthalmia/.notdefand/.notdefwidened/.notdefventricles,/.notdefomphalocele)./.notdef /.notdef Rimonabant/.notdef was/.notdef transferred/.notdef across/.notdef the/.notdef placenta/.notdef and/.notdef secreted/.notdef in/.notdef milk/.notdef in/.notdef rats;/.notdef it/.notdef may/.notdef have/.notdef inhibited/.notdef the/.notdef suckling/.notdefreflex./.notdefUse/.notdefof/.notdefrimonabant/.notdefis/.notdefcontraindicated/.notdefduring/.notdeflactation/.notdef(SPC/.notdef4.3/.notdefand/.notdef4.6);/.notdefit/.notdefshould/.notdefnot/.notdefbe/.notdef used/.notdefduring/.notdefpregnancy/.notdef(SPC/.notdef4.6)./.notdef /.notdef · Local/.notdeftolerance/.notdef/.notdef Rimonabant/.notdefwas/.notdefnot/.notdefirritating/.notdefto/.notdefthe/.notdefskin/.notdefand/.notdefeye/.notdefin/.notdefthe/.notdefrabbit/.notdefand/.notdefwas/.notdefnot/.notdefphototoxic/.notdefor/.notdefphotoallergic/.notdefin/.notdef the/.notdefguinea/.notdefpig./.notdef/.notdef /.notdef /.notdef

/.notdef

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised · Other/.notdeftoxicity/.notdefstudies/.notdef Dependence/.notdef Rimonabant/.notdef did/.notdef not/.notdef display/.notdef reinforcing/.notdef properties,/.notdef but/.notdef rather/.notdef interfered/.notdef with/.notdef the/.notdef establishment/.notdef and/.notdef maintenance/.notdef of/.notdef the/.notdef reinforcing/.notdef process/.notdef of/.notdef compounds/.notdef with/.notdef dependence/.notdef potential./.notdef Besides/.notdef studies/.notdef demonstrating/.notdef precipitation/.notdef of/.notdef cannabinoid/.notdef withdrawal,/.notdef no/.notdef specific/.notdef studies/.notdef on/.notdef withdrawal/.notdef were/.notdef performed./.notdef The/.notdef absence/.notdef of/.notdef appearance/.notdef of/.notdef clinical/.notdef signs/.notdef in/.notdef toxicology/.notdef studies/.notdef with/.notdef a/.notdef recovery/.notdef period/.notdef indicated/.notdefthat/.notdefrimonabant/.notdefhad/.notdefno/.notdefpotential/.notdefto/.notdefproduce/.notdefa/.notdefwithdrawal/.notdefsyndrome./.notdef Ecotoxicity/environmental/.notdefrisk/.notdefassessment/.notdef Rimonabant/.notdefis/.notdefpoorly/.notdefsoluble/.notdefin/.notdefwater/.notdefbut/.notdefis,/.notdefnevertheless,/.notdefexpected/.notdefto/.notdefpartition/.notdefinto/.notdefthe/.notdeforganic/.notdefphase/.notdefof/.notdef waste/.notdef water/.notdef and/.notdef migrate/.notdef to/.notdef the/.notdef aquatic/.notdef part/.notdef of/.notdef the/.notdef environment./.notdef Environmental/.notdef effects/.notdef testing/.notdef for/.notdef rimonabant/.notdef was/.notdef performed/.notdef using/.notdef established/.notdef models/.notdef in/.notdef algae/.notdef ( Pseudokirchneriella/.notdef subcapitata ),/.notdef zooplankton/.notdef ( Daphnia/.notdef magna ),/.notdef rainbow/.notdef trout/.notdef ( Oncorhynchus/.notdef mykiss ),/.notdef and/.notdef activated/.notdef sludge/.notdef respiration/.notdef inhibition./.notdef Using/.notdef the/.notdef results/.notdef from/.notdef most/.notdef sensitive/.notdef organism/.notdef (rainbow/.notdef trout),/.notdef a/.notdef PNEC-value/.notdef of/.notdef 0.048/.notdef µg/litre/.notdefwas/.notdefcalculated./.notdef Using/.notdef the/.notdef forecast/.notdef estimates/.notdef by/.notdef the/.notdef applicant,/.notdef the/.notdef PEC surface/.notdef water /.notdef was/.notdef calculated/.notdef to/.notdef be/.notdef 0.026/.notdef µ g/litre./.notdef The/.notdef applicant/.notdefwas/.notdefrequested/.notdefto/.notdefcarry/.notdefout/.notdefadditional/.notdefstudies/.notdefto/.notdeffurther/.notdefcharacterise/.notdefthe/.notdefimpact/.notdefof/.notdefrimonabant/.notdefon/.notdef the/.notdefenvironment;/.notdefthese/.notdefwill/.notdefbe/.notdefdone/.notdefas/.notdefpost-approval/.notdeffollow-up/.notdefmeasures./.notdef Discussion/.notdefon/.notdefthe/.notdefnon-clinical/.notdefaspects/.notdef The/.notdefpharmacological/.notdefstudies/.notdefadequately/.notdefcharacterised/.notdefthe/.notdefproperties/.notdefand/.notdefprincipal/.notdefprimary/.notdefand/.notdefsecondary/.notdef effects/.notdef of/.notdef rimonabant,/.notdef as/.notdef well/.notdef as/.notdef potential/.notdef harmful/.notdef effects/.notdef on/.notdef essential/.notdef organ/.notdef systems./.notdef Receptor/.notdef binding/.notdef and/.notdef functional/.notdefstudies/.notdefin/.notdef several/.notdef in/.notdef vitro/.notdef and/.notdef in/.notdef vivo /.notdef models/.notdefdemonstrated/.notdefthat/.notdefrimonabant/.notdefis/.notdefa/.notdefselective/.notdef CB1/.notdef antagonist./.notdef Several/.notdef animal/.notdef models/.notdef demonstrated/.notdef the/.notdef potential/.notdef usefulness/.notdef of/.notdef rimonabant/.notdef for/.notdef the/.notdef treatment/.notdef of/.notdef obesity-related/.notdef conditions/.notdef (and/.notdef nicotine/.notdef addiction)./.notdef The/.notdef safety/.notdef pharmacology/.notdef studies/.notdef identified/.notdef the/.notdef CNS/.notdef and/.notdef cardiac/.notdef electrophysiology/.notdef as/.notdef possible/.notdef targets/.notdef for/.notdef rimonabant/.notdef with/.notdef regard/.notdef to/.notdef potential/.notdef adverse/.notdef effects/.notdef in/.notdef man./.notdef Effects/.notdef on/.notdef the/.notdef CNS/.notdef after/.notdef a/.notdef single/.notdef oral/.notdef dose/.notdef comprised/.notdef sedation/.notdef and/.notdef decreased/.notdef muscle/.notdef tone./.notdef A/.notdef proconvulsant/.notdef potential/.notdef for/.notdef rimonabant/.notdef was/.notdef seen/.notdef in/.notdef animals/.notdef when/.notdef combined/.notdef with/.notdef physical/.notdef or/.notdef chemical/.notdef seizure/.notdef inducers,/.notdef or/.notdef with/.notdef stressful/.notdef conditions;/.notdef this/.notdef proconvulsant/.notdef effect/.notdef was/.notdef likely/.notdef to/.notdef be/.notdef related/.notdef to/.notdef the/.notdef blockade/.notdef of/.notdef an/.notdef existing/.notdef endogenous/.notdef cannabinoid/.notdef tone./.notdef Despite/.notdef some/.notdef electrophysiological/.notdef findings,/.notdef the/.notdef non-clinical/.notdef results/.notdef raised/.notdef no/.notdef concerns/.notdef that/.notdef rimonabant/.notdef could/.notdef increase/.notdef the/.notdefrisk/.notdefof/.notdeftorsade-de-points/.notdefor/.notdefother/.notdefcardiac/.notdefarrhythmias/.notdefat/.notdeftherapeutic/.notdefdoses/.notdefin/.notdefhumans. /.notdef The/.notdef results/.notdef of/.notdef the/.notdef pharmacokinetic/.notdef studies/.notdef revealed/.notdef a/.notdef consistent/.notdef picture/.notdef across/.notdef the/.notdef species/.notdef of/.notdef the/.notdef absorption,/.notdef distribution,/.notdef metabolism,/.notdef and/.notdef excretion/.notdef of/.notdef rimonabant:/.notdef rapid/.notdef oral/.notdef absorption,/.notdef a/.notdef low/.notdef to/.notdef moderate/.notdef bioavailability,/.notdef wide/.notdef distribution/.notdef (passes/.notdef the/.notdef blood-brain/.notdef barrier/.notdef and/.notdef placenta),/.notdef high/.notdef protein/.notdef binding,/.notdefextensive/.notdefmetabolism/.notdef(major/.notdefmetabolites/.notdefare/.notdefthe/.notdefsame/.notdefin/.notdefall/.notdefstudied/.notdefspecies,/.notdefincluding/.notdefhumans),/.notdef all/.notdef metabolites/.notdef observed/.notdef in/.notdef humans/.notdef were/.notdef present/.notdef in/.notdef at/.notdef least/.notdef one/.notdef animal/.notdef species,/.notdef long/.notdef terminal/.notdef half-life/.notdef with/.notdefbile//.notdeffaeces/.notdefbeing/.notdefthe/.notdefmajor/.notdefexcretory/.notdefpathway,/.notdefexcreted/.notdefin/.notdefmilk./.notdef One/.notdef of/.notdef the/.notdef major/.notdef metabolic/.notdefpathways/.notdefwas/.notdefhydrolysis/.notdefof/.notdefthe/.notdefamide/.notdefbond/.notdefthat/.notdefbinds/.notdefthe/.notdefpiperidine/.notdefring/.notdefto/.notdef the/.notdef rest/.notdef of/.notdef the/.notdef rimonabant/.notdef molecule,/.notdef producing/.notdef the/.notdef metabolite/.notdef SR141715,/.notdef which/.notdef could,/.notdef theoretically,/.notdef release/.notdef the/.notdef piperidyl/.notdef radical/.notdef as/.notdef N-aminopiperidine/.notdef (NAP)/.notdef in/.notdef equimolar/.notdef amounts./.notdef This/.notdef compound/.notdef is/.notdef mutagenic/.notdefin/.notdefbacteria/.notdefand/.notdefmay/.notdefhave/.notdefother/.notdefgenotoxic/.notdefproperties./.notdefThe/.notdefapplicant/.notdefcalculated/.notdefthat/.notdefappreciable/.notdef amounts/.notdefof/.notdef NAP/.notdef was/.notdef expected/.notdef to/.notdef be/.notdef produced;/.notdef no/.notdef additional/.notdef data/.notdef about/.notdef the/.notdef metabolic/.notdef fate/.notdef of/.notdef NAP/.notdef was/.notdef presented./.notdefThus,/.notdef precise/.notdef estimate/.notdef of/.notdef the/.notdef risk/.notdef for/.notdef humans/.notdef could/.notdef not/.notdef be/.notdef made/.notdef but/.notdef the/.notdef risk/.notdef was/.notdef most/.notdef likely/.notdef very/.notdef low,/.notdef due/.notdef to/.notdef the/.notdef large/.notdef exposure/.notdef margins/.notdef and/.notdef absence/.notdef of/.notdef tumour/.notdef findings/.notdef in/.notdef the/.notdef mouse/.notdef and/.notdef male/.notdef rat./.notdef The/.notdefapplicant/.notdefcommitted/.notdefto/.notdefprovide/.notdefadditional/.notdefdata/.notdefon/.notdefthe/.notdefissue/.notdefas/.notdefa/.notdefpost-approval/.notdeffollow-up/.notdefmeasure./.notdef

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

Medicinal product no longer authorised The/.notdef results/.notdef of/.notdef the/.notdef toxicology/.notdefstudies/.notdefwere/.notdefconsistent/.notdefacross/.notdefspecies./.notdefReduced/.notdefweight/.notdefgain/.notdefor/.notdefweight/.notdefloss/.notdef and/.notdef sometimes/.notdef decreased/.notdef food/.notdef consumption/.notdef were/.notdef seen/.notdef at/.notdef low/.notdef doses/.notdef of/.notdef rimonabant/.notdef in/.notdef all/.notdef species./.notdef These/.notdef findings/.notdefwere/.notdeflikely/.notdef to/.notdefbe/.notdefdue/.notdefto/.notdef a/.notdef combination/.notdefof/.notdefthe/.notdef compound's/.notdefpharmacological/.notdefeffect/.notdefand/.notdefa/.notdefgeneral/.notdef health/.notdef deterioration./.notdef At/.notdef higher/.notdef doses,/.notdef detrimental/.notdef effects/.notdef on/.notdef the/.notdef CNS,/.notdef with/.notdef clonic/.notdef convulsions/.notdef as/.notdef a/.notdef hallmark,/.notdef was/.notdef the/.notdef dominant/.notdef clinical/.notdef finding./.notdef Particularly/.notdef in/.notdef the/.notdef macaques,/.notdef this/.notdef clinical/.notdef picture/.notdef was/.notdef aggravated/.notdefby/.notdeffulminant/.notdefstress/.notdefreactions/.notdefthat/.notdefcould/.notdefbe/.notdeflethal./.notdefThese/.notdefserious/.notdefclinical/.notdefsymptoms/.notdefprompted/.notdefa/.notdef reduction/.notdefof/.notdefthe/.notdefdose/.notdeflevels/.notdefin/.notdefthe/.notdeflater/.notdefstudies,/.notdefespecially/.notdeffor/.notdefthe/.notdefmonkeys./.notdefThere/.notdefwere/.notdefno/.notdefapparent/.notdefsigns/.notdef of/.notdef a/.notdef worsening/.notdef with/.notdef longer/.notdef treatment/.notdef times;/.notdef on/.notdef the/.notdef contrary/.notdef the/.notdef clinical/.notdef symptoms/.notdef tended/.notdef to/.notdef be/.notdef worst/.notdef during/.notdef the/.notdef first/.notdef few/.notdef weeks/.notdef and/.notdef declined/.notdef thereafter./.notdef Mortality,/.notdef generally/.notdef in/.notdef conjunction/.notdef with/.notdef signs/.notdef of/.notdef overall/.notdef health/.notdef deterioration,/.notdef malnutrition/.notdef and/.notdef stress,/.notdef occurred/.notdef at/.notdef higher/.notdef doses/.notdef (mice/.notdef and/.notdef rats/.notdef GLYPH&lt;1&gt; /.notdef 120/.notdef mg/kg/d,/.notdefmacaques/.notdef GLYPH&lt;1&gt; /.notdef45/.notdef mg/kg/d)./.notdefIn/.notdefcontrast,/.notdef'classical'/.notdeftoxicological/.notdeffindings/.notdefwere/.notdefsparse./.notdefThere/.notdefwere/.notdef signs/.notdefof/.notdefinvolvement/.notdefof/.notdefthe/.notdefliver,/.notdefkidneys/.notdefand/.notdefbone/.notdefmarrow,/.notdefbut/.notdefnone/.notdefof/.notdefthese/.notdefprovided/.notdefclear-cut/.notdefevidence/.notdef of/.notdefa/.notdefdirect/.notdeftoxicity/.notdefof/.notdefrimonabant./.notdef/.notdef The/.notdeftoxic/.notdefprofile/.notdefof/.notdefrimonabant/.notdefwas/.notdefnot/.notdeffully/.notdefcharacterized/.notdefas/.notdefthe/.notdefhighest/.notdefexposures/.notdefto/.notdefrimonabant/.notdefin/.notdefthe/.notdef non-clinical/.notdef safety/.notdef studies/.notdef were/.notdef similar/.notdef to/.notdef the/.notdef expected/.notdef exposure/.notdef in/.notdef humans/.notdef after/.notdef the/.notdef therapeutic/.notdef dose./.notdef The/.notdefhighest/.notdefdoses/.notdefused/.notdefin/.notdefthe/.notdeflong-term/.notdefstudies/.notdefcorresponded/.notdefto/.notdefabout/.notdef2-3/.notdeftimes/.notdefhigher/.notdefexposures/.notdefin/.notdefrats/.notdef and/.notdef 1.5/.notdef times/.notdef in/.notdef macaques;/.notdef testing/.notdef of/.notdefhigher/.notdefdoses/.notdefwas/.notdefnot/.notdeffeasible./.notdefThus,/.notdefthe/.notdefnon-clinical/.notdefstudies/.notdefcould/.notdef provide/.notdef no/.notdef reassurance/.notdef regarding/.notdef margins/.notdef to/.notdef the/.notdef clinical/.notdef exposure./.notdef Consequently,/.notdef the/.notdef safe/.notdef use/.notdef of/.notdef rimonabant/.notdef has/.notdef to/.notdef rely/.notdef more/.notdef on/.notdef the/.notdef clinical/.notdef safety/.notdef data/.notdef and/.notdef on/.notdef the/.notdef post-approval/.notdef pharmacovigilance/.notdef programme./.notdef/.notdef /.notdef No/.notdef signs/.notdef of/.notdef genotoxicity/.notdef were/.notdef observed/.notdef in/.notdef a/.notdef standard/.notdef in/.notdef vitro/.notdef package/.notdef or/.notdef in/.notdef a/.notdef mouse/.notdef micronucleus/.notdef test./.notdef However,/.notdefthe/.notdefapplicant/.notdefcommitted/.notdefto/.notdeffurther/.notdefclarify/.notdefthe/.notdefbioactivation/.notdefof/.notdefN-aminopiperidine./.notdef/.notdef The/.notdeftumour/.notdeffindings/.notdefin/.notdefthe/.notdefliver/.notdefand/.notdeffemale/.notdefgenital/.notdeftract/.notdeffound/.notdefin/.notdefthe/.notdeflong/.notdefterm/.notdefrat/.notdefstudy/.notdefwere/.notdefconsidered/.notdef to/.notdef be/.notdef species/.notdef specific/.notdef and/.notdef due/.notdef to/.notdef enzyme/.notdef induction/.notdef and/.notdef chronic/.notdef hormonal/.notdef imbalance/.notdef with/.notdef oestrogen/.notdef stimulation,/.notdefrespectively./.notdefConsequently,/.notdefthese/.notdeftumours/.notdefshould/.notdefnot/.notdefimply/.notdefan/.notdefincreased/.notdefrisk/.notdeffor/.notdefhumans./.notdef /.notdef The/.notdefmost/.notdefremarkable/.notdefeffects/.notdefin/.notdefthe/.notdefreproductive/.notdeftoxicity/.notdefpackage/.notdefwere/.notdefdecreased/.notdefviability/.notdefindex/.notdefand/.notdefpup/.notdef growth/.notdef pre-weaning,/.notdef in/.notdef conjunction/.notdef with/.notdef an/.notdef increased/.notdef incidence/.notdef of/.notdef no/.notdef milk/.notdef in/.notdef the/.notdef stomach;/.notdef the/.notdef mechanism(s)/.notdefof/.notdefthese/.notdefeffects/.notdefwas/.notdefnot/.notdefclear,/.notdefbut/.notdefcould/.notdefbe/.notdefrelated/.notdefto/.notdefan/.notdefeffect/.notdefon/.notdefthe/.notdefsuckling/.notdefreflex./.notdefThere/.notdef were/.notdef malformations/.notdef in/.notdef the/.notdef rabbit/.notdef embryo-foetal/.notdef development/.notdef studies/.notdef (omphalocele/.notdef and/.notdef various/.notdef CNSmalformations)/.notdef that/.notdef could/.notdef be/.notdef due/.notdef to/.notdef rimonabant./.notdef Moreover,/.notdef it/.notdef is/.notdef known/.notdef that/.notdef CB1/.notdef is/.notdef expressed/.notdef in/.notdef many/.notdef parts/.notdefof/.notdefthe/.notdefdeveloping/.notdefbrain/.notdefand/.notdefthat/.notdefthe/.notdefpattern/.notdefchanges/.notdefduring/.notdefdevelopment./.notdefThese/.notdeffindings/.notdefresulted/.notdefin/.notdef a/.notdefwarning/.notdefagainst/.notdefthe/.notdefuse/.notdefof/.notdefrimonabant/.notdefduring/.notdefpregnancy/.notdefand/.notdefin/.notdefa/.notdefcontraindication/.notdefduring/.notdeflactation/.notdef(SPC/.notdef 4.3/.notdefand/.notdef4.6)./.notdef/.notdef The/.notdef finding/.notdef of/.notdef neuropil/.notdef vacuolation/.notdef and/.notdef increased/.notdef GFAP/.notdef staining/.notdef in/.notdef rimonabant/.notdef treated/.notdef mice,/.notdef which/.notdef could/.notdefbe/.notdefa/.notdefsignal/.notdefof/.notdefunderlying/.notdefneuropathology,/.notdefwas/.notdefdiminished/.notdefby/.notdefthe/.notdeflack/.notdefof/.notdefother/.notdefsigns./.notdef/.notdef Finally,/.notdef the/.notdef environmental/.notdef impact/.notdef of/.notdef rimonabant/.notdef needed/.notdef further/.notdef evaluation/.notdef and/.notdef additional/.notdef studies;/.notdef the/.notdef applicant/.notdefcommitted/.notdefto/.notdefcarry/.notdefout/.notdefsuch/.notdefstudies/.notdefas/.notdefa/.notdefpost-approval/.notdeffollow-up/.notdefmeasure./.notdef /.notdef /.notdef 4./.notdef Clinical/.notdefaspects/.notdef /.notdef Introduction/.notdef /.notdef The/.notdef Clinical/.notdef trials/.notdef were/.notdef performed/.notdef in/.notdef accordance/.notdef with/.notdef GCP/.notdef as/.notdef claimed/.notdef by/.notdef the/.notdef applicant./.notdef Further,/.notdef at/.notdef the/.notdef request/.notdef of/.notdef the/.notdef CHMP,/.notdef a/.notdef GCP-inspection/.notdef was/.notdef carried/.notdef out/.notdef at/.notdef two/.notdef of/.notdef the/.notdef 60/.notdef investigational/.notdef sites/.notdef of/.notdef study/.notdef 'RIO-Europe'/.notdef(at/.notdefone/.notdefinvestigator's/.notdefsite/.notdefin/.notdefNetherlands/.notdefand/.notdefone/.notdefin/.notdefSweden)./.notdefThe/.notdefresults/.notdefof/.notdefthe/.notdefinspection/.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

Medicinal product no longer authorised of/.notdef both/.notdef investigator/.notdefsites/.notdefdemonstrated,/.notdefthat/.notdefthe/.notdefdata/.notdefproduced/.notdefby/.notdefthese/.notdefsites/.notdefwere/.notdefverifiable/.notdefand/.notdefreliable/.notdef and/.notdefin/.notdefline/.notdefwith/.notdefthe/.notdefdata/.notdefreported/.notdefto/.notdefthe/.notdefCHMP./.notdef /.notdef The/.notdef applicant/.notdefhas/.notdef provided/.notdefa/.notdefstatement/.notdefto/.notdefthe/.notdefeffect/.notdefthat/.notdefclinical/.notdeftrials/.notdefconducted/.notdefoutside/.notdefthe/.notdefcommunity/.notdef were/.notdefcarried/.notdefout/.notdefin/.notdefaccordance/.notdefwith/.notdefthe/.notdefethical/.notdefstandards/.notdefof/.notdefDirective/.notdef2001/20/EC./.notdef/.notdef /.notdef Pharmacokinetics/.notdef /.notdef The/.notdefPhase/.notdef1/.notdefclinical/.notdefpharmacology/.notdefprogram/.notdefincluded/.notdef36/.notdefstudies./.notdefIn/.notdefaddition,/.notdeftwo/.notdefpopulation/.notdefPK/.notdefanalyses/.notdef were/.notdef performed/.notdef using/.notdef sparse/.notdef data/.notdef from/.notdef a/.notdef large/.notdef number/.notdef of/.notdef patients/.notdef included/.notdef in/.notdef the/.notdef phase/.notdef III/.notdef studies./.notdef Rimonabant/.notdef plasma/.notdef concentration/.notdef was/.notdef determined/.notdef by/.notdef a/.notdef LC/MS/MS/.notdef methods/.notdef in/.notdef main/.notdef PK/.notdef studies./.notdef Pharmacokinetic/.notdef parameters/.notdef were/.notdef determined/.notdef using/.notdef non-compartmental/.notdef models./.notdef Population/.notdef pharmacokinetics/.notdefanalyses/.notdefwere/.notdefconducted/.notdefusing/.notdefWinNonmix/.notdefand/.notdefNONMEM./.notdef /.notdef · Absorption/.notdef/.notdef Rimonabant/.notdefwas/.notdefrapidly/.notdefabsorbed/.notdefupon/.notdeforal/.notdefadministration./.notdefThe/.notdefabsorption/.notdefrate/.notdefwas/.notdefdose/.notdefdependent/.notdefand/.notdef decreased/.notdef with/.notdef increased/.notdef dose./.notdef Peak/.notdef plasma/.notdef concentration/.notdef (Cmax)/.notdef was/.notdef reached/.notdef about/.notdef 2/.notdef hours/.notdef after/.notdef administration/.notdef of/.notdef a/.notdef 20/.notdef mg/.notdef dose./.notdef The/.notdef absolute/.notdef bioavailability/.notdef was/.notdef not/.notdef determined./.notdef Rimonabant/.notdef had/.notdef low/.notdef solubility/.notdef and/.notdef high/.notdef permeability./.notdef Rimonabant/.notdef was/.notdef not/.notdef a/.notdef substrate/.notdef or/.notdef inhibitor/.notdef of/.notdef P-gp./.notdef The/.notdef pharmacokinetics/.notdef were/.notdef roughly/.notdef dose/.notdef proportional/.notdef up/.notdef to/.notdef about/.notdef 20/.notdef mg;/.notdef the/.notdef exposure/.notdef thereafter/.notdef increased/.notdef less/.notdefthan/.notdefin/.notdefproportion/.notdefto/.notdefdose./.notdefDuring/.notdefconcomitant/.notdeffood/.notdefintake/.notdefC max/.notdef increased/.notdefby/.notdefabout/.notdef70%/.notdefand/.notdefAUC/.notdefby/.notdef 50%;/.notdefthe/.notdefSPC/.notdefrecommends/.notdefintake/.notdefwith/.notdefbreakfast/.notdefin/.notdefline/.notdefwith/.notdefthe/.notdefconducted/.notdefphase/.notdefIII/.notdefstudies./.notdefSteady/.notdefstate/.notdef was/.notdefreached/.notdefafter/.notdefa/.notdefmedian/.notdeftime/.notdefof/.notdef13/.notdefdays/.notdefin/.notdefhealthy/.notdefnormal-weight/.notdefvolunteers./.notdefIn/.notdefobese/.notdefpatients/.notdefmedian/.notdef time/.notdefto/.notdef steady/.notdef state/.notdef was/.notdef estimated/.notdefto/.notdefbe/.notdef39/.notdefdays,/.notdefas/.notdefa/.notdefconsequence/.notdefof/.notdeftheir/.notdefhigher/.notdefvolume/.notdefof/.notdefdistribution/.notdef and/.notdeflonger/.notdefhalf-life./.notdef Bioequivalence/.notdef between/.notdef the/.notdef 20/.notdef mg/.notdef tablet/.notdef applied/.notdef for/.notdef and/.notdef the/.notdef capsule/.notdef formulation/.notdef used/.notdef during/.notdef clinical/.notdef development/.notdefwas/.notdefdemonstrated./.notdef/.notdef · Distribution/.notdef Rimonabant/.notdef has/.notdef not/.notdef been/.notdef administered/.notdef intravenously/.notdef to/.notdef humans,/.notdef and/.notdef V ss /.notdef was/.notdef not/.notdef determined./.notdef Data/.notdef on/.notdef V/F/.notdef suggest/.notdef extensive/.notdef distribution./.notdef Rimonabant/.notdef exhibited/.notdef very/.notdef high/.notdef binding/.notdef to/.notdef plasma/.notdef proteins/.notdef (mean/.notdef=/.notdef99.94%),/.notdefmainly/.notdefalbumin./.notdefDue/.notdefto/.notdefthe/.notdeflarge/.notdefvolume/.notdefof/.notdefdistribution,/.notdeflittle/.notdefimpact/.notdefwas/.notdefexpected/.notdefon/.notdef interaction/.notdefcaused/.notdefby/.notdefprotein/.notdefdisplacement,/.notdefin/.notdefspite/.notdefof/.notdefthe/.notdefhigh/.notdefprotein/.notdefbinding/.notdefof/.notdefrimonabant./.notdef/.notdef /.notdef · Elimination/.notdef Rimonabant/.notdef is/.notdef mainly/.notdef eliminated/.notdef by/.notdef metabolism/.notdef and/.notdef subsequent/.notdef biliary/.notdef excretion/.notdef of/.notdef metabolites./.notdef The/.notdef mean/.notdef terminal/.notdef half-life/.notdef of/.notdef rimonabant/.notdef was/.notdef about/.notdef 10/.notdefdays/.notdef in/.notdef healthy/.notdef (normal/.notdef weight)/.notdef subjects/.notdef but/.notdef was/.notdef higher/.notdefin/.notdefobese/.notdefsubjects/.notdef(16/.notdefdays)./.notdefThe/.notdefclearance/.notdef(Cl/F)/.notdefwas/.notdefapproximately/.notdef5/.notdefL/h./.notdefApproximately/.notdef32%/.notdefof/.notdef administered/.notdef rimonabant/.notdef was/.notdef excreted/.notdef as/.notdef unchanged/.notdef drug/.notdef in/.notdef faeces,/.notdef probably/.notdef representing/.notdef unabsorbed/.notdef drug./.notdefNo/.notdefunchanged/.notdefrimonabant/.notdefwas/.notdeffound/.notdefin/.notdefurine./.notdefApproximately/.notdef3%/.notdefof/.notdefa/.notdef20/.notdefmg/.notdefrimonabant/.notdefdose/.notdefwas/.notdef excreted/.notdefin/.notdefurine/.notdefand/.notdefabout/.notdef61%/.notdefof/.notdefthe/.notdefdose/.notdefwas/.notdefeliminated/.notdefin/.notdeffaeces/.notdefover/.notdef312/.notdefhours./.notdefWhen/.notdefextrapolated/.notdef to/.notdef infinity/.notdef about/.notdef 90%/.notdefof/.notdef the/.notdef total/.notdef administered/.notdefdose/.notdefcould/.notdefbe/.notdefaccounted/.notdeffor/.notdef(86/.notdef%/.notdefand/.notdef4%/.notdefin/.notdeffaeces/.notdefand/.notdef urine,/.notdef respectively)./.notdef In/.notdefvitro /.notdef data/.notdef indicated/.notdef that/.notdef rimonabant/.notdef was/.notdef metabolized/.notdef by/.notdef CYP3A4/.notdef and/.notdef in/.notdef lesser/.notdef extent/.notdef amidohydrolase/.notdef(predominantly/.notdefhepatic)/.notdefpathways/.notdefwith/.notdefthe/.notdeffraction/.notdefmetabolized/.notdefvarying/.notdefbetween/.notdef 25%/.notdefto/.notdef63%./.notdefThe/.notdeffollowing/.notdefmetabolites/.notdefof/.notdefrimonabant/.notdefwere/.notdefidentified/.notdefin/.notdefhumans:/.notdefSR141715/.notdef(carboxylic/.notdef acid/.notdef derivative/.notdef of/.notdef rimonabant),/.notdef SR142923/.notdef (hydroxy/.notdef derivative/.notdef on/.notdef the/.notdef piperidine/.notdef ring),/.notdef SR90161/.notdef (propionic/.notdef acid/.notdef derivative/.notdef of/.notdef SR142923),/.notdef glucuronidated/.notdef SR141715/.notdef (H3)/.notdef and/.notdef SR90161,/.notdef hydroxy/.notdef unsaturated/.notdef or/.notdef lactam/.notdef derivative/.notdef of/.notdef rimonabant./.notdef The/.notdef metabolites/.notdef identified/.notdef in/.notdef plasma/.notdef (SR141715,/.notdef SR142923,/.notdefand/.notdefSR90161,/.notdefrepresenting/.notdef11%,/.notdef5%,/.notdefand/.notdef8%/.notdefof/.notdeftotal/.notdefplasma/.notdefradioactivity,/.notdefrespectively)/.notdefwere/.notdef inactive/.notdefagainst/.notdefhuman/.notdefcloned/.notdefCB1/.notdefreceptors./.notdefNo/.notdefconsequences/.notdefof/.notdefgenetic/.notdefpolymorphism/.notdefwere/.notdefexpected,/.notdef as/.notdefrimonabant/.notdefwas/.notdefnot/.notdefmetabolized/.notdefby/.notdefCYP2D6,/.notdefCYP2C9/.notdefor/.notdefCYP2C19/.notdefisoenzymes./.notdef/.notdef /.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised · Variability/.notdef Inter-individual/.notdef variability/.notdef in/.notdef CL/F/.notdef was/.notdef 44-46%/.notdef in/.notdef the/.notdef population/.notdef PK/.notdef studies./.notdef Residual/.notdef variability/.notdef (representing/.notdefintra-individual/.notdefvariability)/.notdefwas/.notdef24%/.notdefin/.notdefPOH0045./.notdefIn/.notdefcrossover/.notdefstudies/.notdefin/.notdefhealthy/.notdefsubjects,/.notdef the/.notdefinter-individual/.notdefvariability/.notdefwas/.notdef41%/.notdeffor/.notdefC max /.notdef and/.notdef53%/.notdeffor/.notdefAUC/.notdefand/.notdefthe/.notdefwithin-subject/.notdefvariability/.notdefwas/.notdef 29%/.notdeffor/.notdefC max /.notdefand/.notdef17%/.notdeffor/.notdefAUC./.notdef · Special/.notdefpopulations/.notdef Two/.notdef large/.notdef population/.notdef pharmacokinetic/.notdef analyses/.notdef and/.notdef specific/.notdef phase/.notdef I/.notdef studies/.notdef were/.notdef conducted/.notdef evaluating/.notdef the/.notdef effect/.notdef of/.notdef age,/.notdef gender,/.notdef race,/.notdef body/.notdef size/.notdef (body/.notdef weight,/.notdefbody/.notdefmass/.notdefindex,/.notdefheight),/.notdefhepatic/.notdeffunction,/.notdefrenal/.notdef function/.notdefand/.notdefdose/.notdefon/.notdefrimonabant/.notdefpharmacokinetics/.notdef(PK)./.notdef/.notdef The/.notdefmain/.notdeffactor/.notdefinfluencing/.notdefrimonabant/.notdefexposure/.notdefwas/.notdefrace/.notdefwith/.notdefAfro-Americans/.notdefhaving/.notdefhigher/.notdefclearance/.notdef and/.notdef hence/.notdef lower/.notdef exposure/.notdef than/.notdef Caucasians/.notdef(43%/.notdeflower/.notdefAUC);/.notdefthis/.notdefis/.notdef reflected/.notdef in/.notdef SPC/.notdef (5.2)./.notdef Volume/.notdef of/.notdef distribution/.notdefincreases/.notdefwith/.notdefweight/.notdefresulting/.notdefin/.notdeflonger/.notdefhalf-life/.notdefand/.notdefsubsequently/.notdeflonger/.notdeftime/.notdefto/.notdefsteady/.notdefstate/.notdef and/.notdef lower/.notdef fluctuations/.notdef at/.notdef steady/.notdef state./.notdef Race,/.notdef other/.notdef than/.notdef Afro-Americans/.notdef or/.notdef gender/.notdef had/.notdef no/.notdef clinically/.notdef relevant/.notdefinfluence/.notdefon/.notdefrimonabant/.notdefPK./.notdefAUC/.notdefwas/.notdefestimated/.notdefto/.notdefbe/.notdef27%/.notdefhigher/.notdefin/.notdefa/.notdef75/.notdefyear/.notdefold/.notdefthan/.notdefin/.notdefa/.notdef44/.notdef year/.notdef old./.notdef However,/.notdef this/.notdef difference/.notdef is/.notdef of/.notdef limited/.notdef clinical/.notdef relevance./.notdef There/.notdef were/.notdef no/.notdef data/.notdef in/.notdef children/.notdef or/.notdef adolescents./.notdef The/.notdef population/.notdef pharmacokinetic/.notdef analyses/.notdef indicated/.notdef that/.notdef rimonabant/.notdef pharmacokinetics/.notdef were/.notdef similar/.notdef between/.notdef healthy/.notdef non-smoking/.notdef subjects,/.notdef patients/.notdef who/.notdef smoke,/.notdef and/.notdef obese/.notdef patients./.notdef The/.notdef applicant/.notdef committed/.notdefto/.notdefprovide/.notdefadditional/.notdefsafety/.notdefdata/.notdefon/.notdefother/.notdefethnic/.notdefgroups/.notdefthan/.notdefAfro-Americans/.notdef(in/.notdefJapanese/.notdefand/.notdef Asiatic/.notdefpatients)/.notdefas/.notdefa/.notdefpost-approval/.notdeffollow-up/.notdefmeasure./.notdef The/.notdef influence/.notdefof/.notdefrenal/.notdeffunction/.notdefon/.notdefthe/.notdefPK/.notdefof/.notdefrimonabant/.notdefwas/.notdefnot/.notdefevaluated/.notdefin/.notdefa/.notdefspecific/.notdefstudy./.notdefBased/.notdefon/.notdef data/.notdef from/.notdef phase/.notdef III/.notdef studies,/.notdef AUC/.notdef was/.notdef estimated/.notdef to/.notdef be/.notdef 40%/.notdef higher/.notdef in/.notdef patients/.notdef with/.notdef moderate/.notdef renal/.notdef impairment/.notdef than/.notdef in/.notdef patients/.notdef with/.notdef normal/.notdef renal/.notdef function./.notdef Data/.notdef were/.notdef too/.notdef sparse/.notdef to/.notdef draw/.notdef conclusions/.notdef in/.notdef patients/.notdefwith/.notdefsevere/.notdefrenal/.notdefimpairment./.notdefRimonabant/.notdefshould/.notdefbe/.notdefused/.notdefwith/.notdefcaution/.notdefin/.notdefpatients/.notdefwith/.notdefmoderate/.notdef renal/.notdef impairment/.notdef and/.notdef use/.notdef is/.notdef not/.notdef recommended/.notdef in/.notdef patients/.notdef with/.notdef severe/.notdef renal/.notdef impairment/.notdef (see/.notdef SPC/.notdef 4.4)./.notdef The/.notdefapplicant/.notdefcommitted/.notdefto/.notdefstudy/.notdefPK/.notdefin/.notdefpatients/.notdefwith/.notdefsevere/.notdefrenal/.notdefimpairment/.notdefas/.notdefa/.notdefpost-approval/.notdeffollowup/.notdefmeasure./.notdef A/.notdef specific/.notdef study/.notdef was/.notdef conducted/.notdef in/.notdef subjects/.notdef with/.notdef mild/.notdef and/.notdef moderate/.notdef hepatic/.notdef impairment./.notdef There/.notdef was/.notdef no/.notdef significant/.notdef difference/.notdef in/.notdef total/.notdef or/.notdef unbound/.notdef AUC/.notdef between/.notdef subjects/.notdef with/.notdef impaired/.notdef hepatic/.notdef function/.notdef and/.notdef control/.notdefsubjects./.notdefA/.notdefprolongation/.notdefof/.notdefhalf-life/.notdefwas/.notdefobserved,/.notdefcaused/.notdefby/.notdefan/.notdefincreased/.notdefvolume/.notdefof/.notdefdistribution./.notdef There/.notdef were/.notdef no/.notdef data/.notdef in/.notdef severe/.notdef hepatic/.notdef impairment./.notdef Rimonabant/.notdef should/.notdef be/.notdef used/.notdef with/.notdef caution/.notdef in/.notdef moderate/.notdef hepatic/.notdefimpairment./.notdefUse/.notdefis/.notdefnot/.notdefrecommended/.notdefin/.notdefpatients/.notdefwith/.notdefsevere/.notdefhepatic/.notdefimpairment/.notdef(see/.notdefSPC/.notdef4.4)./.notdef · Pharmacokinetic/.notdefinteraction/.notdefstudies/.notdef In/.notdefvitro/.notdef The/.notdef in/.notdef vitro/.notdef studies/.notdef suggested/.notdef a/.notdef low/.notdef potential/.notdef for/.notdef inhibition/.notdef or/.notdef induction/.notdef of/.notdef CYP450/.notdef isoenzymes/.notdef by/.notdef rimonabant./.notdefIt/.notdefhad/.notdefmild/.notdefinhibitory/.notdefeffect/.notdefon/.notdefCYP2C8./.notdef In/.notdefvivo/.notdef No/.notdef effect/.notdef of/.notdef rimonabant/.notdef (40/.notdef mg/.notdef o.d./.notdef for/.notdef 8/.notdef days)/.notdef on/.notdef the/.notdef pharmacokinetics/.notdef of/.notdef the/.notdef CYP3A4/.notdef substrate/.notdef midazolam/.notdef (0.03/.notdef mg/kg/.notdef single/.notdef oral/.notdef dose)/.notdef was/.notdef observed/.notdef in/.notdef study/.notdef INT5006./.notdef No/.notdef effect/.notdef of/.notdef rimonabant/.notdef (40/.notdef mg/.notdef o.d./.notdef for/.notdef 8/.notdef days/.notdef and/.notdef 6/.notdef days/.notdef continued/.notdef after/.notdef warfarin/.notdef administration)/.notdef on/.notdef the/.notdef pharmacokinetics/.notdef of/.notdef warfarin/.notdef(30/.notdefmg/.notdefsingle/.notdefdose),/.notdefa/.notdefnarrow/.notdeftherapeutic/.notdefindex/.notdefdrug/.notdefand/.notdefa/.notdefCYP2C9/.notdefsubstrate,/.notdefwas/.notdefobserved/.notdefin/.notdef study/.notdefINT3787./.notdefNo/.notdefeffect/.notdefof/.notdefrimonabant/.notdef(40/.notdefmg/.notdefo.d./.notdeffor/.notdef8/.notdefdays)/.notdefon/.notdefthe/.notdefpharmacokinetics/.notdefof/.notdefdigoxin/.notdef(0.50/.notdef mg/.notdef loading/.notdef dose/.notdef +/.notdef 0.25/.notdef mg/.notdef once-daily),/.notdef a/.notdef narrow/.notdef therapeutic/.notdef index/.notdef drug/.notdef and/.notdef a/.notdef P-gp/.notdef substrate/.notdef was/.notdef observed/.notdefin/.notdefstudy/.notdefINT3786./.notdefStudy/.notdefINT4478/.notdefshowed/.notdefthat/.notdefrimonabant/.notdef(40/.notdefmg/.notdefo.d./.notdeffor/.notdef8/.notdefdays)/.notdefdid/.notdefnot/.notdefaffect/.notdef the/.notdefpharmacokinetics/.notdefof/.notdefnicotine/.notdef(21/.notdefmg/.notdefonce-daily)./.notdefStudy/.notdefINT4738/.notdefshowed/.notdefthat/.notdefrimonabant/.notdef(40/.notdefmg/.notdefo.d./.notdef for/.notdef8/.notdefdays)/.notdefdid/.notdefnot/.notdefaffect/.notdefthe/.notdefpharmacokinetics/.notdefof/.notdeforal/.notdefcontraceptives/.notdef(0.03/.notdefmg/.notdefethinylestradiol/.notdef+/.notdef0.15/.notdefmg/.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

<!-- image -->

/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef/.notdef

2

3

Medicinal product no longer authorised levonorgestrel/.notdefonce-daily)./.notdef Seven/.notdef days/.notdef of/.notdef treatment/.notdef with/.notdef a/.notdef daily/.notdef oral/.notdef dose/.notdef of/.notdef 200/.notdef mg/.notdef ketoconazole/.notdef increased/.notdef C max ,/.notdef AUC0-24h,/.notdef and/.notdef AUCinf/.notdef of/.notdef rimonabant/.notdef by/.notdef 1.42/.notdef (90%/.notdef C.I.:/.notdef 1.18,/.notdef 1.70),/.notdef 1.55/.notdef (90%/.notdef C.I.:/.notdef 1.43,/.notdef 1.68),/.notdef and/.notdef 2.04/.notdef (90%/.notdef C.I.:/.notdef 1.89,/.notdef2.23)-fold,/.notdefrespectively/.notdef(study/.notdefINT3785)./.notdefA/.notdefsmall/.notdefbut/.notdefstatistically/.notdefsignificant/.notdefdifference/.notdefbetween/.notdefthe/.notdef t 1/2/.notdef values/.notdef of/.notdef rimonabant/.notdef with/.notdef and/.notdef without/.notdef ketoconazole/.notdef treatment/.notdef was/.notdef observed./.notdef No/.notdef differences/.notdef were/.notdef observed/.notdef for/.notdef the/.notdef t max /.notdef after/.notdef both/.notdef treatments./.notdef Thus,/.notdef caution/.notdef is/.notdef advised/.notdef during/.notdef combined/.notdef treatment/.notdef with/.notdef potent/.notdef CYP3A4/.notdef inhibitors/.notdef (ketoconazole,/.notdef itraconazole,/.notdef ritonavir,/.notdef telithromycin,/.notdef clarithromycin/.notdef and/.notdef nefazodone)./.notdef(See/.notdefSPC/.notdef4.5)./.notdef In/.notdef study/.notdef INT3802/.notdefcoadministration/.notdefof/.notdef120/.notdefmg/.notdefTID/.notdeffor/.notdef6/.notdefdays/.notdefof/.notdeforlistat,/.notdefa/.notdefdrug/.notdefused/.notdefin/.notdefthe/.notdefmanagement/.notdef of/.notdefobesity/.notdefbut/.notdefno/.notdefsubstrate/.notdefor/.notdefinhibitor/.notdefof/.notdefCYP/.notdefenzymes,/.notdefhad/.notdefa/.notdefsignificant,/.notdefbut/.notdefsmall,/.notdefeffect/.notdefon/.notdefmean/.notdefC max /.notdef (0.72-fold)/.notdefof/.notdefrimonabant/.notdef(40/.notdefmg)./.notdefNone/.notdefof/.notdefthe/.notdefother/.notdefpharmacokinetic/.notdefparameters/.notdefwere/.notdefaffected./.notdef Coadministration/.notdefof/.notdef500/.notdefmg/.notdefTID/.notdefof/.notdeffamciclovir,/.notdefan/.notdefantiviral/.notdefdrug,/.notdefhad/.notdefno/.notdefeffect/.notdefon/.notdefthe/.notdefpharmacokinetics/.notdef of/.notdef rimonabant/.notdef (40/.notdef mg)/.notdef (study/.notdef INT5501)./.notdef Famciclovir/.notdef is/.notdef metabolized/.notdef in/.notdef the/.notdef liver,/.notdef but/.notdef the/.notdef P450/.notdef cytochrome/.notdefsystem/.notdefis/.notdefnot/.notdefinvolved./.notdef Pharmacodynamics/.notdef · Mechanism/.notdefof/.notdefaction/.notdef Rimonabant/.notdefis/.notdefa/.notdefselective/.notdefantagonist/.notdefof/.notdefthe/.notdefcannabinoid/.notdeftype/.notdef1/.notdef(CB1)/.notdefreceptors/.notdefin/.notdefthe/.notdefCNS./.notdef/.notdef At/.notdef the/.notdef level/.notdef of/.notdef the/.notdef CNS,/.notdef and/.notdef in/.notdef particular/.notdef the/.notdef mesolimbic/.notdef system,/.notdefthe/.notdef majority/.notdefof/.notdefdata/.notdefwith/.notdefregard/.notdefto/.notdefthe/.notdef cannabinoid/.notdefreceptors/.notdefis/.notdefderived/.notdeffrom/.notdefthe/.notdeftherapeutic/.notdefand/.notdefrecreational/.notdefuse/.notdefof/.notdefits/.notdefprimary/.notdefligand,/.notdefcannabis./.notdef Cannabis/.notdefinduces/.notdefpsychotic/.notdeffeatures/.notdefand/.notdefpsychosis/.notdefat/.notdefchronic/.notdefuse,/.notdefand/.notdefmay/.notdefeven/.notdeffacilitate/.notdefthe/.notdeffirst/.notdefonset/.notdef of/.notdef schizophrenia 1 ./.notdef Cannabis/.notdefmay/.notdefinduce/.notdefanxiety/.notdefand/.notdefdepression 2 ,/.notdef and/.notdefcognitive/.notdefimpairment,/.notdefespecially/.notdefof/.notdef attention/.notdef and/.notdef memory 3 ./.notdef On/.notdef the/.notdef contrary,/.notdef decrease/.notdef in/.notdef the/.notdef availability/.notdef of/.notdef dopamine/.notdef in/.notdef the/.notdef CNS/.notdef may/.notdef cause/.notdef depression,/.notdef and/.notdef is/.notdef one/.notdef of/.notdef the/.notdef basic/.notdef principles/.notdef behind/.notdef the/.notdef use/.notdef of/.notdef antidepressants./.notdef Rimonabant/.notdef indirectly/.notdef decreases/.notdefdopamine/.notdefrelease/.notdefin/.notdefdifferent/.notdefbrain/.notdefareas/.notdefby/.notdefblocking/.notdefthe/.notdefCB1/.notdefreceptor./.notdef/.notdef The/.notdef mode/.notdef of/.notdef action/.notdef of/.notdef rimonabant/.notdef with/.notdef regard/.notdef to/.notdef obesity/.notdef is/.notdef interference/.notdef with/.notdef feelings/.notdef of/.notdef hunger/.notdef and/.notdef satiety/.notdef in/.notdef the/.notdef hypothalamic/.notdef region./.notdef In/.notdef addition/.notdef it/.notdef has/.notdef effect/.notdef on/.notdef the/.notdef peripheral/.notdef adipocytes./.notdef The/.notdef applicant/.notdef suggested/.notdef that/.notdef in/.notdef smoking/.notdef cessation/.notdef its/.notdef mode/.notdef of/.notdef action/.notdef is/.notdef based/.notdef on/.notdef antagonism/.notdef of/.notdef CB1/.notdef receptors/.notdef expressed/.notdef in/.notdef the/.notdef mesolimbic/.notdef dopamine/.notdef system,/.notdef a/.notdef brain/.notdef circuit/.notdef that/.notdef is/.notdef involved/.notdef in/.notdef addictive/.notdef behaviour;/.notdef rimonabant/.notdef would/.notdef antagonize/.notdef nicotine-seeking/.notdef behaviour/.notdef in/.notdef animals,/.notdef through/.notdef blockade/.notdef of/.notdef dopamine/.notdef release/.notdefin/.notdefthis/.notdefarea,/.notdefwhich/.notdefis/.notdefalso/.notdefreferred/.notdefto/.notdefas/.notdefthe/.notdefCNS/.notdefreward/.notdefsystem 4 ./.notdef/.notdef · Primary/.notdefand/.notdefSecondary/.notdefpharmacology/.notdef The/.notdefpharmacodynamics/.notdefof/.notdefrimonabant/.notdefwas/.notdefinvestigated/.notdefin/.notdefnumerous/.notdefseparate/.notdefstudies/.notdef(s ome/.notdefexamples/.notdefare/.notdef reported/.notdefbelow)./.notdef Study/.notdefin/.notdefobesity/.notdef The/.notdef effects/.notdef of/.notdef 7-day/.notdef repeated/.notdef doses/.notdef of/.notdef 20/.notdef mg/.notdef rimonabant/.notdef on/.notdef hunger,/.notdef satiation,/.notdef satiety,/.notdef and/.notdef food/.notdef consumption,/.notdefcompared/.notdefwith/.notdef placebo,/.notdef to/.notdef explore/.notdef the/.notdef effect/.notdef of/.notdef rimonabant/.notdef on/.notdef hedonic/.notdef ratings/.notdef of/.notdef sucrose/.notdef 1 /.notdefMaki/.notdefP/.notdefet/.notdefal./.notdefPredictors/.notdefof/.notdefschizophrenia-a/.notdefreview./.notdefBr/.notdefMed/.notdefBull/.notdef2005;/.notdef73:/.notdef1-15./.notdef /.notdefRaphael/.notdefB/.notdefet/.notdefal./.notdefComorbidity:/.notdefcannabis/.notdefand/.notdefcomplexity./.notdefJ/.notdefPsychiatr/.notdefPract/.notdef2005;/.notdef11/.notdef(3):/.notdef161-176)/.notdef /.notdefLundqvist/.notdefT./.notdefCognitive/.notdefconsequences/.notdefof/.notdefcannabis/.notdefuse:/.notdefcomparison/.notdefwith/.notdefabuse/.notdefof/.notdefstimulants/.notdefand/.notdefheroin/.notdefwith/.notdefregard/.notdefto/.notdefattention,/.notdefmemory/.notdef and/.notdefexecutive/.notdeffunctions./.notdefPharmacol/.notdefBiochem/.notdefBehav/.notdef2005;/.notdef81:/.notdef319-330./.notdef 4 /.notdefAdinoff/.notdefB./.notdefNeurobiologic/.notdefprocesses/.notdefin/.notdefdrug/.notdefreward/.notdefand/.notdefaddiction./.notdefHarv/.notdefRev/.notdefPsychiatry/.notdef2004;/.notdef12:/.notdef305-320./.notdef/.notdef

/.notdef

<!-- image -->

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised alone/.notdef and/.notdef in/.notdef food/.notdef vehicle,/.notdef and/.notdef the/.notdef effects/.notdef of/.notdef rimonabant/.notdef on/.notdef food/.notdef consumption/.notdef were/.notdef studied./.notdef Visual/.notdef Analoque/.notdef Scale/.notdef (VAS)/.notdef scores/.notdef for/.notdef hunger,/.notdef recorded/.notdef before/.notdef self-selected/.notdef meals,/.notdef and/.notdef cumulated/.notdef over/.notdef one/.notdef week,/.notdefwere/.notdef statistically/.notdefsignificantly/.notdefreduced/.notdefwith/.notdefrimonabant/.notdefwhen/.notdefcompared/.notdefwith/.notdefplacebo/.notdef(p=0.0355)./.notdef The/.notdef daily/.notdef caloric/.notdef intake/.notdef was/.notdef consistently/.notdef lower/.notdef (although/.notdef not/.notdef statistically/.notdef significant)/.notdef with/.notdef rimonabant/.notdef compared/.notdef with/.notdef placebo./.notdef A/.notdef reduction/.notdef in/.notdef subjects'/.notdef mean/.notdef body/.notdef weight/.notdef was/.notdef observed/.notdef following/.notdef 7-day/.notdef treatment/.notdef with/.notdef rimonabant/.notdef (-620/.notdef g);/.notdef the/.notdef difference/.notdef versus/.notdef placebo/.notdef (-720/.notdef g)/.notdef was/.notdef statistically/.notdef significant/.notdef (p=0.008)./.notdefThere/.notdefwas/.notdefno/.notdeftreatment/.notdefeffect/.notdefobserved/.notdefon/.notdefeating/.notdefdisorder/.notdefinventory/.notdefor/.notdefBeck/.notdefdepression/.notdefscore./.notdef/.notdef Antagonism/.notdefof/.notdefcannabis/.notdefeffects/.notdef In/.notdef a/.notdef study/.notdef the/.notdef 90/.notdef mg/.notdef dose/.notdef of/.notdef rimonabant/.notdef produced/.notdef inhibition/.notdef of/.notdef cannabis-induced/.notdef effects,/.notdef being/.notdef statistically/.notdef significant/.notdef for/.notdef VAS/.notdef composite/.notdef score./.notdef In/.notdef a/.notdef second/.notdef study,/.notdef rimonabant/.notdef at/.notdef both/.notdef doses/.notdef (90/.notdef mg/.notdef single/.notdefdoses,/.notdef40/.notdefmg/.notdefrepeated/.notdefdoses)/.notdefinhibited/.notdefcannabis/.notdefinduced/.notdefheart/.notdefrate/.notdefincrease./.notdefThe/.notdefresults/.notdefsuggested/.notdef that/.notdef rimonabant/.notdef could/.notdef attenuate/.notdef the/.notdef effects/.notdef of/.notdef smoked/.notdef cannabis;/.notdef since/.notdef rimonabant/.notdef did/.notdef not/.notdef affect/.notdef the/.notdef pharmacokinetics/.notdef of/.notdef cannabis,/.notdef this/.notdef effect/.notdef was/.notdef considered/.notdef to/.notdef be/.notdef due/.notdef to/.notdef its/.notdef antagonistic/.notdef effects/.notdef on/.notdef CB1/.notdef receptors./.notdef/.notdef Effects/.notdefon/.notdefcognitive/.notdeffunctions/.notdef The/.notdef impact/.notdef of/.notdef rimonabant/.notdef on/.notdef cognitive/.notdef function/.notdef was/.notdef assessed/.notdef in/.notdef various/.notdef clinical/.notdef pharmacology/.notdef studies./.notdef The/.notdef overall/.notdef analysis/.notdef of/.notdef this/.notdef large/.notdef database/.notdef lead/.notdef to/.notdef the/.notdef conclusion/.notdef that/.notdef rimonabant/.notdef is/.notdef devoid/.notdef of/.notdef any/.notdef significant/.notdef effect/.notdef on/.notdef cognitive/.notdef abilities,/.notdef and/.notdef in/.notdef particular/.notdef does/.notdef not/.notdef show/.notdef any/.notdef sedative/.notdef or/.notdef stimulant/.notdef properties,/.notdefeven/.notdefat/.notdefhigh/.notdefdoses/.notdef(300/.notdefmg/.notdefsingle/.notdefdoses,/.notdef60/.notdefmg/.notdef21-day/.notdefrepeated/.notdefdoses)/.notdef Electrophysiological/.notdefeffects/.notdef Results/.notdef from/.notdef studies/.notdef investigating/.notdef effects/.notdef on/.notdef EEG/.notdef showed/.notdef that/.notdef there/.notdef were/.notdef unspecific/.notdef changes/.notdef showing/.notdef that/.notdefrimonabant/.notdefcrossed/.notdefthe/.notdefblood-brain/.notdefbarrier./.notdef/.notdef The/.notdef effect/.notdef on/.notdef ECG/.notdef parameters/.notdef of/.notdef rimonabant/.notdef 20/.notdef mg/.notdef and/.notdef 60/.notdef mg/.notdef compared/.notdef to/.notdef placebo/.notdef and/.notdef with/.notdef moxifloxacin/.notdef400/.notdefmg/.notdefas/.notdefa/.notdefpositive/.notdefcontrol/.notdefwas/.notdefstudied./.notdefThere/.notdefwas/.notdefno/.notdefevidence/.notdefthat/.notdefrimonabant/.notdefprolonged/.notdef ventricular/.notdefrepolarisation./.notdefThere/.notdefwas/.notdefno/.notdefsignificant/.notdefrelationship/.notdefbetween/.notdefthe/.notdefQT/.notdefchanges/.notdeffrom/.notdefbaseline/.notdefas/.notdef measured/.notdefby/.notdefthe/.notdefHolter/.notdefmethod/.notdefor/.notdeffrom/.notdefextracted/.notdefECGs/.notdefand/.notdefrimonabant/.notdefplasma/.notdefconcentrations./.notdef/.notdef PK/PD A/.notdefrelationship/.notdefbetween/.notdefweight/.notdefdecrease/.notdefand/.notdefconcentration/.notdefwas/.notdefshown./.notdefThe/.notdefvariability/.notdefin/.notdefweight/.notdefreduction/.notdef was/.notdefvery/.notdeflarge./.notdefThe/.notdefrelationship/.notdefbetween/.notdefexposure/.notdefand/.notdefweight/.notdefreduction/.notdefwas/.notdefanalysed/.notdefin/.notdefdifferent/.notdefPK/PD/.notdef models./.notdef With/.notdef a/.notdef Hill/.notdef model,/.notdef E max /.notdef was/.notdef estimated/.notdef to/.notdef be/.notdef about/.notdef 6.5/.notdef kg/.notdef and/.notdef AUC 50 /.notdef 1530/.notdef ng GLYPH&lt;2&gt; h/ml./.notdef With/.notdef the/.notdef exposure/.notdefobtained/.notdefwith/.notdef20/.notdefmg/.notdefq.d./.notdef(AUC/.notdef3800/.notdefng GLYPH&lt;2&gt; h/ml)/.notdefa/.notdeflarge/.notdefpart/.notdefof/.notdefthe/.notdefpatients/.notdefwere/.notdefat/.notdefthe/.notdefflat/.notdefpart/.notdefof/.notdef the/.notdefconcentration/.notdefresponse/.notdefcurve/.notdefsupporting/.notdefthe/.notdefchosen/.notdefdose./.notdef/.notdef Clinical/.notdefefficacy/.notdef/.notdef The/.notdef clinical/.notdef dossier/.notdef comprised/.notdef of/.notdef two/.notdef parts,/.notdef one/.notdef concerning/.notdef obesity/.notdef and/.notdef related/.notdef disorders/.notdef (Obesity/.notdef program),/.notdefand/.notdefone/.notdefconcerning/.notdefsmoking/.notdefcessation./.notdefThese/.notdefwill/.notdefbe/.notdefdiscussed/.notdefseparately./.notdef OBESITY/.notdef In/.notdefsupport/.notdefof/.notdefthe/.notdefefficacy/.notdefof/.notdefrimonabant/.notdefin/.notdefthe/.notdeftreatment/.notdefof/.notdefobesity/.notdefand/.notdefrelated/.notdefdisorders/.notdefsix/.notdefstudies/.notdefwere/.notdef submitted:/.notdef1/.notdef dose-ranging/.notdefstudy/.notdef(DRI3388;/.notdefbased/.notdefon/.notdefthe/.notdefresults/.notdefof/.notdefthis/.notdef study/.notdef the/.notdef 5/.notdef mg/.notdef and/.notdef 20/.notdef mg/.notdef doses/.notdef were/.notdef selected/.notdef for/.notdef Phase/.notdef III/.notdef studies);/.notdef 1/.notdef study/.notdef investigating/.notdef the/.notdef effect/.notdef of/.notdef 40/.notdef mg/.notdef of/.notdef rimonabant/.notdef versus/.notdef placebo/.notdef on/.notdef energy/.notdef expenditure/.notdef and/.notdef food/.notdef intake/.notdef (PDY3796);/.notdef 4/.notdef adequate/.notdef and/.notdef well-controlled/.notdef Phase/.notdef III/.notdef studies,/.notdef RIO-North/.notdef America/.notdef (EFC4743),/.notdef RIO-Europe/.notdef (EFC4733),/.notdef RIO-Lipids/.notdef (EFC4735),/.notdef and/.notdef RIODiabetes/.notdef (EFC4736)/.notdef were/.notdef conducted/.notdef to/.notdef demonstrate/.notdef the/.notdef efficacy/.notdef and/.notdef safety/.notdef of/.notdef 2/.notdef doses/.notdef of/.notdef rimonabant/.notdef 5/.notdef

/.notdef

/.notdef

/.notdef

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

|                                          | /.notdef                                                                          | Placebo/.notdef N,/.notdefmean,/.notdef(SD)/.notdef                                       | SR/.notdef5/.notdefmg/.notdef N,/.notdefmean,/.notdef(SD)/.notdef   | SR/.notdef10/.notdefmg/.notdef N,/.notdefmean,/.notdef(SD)/.notdef SR/.notdef20/.notdefmg/.notdef N,/.notdefmean,/.notdef(SD)/.notdef   |
|------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Mean/.notdef Change/.notdef (kg)/.notdef | Week/.notdef16,/.notdefEE/.notdefpop/.notdef                                      | 40,/.notdef-1.1/.notdef(2.7)/.notdef/.notdef 45,/.notdef-3.4/.notdef(4.2)/.notdef/.notdef | 39,/.notdef-3.7/.notdef(3.4)/.notdef/.notdef                        | 51,/.notdef-4.5/.notdef(3.6)/.notdef                                                                                                    |
| Mean/.notdef Change/.notdef (kg)/.notdef | LOCF,/.notdefITT/.notdef                                                          | 70,/.notdef-0.5/.notdef(3.7)/.notdef 61,/.notdef-2.5/.notdef(4.2)/.notdef                 | 66,/.notdef-2.7/.notdef(3.3)/.notdef                                | 68,/.notdef-3.8/.notdef(3.7)/.notdef                                                                                                    |
| Percent/.notdef change/.notdef           | Week/.notdef16,/.notdefEE/.notdefpop/.notdef 40,/.notdef-1.2/.notdef(2.8)/.notdef | 45,/.notdef-3.6/.notdef(4.2)/.notdef                                                      | 39,/.notdef-4.0/.notdef(3.5)/.notdef                                | 51,/.notdef-4.8/.notdef(4.1)/.notdef                                                                                                    |
| Percent/.notdef change/.notdef           | LOCF,/.notdefITT/.notdef 70,/.notdef-0.6/.notdef(3.5)/.notdef                     | 61,/.notdef-2.6/.notdef(4.3)/.notdef                                                      | 66,/.notdef-2.8/.notdef(3.3)/.notdef                                | 68,/.notdef-4.0/.notdef(4.1)/.notdef                                                                                                    |

/.notdef

/.notdef

/.notdef

<!-- image -->

Medicinal product no longer authorised mg/.notdef and/.notdef 20/.notdef mg/.notdef versus/.notdef placebo./.notdef This/.notdef clinical/.notdef development/.notdef program/.notdef was/.notdef designed/.notdef in/.notdef accordance/.notdef with/.notdef the/.notdef clinical/.notdefdevelopment/.notdefguidelines/.notdefof/.notdefdrugs/.notdefin/.notdefobesity,/.notdefboth/.notdefin/.notdefEurope/.notdefand/.notdefin/.notdefthe/.notdefUSA./.notdef · Dose/.notdefresponse/.notdefstudies/.notdef The/.notdef PDY3796/.notdef study/.notdef was/.notdef as/.notdef a/.notdef double-blind,/.notdef parallel/.notdef group,/.notdef placebo-controlled/.notdef exploratory/.notdef study/.notdef of/.notdef the/.notdef effects/.notdef of/.notdef 4-week/.notdef of/.notdef rimonabant/.notdef 40/.notdef mg/.notdef daily/.notdef on/.notdef energy/.notdef expenditure/.notdef (primary/.notdef endpoint)/.notdef and/.notdef food/.notdef consumption/.notdefin/.notdef45/.notdefobese/.notdefvolunteers./.notdefThe/.notdefpatients/.notdefwere/.notdefnot/.notdefon/.notdefa/.notdefrestrictive/.notdefdiet,/.notdefand/.notdefthe/.notdefpharmacodynamic/.notdef activity/.notdef of/.notdef rimonabant/.notdef was/.notdef assessed/.notdef primarily/.notdef by/.notdef measuring/.notdef total/.notdef energy/.notdef expenditure/.notdef in/.notdef a/.notdef calorimetric/.notdef chamber./.notdefEnergy/.notdefintake/.notdefwas/.notdefmeasured/.notdefat/.notdefbaseline/.notdefand/.notdefendpoint/.notdefin/.notdefbuffet/.notdefsessions/.notdefand/.notdefthe/.notdefamount/.notdefof/.notdeffood/.notdef consumed/.notdefby/.notdefthe/.notdef patients/.notdef who/.notdef were/.notdef offered/.notdef a/.notdef cold/.notdef buffet-like/.notdef meal/.notdef at/.notdef noon./.notdef Compared/.notdef with/.notdef placebo,/.notdef40/.notdef mg/.notdef rimonabant/.notdefreduced/.notdefthe/.notdefmean/.notdeftotal/.notdefenergy/.notdefintake/.notdefand/.notdef the/.notdef mean/.notdef energy/.notdef intake/.notdef from/.notdefcarbohydrate/.notdefand/.notdef fat./.notdefBody/.notdefweight/.notdefdecreased/.notdefby/.notdef-4.3/.notdef±/.notdef1.8/.notdefkg/.notdefin/.notdefthe/.notdef40/.notdefmg/.notdefgroup/.notdefversus/.notdef-1.7/.notdef±/.notdef1.7/.notdefkg/.notdefin/.notdefthe/.notdefplacebo/.notdefgroup/.notdef at/.notdefweek/.notdef6/.notdeffollow-up/.notdefvisit./.notdefNo/.notdefsignificant/.notdefdifference/.notdefin/.notdefenergy/.notdefexpenditure/.notdefwas/.notdefseen/.notdefbetween/.notdefthe/.notdeftreatment/.notdef groups./.notdef The/.notdef DRI3388/.notdef study/.notdef was/.notdef the/.notdef principal/.notdef clinical/.notdef dose/.notdef ranging/.notdef study/.notdef in/.notdef treatment/.notdef of/.notdef obesity/.notdef and/.notdef was/.notdef performed/.notdef as/.notdef a/.notdef double-blind,/.notdef placebo-controlled/.notdef study/.notdef evaluating/.notdef the/.notdef efficacy/.notdef and/.notdef safety/.notdef of/.notdef 3/.notdef doses/.notdef of/.notdef rimonabant/.notdef in/.notdef 287/.notdef obese/.notdef patients/.notdef (30/.notdef kg/m 2 GLYPH&lt;3&gt; BMI GLYPH&lt;3&gt; 40/.notdef kg/m 2 )/.notdef over/.notdef 16/.notdef weeks./.notdef Patients/.notdef were/.notdef randomly/.notdef allocated/.notdef to/.notdef 5,/.notdef 10/.notdef or/.notdef 20/.notdef mg/day/.notdef of/.notdef rimonabant/.notdef or/.notdef placebo/.notdef after/.notdef a/.notdef 2-week/.notdef single-blind/.notdef placebo/.notdef run-in/.notdef period/.notdefand/.notdefa/.notdefmodest/.notdefhypocaloric/.notdef(-500/.notdefkcal/day)/.notdefdiet./.notdefThe/.notdefprimary/.notdefefficacy/.notdefoutcome/.notdefwas/.notdefassessed/.notdefby/.notdefthe/.notdef mean/.notdefchange/.notdefin/.notdefbody/.notdefweight/.notdefin/.notdefboth/.notdefthe/.notdefintention-to-treat/.notdef(ITT;/.notdef265/.notdefpatients)/.notdefand/.notdefefficacy/.notdefevaluable/.notdef(EE)/.notdef (175/.notdefpatients)/.notdefpopulations./.notdefThe/.notdefITT/.notdefcorresponded/.notdefto/.notdefall/.notdefpatients/.notdefwho/.notdefwere/.notdefrandomised/.notdefand/.notdeftook/.notdefat/.notdefleast/.notdef1/.notdef dose/.notdef of/.notdef study/.notdef medication:/.notdef The/.notdef EE/.notdef population/.notdef excluded/.notdef ITT/.notdef patients/.notdef who/.notdef had/.notdef 1/.notdef or/.notdef more/.notdef major/.notdef protocol/.notdef violations/.notdefand/.notdef those/.notdef who/.notdef failed/.notdef to/.notdef complete/.notdef their/.notdef prescribed/.notdef dosing./.notdef A/.notdef significant/.notdef treatment/.notdef effect/.notdef of/.notdef all/.notdef doses/.notdef of/.notdef rimonabant/.notdef was/.notdef observed/.notdef with/.notdef 20-34%/.notdef of/.notdef patients/.notdef on/.notdef rimonabant/.notdef losing/.notdef GLYPH&lt;1&gt; 5%/.notdef of/.notdef their/.notdef baseline/.notdef body/.notdef weight,/.notdef compared/.notdef with/.notdef 7%/.notdef in/.notdef the/.notdef placebo/.notdef group/.notdef (p/.notdef =/.notdef 0.0395/.notdef for/.notdef 5/.notdef mg,/.notdef 0.0045/.notdef for/.notdef 10/.notdef mg,/.notdef and/.notdef p/.notdef =/.notdef 0.0001/.notdeffor/.notdef20/.notdefmg,/.notdefrespectively);/.notdefsee/.notdefTable/.notdef1/.notdefbelow./.notdef Table/.notdef1:/.notdefStudy/.notdefDRI3388,/.notdefweight/.notdefreduction/.notdefafter/.notdef16/.notdefweeks/.notdefof/.notdeftreatment,/.notdef(rimonabant=SR)/.notdef · Main/.notdefstudies METHODS/.notdef Four/.notdef phase/.notdef III/.notdef clinical/.notdef trials/.notdef were/.notdef conducted/.notdef in/.notdef the/.notdef treatment/.notdef of/.notdef obesity/.notdef and/.notdef obesity-related/.notdef metabolic/.notdef disorders./.notdef(See/.notdefTable/.notdef2/.notdefbelow.)/.notdef The/.notdef studies/.notdef were/.notdef double-blind,/.notdef placebo-controlled/.notdef with/.notdef 3/.notdef parallel/.notdef treatment/.notdef groups/.notdef (20/.notdef mg/.notdef or/.notdef 5/.notdef mg/.notdef of/.notdef rimonabant/.notdefor/.notdefplacebo);/.notdefthey/.notdefhad/.notdefthe/.notdefsame/.notdefprimary/.notdefendpoint/.notdefand/.notdefsimilar/.notdefsecondary/.notdefendpoints/.notdef(adapted/.notdefto/.notdef the/.notdef specific/.notdef population/.notdef recruited/.notdef in/.notdef a/.notdef given/.notdef study/.notdef and/.notdef the/.notdef tests/.notdef performed);/.notdef the/.notdef same/.notdef inclusion/.notdef and/.notdef exclusion/.notdef criteria/.notdef were/.notdef used/.notdef (except/.notdef for/.notdef those/.notdef to/.notdef define/.notdef specific/.notdef populations);/.notdef the/.notdef scheduled/.notdef visits/.notdef were/.notdef planned/.notdefat/.notdefthe/.notdefsame/.notdeftime/.notdefpoints./.notdef

/.notdef

/.notdef

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

| Study/.notdef                                                                                                                                                        | Number/.notdef of/.notdef study/.notdef centers/.notdef                                                                                                                               | Treatment/.notdefarms/.notdef                                                                                                                                                          | Number/.notdef of/.notdef patients/.notdef entered//.notdef completed/.notdef   | Treatment/.notdef Duration/.notdef   | Diagnosis,/.notdef Inclusion/.notdefcriteria/.notdef                                                                                                                                                                                                                                                   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| EFC4743/.notdef RIO-North/.notdef America/.notdef Year/.notdef1/.notdef /.notdef                                                                                     | 72/.notdef USA,/.notdef Canada/.notdef                                                                                                                                                | Rimonabant/.notdef5/.notdefmg/.notdef Rimonabant/.notdef20/.notdefmg/.notdef Placebo/.notdef                                                                                           | 1214/620/.notdef 1219/673/.notdef 607/309/.notdef                               | 52/.notdefweeks/.notdef              | BMI/.notdef GLYPH<1> 30/.notdefkg/m²/.notdef or/.notdefBMI>27/.notdefkg/m²/.notdef with/.notdefhypertension a /.notdef and/or/.notdefdyslipidaemia b ./.notdef Stable/.notdefbody/.notdefweight./.notdef Dietary/.notdefrestrictions./.notdef Type/.notdef2/.notdefdiabetes/.notdef excluded./.notdef  |
| Year/.notdef2/.notdef Re-randomisation/.notdef of/.notdefactive/.notdef treatment/.notdef groups/.notdefto/.notdefsame/.notdef dose/.notdefor/.notdefplacebo/.notdef | Year/.notdef2/.notdef Re-randomisation/.notdef of/.notdefactive/.notdef treatment/.notdef groups/.notdefto/.notdefsame/.notdef dose/.notdefor/.notdefplacebo/.notdef                  | Rimonabant/.notdef5/.notdefmg/Placebo/.notdef Rimonabant/.notdef5/5/.notdefmg/.notdef Rimonabant20mg/Placebo/.notdef Rimonabant/.notdef20/20/.notdefmg/.notdef Placebo/Placebo/.notdef | 300/210/.notdef 300/215/.notdef 326/225/.notdef 333/257/.notdef 298/214/.notdef | 52/.notdefweeks/.notdef              | Patients/.notdeffrom/.notdef Year/.notdef1/.notdefwho/.notdef achieved/.notdef1/.notdefyear/.notdefof/.notdef treatment./.notdef                                                                                                                                                                       |
| EFC4733/.notdef RIO-Europe/.notdef                                                                                                                                   | 60/.notdef Belgium,/.notdef Finland,/.notdef France,/.notdef Germany,/.notdef Netherlands Sweden,/.notdef USA/.notdef                                                                 | Rimonabant/.notdef5/.notdefmg/.notdef Rimonabant/.notdef20/.notdefmg/.notdef Placebo/.notdef                                                                                           | no longer 603/379/288/.notdef 599/363/268/.notdef 305/178/128/.notdef           | 104/.notdefweeks/.notdef             | BMI/.notdef GLYPH<1> 30/.notdefkg/m²/.notdef or/.notdefBMI>27/.notdefkg/m²/.notdef with/.notdefhypertension a /.notdef and/or/.notdef dyslipidaemia b. /.notdef Stable/.notdefbody/.notdefweight./.notdef Dietary/.notdefrestrictions./.notdef Type/.notdef2/.notdefdiabetes/.notdef excluded./.notdef |
| EFC4735/.notdef RIO-Lipids/.notdef                                                                                                                                   | 67/.notdef Australia/.notdef Finland,/.notdef Italy,/.notdef Spain,/.notdef Sweden,/.notdef Switzerland Canada,/.notdef USA/.notdef                                                   | product Rimonabant/.notdef5/.notdefmg/.notdef Rimonabant/.notdef20/.notdefmg/.notdef Placebo/.notdef                                                                                   | 345/208/.notdef 346/221/.notdef 342/214/.notdef /.notdef                        | 52/.notdefweeks/.notdef              | BMI/.notdef>27/.notdefkg/m²/.notdefand/.notdef GLYPH<3> 40/.notdefkg/m²./.notdef Untreated/.notdef Dyslipidaemia c ./.notdef Stable/.notdefbody/.notdefweight./.notdef Dietary/.notdefrestrictions./.notdef Type/.notdef2/.notdefdiabetes/.notdef excluded./.notdef                                    |
| EFC4736/.notdef RIO- Diabetes/.notdef                                                                                                                                | 159/.notdef Belgium,/.notdef Czech/.notdefRep.,/.notdef France,/.notdef Poland,/.notdef Germany,/.notdef Netherlands/.notdef Finland,/.notdef UK,/.notdef USA,/.notdef Canada/.notdef | Rimonabant/.notdef5/.notdefmg/.notdef Rimonabant/.notdef20/.notdefmg/.notdef Placebo/.notdef                                                                                           | 358/232/.notdef 339/229/.notdef 348/231/.notdef /.notdef                        | 52/.notdefweeks/.notdef              | BMI/.notdef>27/.notdefkg/m²/.notdefand/.notdef GLYPH<3> 40/.notdefkg/m²./.notdef Treated/.notdeftype/.notdef2/.notdef Diabetes d ./.notdef Stable/.notdefbody/.notdefweight./.notdef Dietary/.notdefrestrictions./.notdef                                                                              |

Medicinal product no longer authorised Study/.notdefparticipants,/.notdeftreatments/.notdef Table/.notdef2:/.notdefSummary/.notdefof/.notdefthe/.notdeffour/.notdefmain/.notdefstudies/.notdefin/.notdefthe/.notdefobesity-related/.notdefindications/.notdef a drug-treated/.notdeffor/.notdefhypertension/.notdefand/or/.notdefBP/.notdef GLYPH&lt;1&gt; /.notdef140/.notdefand/or/.notdef90/.notdefmmHg b drug-treated/.notdeffor/.notdefdyslipidaemia/.notdefand/orLDL-cholesterol/.notdef GLYPH&lt;1&gt; /.notdef 3.36/.notdefmmol/L/.notdefand/or/.notdefHDL-cholesterol/.notdef&lt;1.03/.notdefmmol/L/.notdefand/or/.notdef triglyceridemia/.notdef GLYPH&lt;1&gt; 1.69/.notdefmmol/L /.notdef c low/.notdef HDL-C/.notdef defined/.notdef by/.notdef the/.notdef total-C/HDL-C/.notdef ratio/.notdef &gt;4.5/.notdef in/.notdef women/.notdef or/.notdef &gt;5/.notdef in/.notdef men/.notdef and/or/.notdef elevated/.notdef TG/.notdef (TG/.notdef &gt;1.69/.notdef mmol/L),/.notdefand/.notdefwho/.notdefwere/.notdefnot/.notdefreceiving/.notdefdrug/.notdeftreatment/.notdeffor/.notdeftheir/.notdefabnormal/.notdeflipid/.notdefprofile./.notdef d treatment/.notdefwith/.notdefbiguanides/.notdef or /.notdefsulfonylureas/.notdef

/.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

| Efficacy/.notdef parameters/.notdef   | EFC4743/.notdef RIO-North/.notdefAmerica/.notdef                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | EFC4733/.notdef RIO-Europe/.notdef                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | EFC4735/.notdef RIO-Lipids/.notdef                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | EFC4736/.notdef RIO-Diabetes/.notdef                                                                                                                                                                                                                                                                                    |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary/.notdef                       | Weight/.notdefloss/.notdef and/.notdefweight/.notdef maintenance/.notdefover/.notdefa/.notdef period/.notdefof/.notdefone/.notdefyear/.notdef /.notdef Prevention/.notdefof/.notdef weight/.notdefregain/.notdefduring/.notdefa/.notdef second/.notdefyear/.notdefof/.notdef treatment/.notdefin/.notdef obese/.notdefpatients/.notdefwith/.notdefor/.notdef without/.notdefcomorbidities/.notdef                                                                                                                                     | Weight/.notdefloss/.notdefand/.notdef weight/.notdefmaintenance/.notdef over/.notdefa/.notdefperiod/.notdefof/.notdefone/.notdef year./.notdef                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | longer Weight/.notdefloss/.notdefand/.notdef weight/.notdefmaintenance/.notdef over/.notdefa/.notdefperiod/.notdefof/.notdefone/.notdef year./.notdef                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Weight/.notdefloss/.notdefand/.notdef weight/.notdefmaintenance/.notdef over/.notdefa/.notdefperiod/.notdefof/.notdefone/.notdef year./.notdef                                                                                                                                                                          |
| Secondary/.notdef                     | The/.notdefeffect/.notdefover/.notdefa/.notdef period/.notdefof/.notdef2/.notdefyears/.notdefon:/.notdef -Weight/.notdefmaintenance/.notdef -Hypertension/.notdef/.notdef -Dyslipidaemia/.notdef/.notdef -Quality/.notdefof/.notdeflife/.notdef -Safety/.notdefand/.notdef tolerability/.notdef/.notdef -Withdrawal-emergent/.notdef disorders/.notdefin/.notdef obese/.notdefpatients/.notdefwho/.notdef are/.notdefre-randomized/.notdefto/.notdef placebo/.notdefafter/.notdefone/.notdefyear/.notdef of/.notdeftreatment./.notdef | product no The/.notdefeffect/.notdefover/.notdefa/.notdef period/.notdefof/.notdef2/.notdefyears/.notdefon:/.notdef -Weight/.notdefloss/.notdefand/.notdef weight/.notdefmaintenance/.notdef -Hypertension/.notdef -Dyslipidaemia/.notdef -Glucose/.notdeftolerance/.notdef status/.notdef(OGTT):/.notdefrate/.notdefof/.notdef deterioration/.notdefof/.notdef glucose/.notdeftolerance/.notdef status,/.notdefrate/.notdefof/.notdef improvement/.notdefof/.notdef glucose/.notdeftolerance/.notdef status/.notdef -Fasting/.notdefblood/.notdef glucose/.notdefand/.notdefinsulin/.notdef -Quality/.notdefof/.notdeflife,/.notdef satisfaction,/.notdeffood/.notdef behaviour/.notdef -Food/.notdefintake/.notdefand/.notdef compliance/.notdefto/.notdefdietary/.notdef prescription./.notdef | The/.notdefeffect/.notdefover/.notdefa/.notdef period/.notdefof/.notdef1/.notdefyear/.notdefon:/.notdef -Dyslipidaemia/.notdef (triglycerides,/.notdefHDL- C,/.notdefLDL-C,/.notdefsmall/.notdef dense/.notdefLDL/.notdefparticles/.notdef and/.notdefother/.notdeflipid/.notdef parameters)/.notdef/.notdef -Hypertension,/.notdef -Glucose/.notdeftolerance/.notdef status/.notdef(OGTT):/.notdefrate/.notdefof/.notdef progression/.notdefto/.notdefthe/.notdef development/.notdefof/.notdef impaired/.notdefglucose/.notdef tolerance/.notdefand/.notdeftype/.notdef2/.notdef diabetes,/.notdefrate/.notdefof/.notdef improvement/.notdefof/.notdef glucose/.notdeftolerance/.notdef status./.notdef -Fasting/.notdefglycemia/.notdefand/.notdef insulinemia/.notdef -Quality/.notdefof/.notdeflife,/.notdef satisfaction,/.notdefhunger/.notdef scale./.notdef -Food/.notdefintake/.notdefand/.notdef compliance/.notdefto/.notdefdietary/.notdef prescription./.notdef | The/.notdefeffect/.notdefover/.notdefa/.notdef period/.notdefof/.notdef1/.notdefyear/.notdefon:/.notdef -Glycemic/.notdefcontrol/.notdef/.notdef -Hypertension/.notdef -Dyslipidaemia/.notdef/.notdef -Quality/.notdefof/.notdeflife/.notdef/.notdef -The/.notdefsafety/.notdefand/.notdef tolerability/.notdef/.notdef |

/.notdef

Medicinal product no longer authorised The/.notdef main/.notdef exclusion/.notdef criteria/.notdef were/.notdef standard/.notdef for/.notdef phase/.notdef III/.notdef studies,/.notdef i.e./.notdef any/.notdef severe/.notdef medical/.notdef condition/.notdef that/.notdef would/.notdef interfere/.notdef with/.notdef the/.notdef participation/.notdef of/.notdef the/.notdef patient/.notdef in/.notdef long-term/.notdef studies/.notdef (including/.notdef presence/.notdef of/.notdef any/.notdef clinically/.notdefsignificant/.notdefcardiovascular/.notdefor/.notdefpulmonary/.notdefdisease/.notdefaccording/.notdefto/.notdefthe/.notdefinvestigator,/.notdefhistory/.notdefof/.notdefstroke/.notdef within/.notdef six/.notdef months/.notdef prior/.notdef to/.notdef screening/.notdef visit,/.notdef presence/.notdef of/.notdef treated/.notdef epilepsy,/.notdef presence/.notdef of/.notdef any/.notdef clinically/.notdef significant/.notdefhepatic/.notdefor/.notdefgastrointestinal/.notdefdisease/.notdefaccording/.notdefto/.notdefthe/.notdefinvestigator,/.notdefcreatininemia/.notdef&gt;/.notdef150/.notdefµ mol/L),/.notdef concomitant/.notdef drugs/.notdef that/.notdef would/.notdef have/.notdef any/.notdef impact/.notdef on/.notdef body/.notdef weight,/.notdef patients/.notdef with/.notdef DSM-IV/.notdef defined/.notdef eating/.notdef disorders,/.notdefpatients/.notdefwith/.notdefa/.notdefhistory/.notdefof/.notdefsevere/.notdefdepression./.notdef/.notdef Outcomes/.notdefand/.notdefendpoints/.notdef The/.notdefprimary/.notdefand/.notdefsecondary/.notdefefficacy/.notdefparameters/.notdefare/.notdefsummarised/.notdefin/.notdefTable/.notdef3/.notdefbelow./.notdef Table/.notdef3:/.notdefSummary/.notdefof/.notdefprimary/.notdefand/.notdefsecondary/.notdefefficacy/.notdefparameters,/.notdefmain/.notdefstudies/.notdef

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised In/.notdef the/.notdef CHMP/.notdefguideline/.notdefon/.notdefdrugs/.notdefused/.notdefin/.notdefweight/.notdefcontrol/.notdefa/.notdefweight/.notdefloss/.notdefof/.notdef10/.notdef%/.notdefis/.notdefconsidered/.notdefto/.notdefbe/.notdefa/.notdefvalid/.notdef primary/.notdefefficacy/.notdefcriterion./.notdefSuch/.notdefresponder/.notdefanalyses/.notdefwere/.notdefincluded/.notdefas/.notdefsecondary/.notdefefficacy/.notdefparameters/.notdefin/.notdefthe/.notdef RIO-programme./.notdefSleep/.notdefapnoea/.notdefepisodes/.notdefwere/.notdefnot/.notdefrecorded./.notdef The/.notdef prevalence/.notdefof/.notdefmetabolic/.notdefsyndrome/.notdefwas/.notdefanalysed/.notdefin/.notdefthe/.notdefpooled/.notdefpopulation/.notdeffrom/.notdefthe/.notdeffour/.notdefstudies./.notdefThe/.notdef criteria/.notdefrecommended/.notdefby/.notdefthe/.notdefNational/.notdefCholesterol/.notdefEducation/.notdefProgram-/.notdefAdult/.notdefTreatment/.notdefPanel/.notdefIII/.notdef(NCEPATPIII)/.notdef were/.notdef used/.notdef (ie,/.notdef waist/.notdef circumference/.notdef &gt;88/.notdef cm/.notdef in/.notdef females/.notdef or/.notdef &gt;102/.notdef cm/.notdef in/.notdef males,/.notdef HDL-C&lt;1.295/.notdef mmol/L/.notdef in/.notdef females/.notdef or/.notdef &lt;1.036/.notdef mmol/L/.notdef in/.notdef males,/.notdef TG GLYPH&lt;1&gt; 1.69/.notdef mmol/L,/.notdef systolic/.notdef blood/.notdef pressure/.notdef (SBP)/.notdef GLYPH&lt;1&gt; 130/.notdef mmHg,/.notdefdiastolic/.notdefblood/.notdefpressure/.notdef(DBP)/.notdef GLYPH&lt;1&gt; 85/.notdefmmHg,/.notdeffasting/.notdefglucose/.notdef GLYPH&lt;1&gt; 6.11/.notdefmmol/L)/.notdefand/.notdefthe/.notdefpercentages/.notdefof/.notdef patients/.notdefhaving/.notdefat/.notdefleast/.notdef3/.notdefout/.notdefof/.notdefthe/.notdef5/.notdefcriteria/.notdefof/.notdefthe/.notdefmetabolic/.notdefsyndrome/.notdefat/.notdefendpoint/.notdefwere/.notdefcompared./.notdef/.notdef Objectives/.notdef Objective/.notdefof/.notdefall/.notdef4/.notdefstudies/.notdefwas/.notdefto/.notdefestablish/.notdefthe/.notdeflong-term/.notdefefficacy/.notdefand/.notdefsafety/.notdefof/.notdefrimonabant/.notdefin/.notdefthe/.notdeftreatment/.notdef of/.notdefobesity/.notdefand/.notdefobesity-related/.notdefmetabolic/.notdefdisorders./.notdef Sample/.notdefsize/.notdef In/.notdef order/.notdef to/.notdef have/.notdef sufficient/.notdef power/.notdef to/.notdef detect/.notdef a/.notdef statistical/.notdef significant/.notdef difference/.notdef between/.notdef placebo/.notdef and/.notdef rimonabant,/.notdefthe/.notdeftotal/.notdefnumber/.notdefof/.notdef subjects/.notdefneeded/.notdefwas/.notdef1400/.notdef subjects/.notdefin/.notdef RIO-Europe/.notdef(difference/.notdefin/.notdefweight/.notdef loss/.notdefbetween/.notdefrimonabant/.notdefand/.notdefplacebo/.notdefafter/.notdefone/.notdefyear/.notdef3/.notdefkg,/.notdefSD=/.notdef10/.notdefkg,/.notdef α /.notdef=/.notdef0.025,/.notdefpower/.notdef=/.notdef0.96,/.notdef30%/.notdefdropout/.notdef rate),/.notdef 990/.notdef subjects/.notdef in/.notdef RIO-Lipids/.notdef and/.notdef RIO-Diabetes/.notdef (difference/.notdef in/.notdef weight/.notdef loss/.notdef between/.notdef rimonabant/.notdef placebo/.notdefafter/.notdefone/.notdefyear/.notdef3/.notdefkg,/.notdefSD=/.notdef10/.notdefkg,/.notdef α /.notdef=/.notdef 0.025,/.notdefpower/.notdef=/.notdef0.96,/.notdef30%/.notdefdrop-out/.notdefrate),/.notdefand/.notdef2800/.notdefsubjects/.notdef in/.notdef RIO-North-America/.notdef (first/.notdef year/.notdef analysis:/.notdef 560/.notdef subjects/.notdef in/.notdef the/.notdef placebo/.notdef arm/.notdef and/.notdef 1120/.notdef subjects/.notdef in/.notdef the/.notdef rimonabant/.notdefarms;/.notdefdifference/.notdefin/.notdefweight/.notdefafter/.notdefone/.notdefyear/.notdefbetween/.notdefrimonabant/.notdefand/.notdefplacebo/.notdef3/.notdefkg,/.notdefSD/.notdef=/.notdef10/.notdefkg,/.notdef two-sided/.notdef α /.notdef =/.notdef 0.025,/.notdef power/.notdef =/.notdef 0.99,/.notdef 34%/.notdef drop-out/.notdef rate;/.notdef second/.notdef year/.notdef analysis/.notdef 740/.notdef subjects/.notdef in/.notdef each/.notdef rerandomised/.notdefarm;/.notdefdifference/.notdefin/.notdefweight/.notdefgain/.notdefafter/.notdef2/.notdefyears/.notdef2.5/.notdefkg,/.notdefSD/.notdef=/.notdef10/.notdefkg,/.notdeftwo-sided/.notdef α /.notdef=/.notdef0.025,/.notdefpower/.notdef=/.notdef 0.88)./.notdef/.notdef Randomisation,/.notdefBlinding/.notdef(masking)/.notdef After/.notdef a/.notdef 4-week/.notdef run-in/.notdef period/.notdef on/.notdef diet,/.notdef subjects/.notdef compliant/.notdef to/.notdef dietary/.notdef instruction/.notdef and/.notdef treatment/.notdef were/.notdef randomised/.notdef to/.notdef placebo,/.notdef rimonabant/.notdef 5/.notdef mg/.notdef or/.notdef rimonabant/.notdef 20/.notdef mg./.notdef Blinding/.notdef was/.notdef ensured/.notdef by/.notdef identical/.notdef capsules/.notdef and/.notdef standard/.notdef operational/.notdef procedures./.notdef Duration/.notdef of/.notdef the/.notdef double-blind/.notdef period/.notdef was/.notdef 1/.notdef or/.notdef 2/.notdef years./.notdef In/.notdef RIO-North-America/.notdefsubjects/.notdefwere/.notdefre-randomised/.notdefafter/.notdefone/.notdefyear./.notdef Randomisation/.notdefwas/.notdefperformed/.notdefcentrally./.notdefIn/.notdefRIO-North-America/.notdefand/.notdefRIO-Europe/.notdefrandomisation/.notdefratio/.notdefwas/.notdef 1:2:2/.notdeffor/.notdefthe/.notdefplacebo,/.notdef5/.notdefmg/.notdefand/.notdef20/.notdefmg/.notdefarm/.notdefrespectively./.notdefIn/.notdefRIO-/Lipids/Diabetes/.notdefthe/.notdefrandomisation/.notdefratio/.notdef was/.notdef 1:1:1./.notdef Randomisation/.notdef was/.notdef stratified/.notdef by/.notdef degree/.notdef of/.notdef weight/.notdef loss/.notdef in/.notdef the/.notdef screening/.notdef phase/.notdef on/.notdef diet/.notdef alone/.notdef (less/.notdef that/.notdef 2/.notdef kg/.notdef weight/.notdef loss/.notdef versus/.notdef more/.notdef than/.notdef2/.notdefkg/.notdefweight/.notdefloss)./.notdefAdditional/.notdefstratification/.notdeffactors/.notdefwere/.notdefTGstatus/.notdef( ≤ /.notdef4.0/.notdef g/l/.notdef versus/.notdef &gt;4.0/.notdef g/l)/.notdef in/.notdef RIO-Lipids/.notdef and/.notdefanti-diabetic/.notdeftreatment/.notdef(biguanides/.notdefvs./.notdefsulfonylureas)/.notdef in/.notdefRIO-Diabetes./.notdef/.notdef In/.notdef RIO-North-America/.notdef subjects/.notdef in/.notdef the/.notdef rimonabant/.notdef arms/.notdef were/.notdef re-randomised/.notdef to/.notdef placebo/.notdef or/.notdef to/.notdef the/.notdef same/.notdef dose/.notdef of/.notdef rimonabant/.notdef after/.notdef one/.notdef year./.notdef Patients/.notdef initially/.notdef randomised/.notdef in/.notdef the/.notdef placebo/.notdef group/.notdef remained/.notdef on/.notdef placebo./.notdef After/.notdef re-randomisation/.notdef there/.notdef were/.notdef 5/.notdef groups/.notdef with/.notdef an/.notdef equal/.notdef number/.notdef of/.notdef patients:/.notdef placebo year/.notdef 1 -placeboyear/.notdef 2, /.notdef 5/.notdefmg/.notdef rimonabantyear/.notdef 1 -placeboyear/.notdef 2 ,/.notdef 5/.notdef mg/.notdef rimonabantyear/.notdef 1 -5/.notdef mg/.notdef rimonabantyear/.notdef 2 ,/.notdef 20/.notdef mg/.notdef rimonabantyear/.notdef1 -placeboyear/.notdef2/.notdef and/.notdef20/.notdefmg/.notdefrimonabant year/.notdef 1 -20/.notdefmg/.notdefrimonabant year/.notdef 2 ./.notdef Weight/.notdefchange/.notdefbetween/.notdef12/.notdefyears/.notdefwas/.notdefto/.notdefbe/.notdefused/.notdefto/.notdefsupport/.notdefthe/.notdefclaim/.notdefof/.notdefreduction/.notdefin/.notdefweight/.notdefregain/.notdefafter/.notdefprior/.notdefweight/.notdefloss./.notdef Statistical/.notdefmethods/.notdef The/.notdef primary/.notdef analysis/.notdef dataset/.notdef was/.notdef the/.notdef intention-to-treat/.notdef (ITT)/.notdef population/.notdef defined/.notdef as/.notdef all/.notdef randomised/.notdef subjects/.notdef who/.notdef received/.notdef at/.notdef least/.notdef one/.notdef dose/.notdef of/.notdef double-blind/.notdef study/.notdef drug,/.notdef had/.notdef at/.notdef least/.notdef one/.notdef post-baseline/.notdef assessment/.notdef and/.notdef a/.notdef baseline/.notdef assessment./.notdef For/.notdef RIO-North-America/.notdef the/.notdef ITT-population/.notdef was/.notdef defined/.notdef for/.notdef 3/.notdef periods/.notdef i.e./.notdef the/.notdef one-year/.notdef intent-to-treat/.notdefpopulation/.notdef (ITT1),/.notdef the/.notdef year/.notdef two/.notdef intent-to-treat/.notdefpopulation/.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

<!-- image -->

| /.notdef                                                                         | RIO-North-America/.notdef                                                                                                                                                                                                        | RIO-Europe/.notdef                                                                                                                                                                                                                                                                                                                                                                                                                        | RIO-Lipids/.notdef                                                                                                                                                                                                                      | RIO-Diabetes/.notdef                                                                                                                                                                                                                   |
|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Confirmative/.notdef end/.notdefpoints /.notdef                                  | /.notdef /.notdef                                                                                                                                                                                                                | /.notdef /.notdef                                                                                                                                                                                                                                                                                                                                                                                                                         | /.notdef /.notdef                                                                                                                                                                                                                       | /.notdef /.notdef /.notdef                                                                                                                                                                                                             |
| /.notdef Primary/.notdef/.notdef /.notdef                                        | /.notdef Body/.notdefweight/.notdefat/.notdef1/.notdefy/.notdef Body/.notdefweight/.notdefregain/.notdefat/.notdef2/.notdefy/.notdef                                                                                             | /.notdef Body/.notdefweight/.notdefat/.notdef1/.notdefy/.notdef /.notdef                                                                                                                                                                                                                                                                                                                                                                  | /.notdef Body/.notdefweight/.notdefat/.notdef1/.notdefy/.notdef /.notdef                                                                                                                                                                | Body/.notdefweight/.notdefat/.notdef1y/.notdef /.notdef                                                                                                                                                                                |
| /.notdef /.notdef /.notdef Secondary/.notdef /.notdef /.notdef /.notdef /.notdef | /.notdef /.notdef %/.notdefchange/.notdefin/.notdefHDL-C/.notdef %/.notdefwith/.notdefmetabolic/.notdefsyndrome/.notdef /.notdef /.notdef                                                                                        | /.notdef /.notdef /.notdef %/.notdefchange/.notdefin/.notdefHDL-C/.notdef %/.notdefchange/.notdefin/.notdefTG/.notdef %/.notdefwith/.notdefimproved/.notdefOGTT/.notdefat/.notdef 1/.notdefyear/.notdef %/.notdefwith/.notdefmetabolic/.notdef syndrome/.notdef                                                                                                                                                                           | longer /.notdef %/.notdefchange/.notdefin/.notdefHDL-C/.notdef %/.notdefchange/.notdefin/.notdefTG/.notdef %/.notdefwith/.notdefimproved/.notdefOGTT /.notdef /.notdef /.notdef %/.notdefwith/.notdefmetabolic/.notdef syndrome/.notdef | /.notdef /.notdef Absolute/.notdefchange/.notdefin/.notdef HbA 1c /.notdef %/.notdefchange/.notdefin/.notdefHDL-C/.notdef %/.notdefchange/.notdefin/.notdefTG/.notdef %/.notdefwith/.notdefmetabolic/.notdef syndrome/.notdef /.notdef |
| Supportive/.notdef endpoints/.notdef /.notdef                                    | /.notdef /.notdef At/.notdef2/.notdefyears:/.notdef/.notdef Weight/.notdefloss/.notdef//.notdef-/.notdefmaintenance/.notdef//.notdef/.notdef Metabolic/.notdefsyndrome/.notdefat/.notdef2/.notdef years/.notdef/.notdef /.notdef | no /.notdef /.notdef /.notdef At/.notdef2/.notdefyears:/.notdef /.notdef Weight/.notdefloss/.notdef//.notdef-maintenance/.notdef //.notdefOGTT/.notdef//.notdef Improved/.notdefOGTT/.notdef//.notdef Metabolic/.notdefsyndrome/.notdef Waist/.notdefcircumference;/.notdefTriglycerides,/.notdefTotal/.notdefcholesterol/HDL-cholesterol/.notdefratio,/.notdefFasting/.notdefglucose,/.notdefFasting/.notdefinsulin,/.notdefOGTT/.notdef | /.notdef TG/.notdefby/.notdefbaseline/.notdefTG/.notdeflevels/.notdef HDL-cholesterol/.notdefby/.notdef baseline/.notdefHDL-cholesterol/.notdef levels/.notdef OGTT/.notdefat/.notdef1/.notdefyear/.notdef                              | /.notdef Reduction/.notdefin/.notdefanti- diabetic/.notdefmedication/.notdef/.notdef                                                                                                                                                   |

/.notdef

/.notdef

/.notdef

<!-- image -->

Medicinal product no longer authorised including/.notdef the/.notdef subjects/.notdef re-randomised/.notdef for/.notdef the/.notdef efficacy/.notdef analysis/.notdef in/.notdef week/.notdef 52/.notdef through/.notdef 104/.notdef (ITT2)/.notdef and/.notdef the/.notdef intent-to-treat/.notdefpopulation/.notdef for/.notdef the/.notdef whole/.notdef two/.notdef year/.notdef study/.notdef period/.notdef (week/.notdef 0-104). /.notdef A/.notdef last/.notdef observation/.notdef carried/.notdef forward/.notdefprocedure/.notdefwas/.notdeffollowed/.notdeffor/.notdefpost/.notdefbaseline/.notdefmissing/.notdefvalues./.notdef/.notdef For/.notdef the/.notdef primary/.notdef endpoint,/.notdef weight/.notdef loss/.notdef at/.notdef one/.notdef year,/.notdef an/.notdef ANOVA/.notdef was/.notdef performed/.notdef with/.notdef treatment/.notdef and/.notdef randomisation/.notdef strata/.notdef as/.notdef fixed/.notdef effects./.notdef Prevention/.notdef of/.notdef weight/.notdef regain/.notdef during/.notdef the/.notdef second/.notdef year,/.notdef the/.notdef other/.notdef primary/.notdef endpoint/.notdef of/.notdef RIO-North-America,/.notdef was/.notdef analysed/.notdef by/.notdef ANCOVA/.notdef with/.notdef treatment/.notdef after/.notdef rerandomisation,/.notdef randomisation/.notdef strata/.notdef as/.notdef fixed/.notdef effects./.notdef Each/.notdef re-randomised/.notdef group/.notdef was/.notdef compared/.notdef to/.notdef their/.notdef corresponding/.notdefplacebo/.notdefgroup./.notdefFor/.notdefthe/.notdefsecondary/.notdefendpoints/.notdefan/.notdefANOVA/.notdefwas/.notdefused/.notdeffor/.notdefcontinuous/.notdefvariables/.notdef and/.notdefa/.notdefChi-square/.notdefor/.notdefFisher's/.notdefexact/.notdeftest/.notdeffor/.notdefcategorical/.notdefsecondary/.notdefvariables./.notdef/.notdef Table/.notdef4: /.notdef Endpoints/.notdef//.notdefanalysis/.notdef//.notdefsubgroups/.notdef The/.notdef confirmatory/.notdef secondary/.notdef endpoints/.notdef were/.notdef intended/.notdef 'to/.notdef be/.notdef used/.notdef as/.notdef part/.notdef of/.notdef a/.notdef formal/.notdef decision/.notdef making/.notdef process/.notdef to/.notdef determine/.notdef a/.notdef regulatory/.notdef claim'. /.notdef A/.notdef hierarchical/.notdeftesting/.notdefstrategy/.notdefwas/.notdefimplemented/.notdefin/.notdefeach/.notdefstudy/.notdef to/.notdef ensure/.notdef a/.notdef global/.notdef type/.notdef 1/.notdef error/.notdef rate/.notdef of/.notdef 5%./.notdef If/.notdef significance/.notdef was/.notdef reached/.notdef for/.notdef weight/.notdef loss/.notdef at/.notdef 1/.notdef year/.notdef then/.notdef the/.notdef next/.notdef confirmatory/.notdef endpoint/.notdef was/.notdef to/.notdef be/.notdef tested/.notdef for/.notdef the/.notdef corresponding/.notdef dose/.notdef at/.notdef a/.notdef 5%/.notdef level./.notdef If/.notdef both/.notdef doses/.notdef reached/.notdef significance/.notdef for/.notdef weight/.notdef loss/.notdef at/.notdef 1/.notdef year/.notdef the/.notdef modified/.notdef Bonferroni/.notdef procedure/.notdef (Hochberg)/.notdef was/.notdef to/.notdef be/.notdef applied/.notdeffor/.notdefthat/.notdefendpoint./.notdef To/.notdef evaluate/.notdefthe/.notdefrelationship/.notdefbetween/.notdefweight/.notdefloss/.notdefand/.notdefsecondary/.notdefendpoints/.notdefan/.notdefanalysis/.notdefof/.notdefcovariance/.notdefwas/.notdef performed/.notdef for/.notdef continuous/.notdef parameters/.notdef and/.notdef a/.notdef logistic/.notdef regression/.notdef model/.notdef for/.notdef categorical/.notdef parameters./.notdef The/.notdef model/.notdefincluded/.notdefweight/.notdefloss/.notdefas/.notdefan/.notdefadditional/.notdefcovariate./.notdef/.notdef For/.notdef the/.notdef intent-to-treat/.notdef population,/.notdef weight/.notdef loss/.notdef at/.notdef one/.notdef year/.notdef and/.notdef weight/.notdef re-gain/.notdef were/.notdef examined/.notdef using/.notdef a/.notdef number/.notdefof/.notdefcovariates/.notdef(including/.notdefage,/.notdefgender,/.notdefrace,/.notdefBMI,/.notdefsmoking/.notdefstatus,/.notdefeducation/.notdefstatus,/.notdefsocio-economic/.notdef status,/.notdefconcomitant/.notdefmedications,/.notdefwaist/.notdefcircumference,/.notdefhistory/.notdefof/.notdefdiabetes,/.notdefhistory/.notdefof/.notdefhypertension,/.notdefhistory/.notdef of/.notdef dyslipidaemia,/.notdef caloric/.notdef intake/.notdef at/.notdef baseline)/.notdef to/.notdef examine/.notdef their/.notdef potential/.notdef effects./.notdef To/.notdef investigate/.notdef the/.notdef relationship/.notdef between/.notdef treatment/.notdef and/.notdef covariate,/.notdef each/.notdef factor/.notdef was/.notdef analysed/.notdef statistically/.notdef using/.notdef a/.notdef two-way/.notdef analysis/.notdef of/.notdef variance/.notdef model/.notdef with/.notdef terms/.notdef for/.notdef treatment,/.notdef the/.notdef covariate,/.notdef and/.notdef the/.notdef treatment/.notdef by/.notdef covariate/.notdef interaction./.notdef/.notdef

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised RESULTS/.notdef Baseline/.notdefdata/.notdef Table/.notdef5/.notdefbelow/.notdefdescribes/.notdefsome/.notdefbaseline/.notdefcharacteristics/.notdefof/.notdefthe/.notdefstudy/.notdefpopulations./.notdef Table/.notdef5:/.notdefSome/.notdefbaseline/.notdefcharacteristics/.notdefof/.notdefthe/.notdefobesity/.notdefstudy/.notdefpopulations/.notdef Approximately/.notdef 55-60%/.notdef of/.notdef the/.notdef included/.notdef patients/.notdef had/.notdef dyslipidaemia/.notdef at/.notdef baseline/.notdef in/.notdef the/.notdef different/.notdef studies/.notdef (100%/.notdef in/.notdef the/.notdef RIO-lipids)./.notdef Prevalence/.notdef of/.notdef hypertension/.notdef was/.notdef between/.notdef 27/.notdef and/.notdef 61/.notdef %/.notdef with/.notdef the/.notdef highest/.notdef prevalence/.notdefin/.notdefthe/.notdefRIO-diabetes/.notdefstudy;/.notdefthe/.notdefnumber/.notdefof/.notdefpatients/.notdeftreated/.notdeffor/.notdefhypertension/.notdefvaried/.notdeffrom/.notdef55%/.notdefin/.notdef RIO-Europe/.notdef to/.notdef 93%/.notdef in/.notdef RIO/.notdef diabetes/.notdef and/.notdef was/.notdef approximately/.notdef 68%/.notdef in/.notdef the/.notdef RIO-North/.notdef America/.notdef and/.notdef RIOLipids/.notdef studies./.notdef Mean/.notdef BMI/.notdef varied/.notdef between/.notdef 33.3/.notdef and/.notdef 37.6/.notdef kg/m 2 ./.notdef Forty-six/.notdef per-cents/.notdef of/.notdef the/.notdef patients/.notdef were/.notdef either/.notdefcurrent/.notdefor/.notdefformer/.notdefsmokers./.notdef/.notdef Overall,/.notdef 46.5%/.notdef of/.notdef the/.notdef patients/.notdef included/.notdef in/.notdef the/.notdef RIO/.notdef studies/.notdef had/.notdef metabolic/.notdef syndrome/.notdef with/.notdef prevalences/.notdef of/.notdef 35,/.notdef41,/.notdef54/.notdefand/.notdef79%/.notdefin/.notdefthe/.notdefRIO-North/.notdefAmerica,/.notdefRIO-Europe,/.notdefRIO-Lipids/.notdefand/.notdefRIO-Diabetes,/.notdefrespectively./.notdef/.notdef No/.notdef imbalances/.notdef between/.notdef treatment/.notdef groups/.notdef within/.notdef the/.notdef studies/.notdef with/.notdef regard/.notdef to/.notdef demographics,/.notdef BMI/.notdef or/.notdef comorbidities/.notdefwere/.notdefseen./.notdefThe/.notdeflow/.notdefproportion/.notdefof/.notdefmen/.notdefin/.notdefthe/.notdefRIO-Europe/.notdefand/.notdefRIO/.notdefNorth/.notdefAmerica/.notdefwas/.notdefnoted./.notdef Elderly/.notdefpatients/.notdef(&gt;75/.notdefyears/.notdefof/.notdefage)/.notdefwere/.notdefpoorly/.notdefrepresented,/.notdefwhich/.notdefis/.notdefreflected/.notdefin/.notdefthe/.notdefSPC/.notdef(4.4)./.notdef Overall,/.notdef the/.notdef percentages/.notdef of/.notdef patients/.notdef who/.notdef completed/.notdef 1/.notdef year/.notdef of/.notdef treatment/.notdef were/.notdef 52.5%/.notdef in/.notdef RIO-North/.notdef America,/.notdef 60.8%/.notdef in/.notdef RIO-Europe,/.notdef 62.1%/.notdef in/.notdef RIO-Lipids/.notdef and/.notdef 66.1%/.notdef in/.notdef RIO-Diabetes./.notdef The/.notdef total/.notdef dropout/.notdef rates/.notdef were/.notdef rather/.notdef similar/.notdef in/.notdef the/.notdef different/.notdef treatment/.notdef groups/.notdef but/.notdef generally/.notdef higher/.notdef due/.notdef to/.notdef adverse/.notdef events/.notdef in/.notdef the/.notdef20/.notdefmg/.notdefgroup/.notdefand/.notdefhigher/.notdefdue/.notdefto/.notdefpatients'/.notdefrequest/.notdefin/.notdefthe/.notdefplacebo/.notdefand/.notdef5/.notdefmg/.notdefgroups./.notdef/.notdef The/.notdef high/.notdef withdrawal/.notdefrates/.notdef were/.notdef noted/.notdef but/.notdef not/.notdef unexpected/.notdef in/.notdefthis/.notdefkind/.notdefof/.notdefstudies/.notdefand/.notdefthey/.notdefare/.notdefessentially/.notdef similar/.notdefto/.notdefthose/.notdefobserved/.notdefin/.notdefearlier/.notdefsimilar/.notdeftrials/.notdefwith/.notdefweight/.notdefreducing/.notdefagents./.notdef Outcomes/.notdefand/.notdefestimation/.notdef /.notdef Body/.notdefweight/.notdefand/.notdefrelated/.notdefendpoints/.notdef The/.notdef effect/.notdef of/.notdef rimonabant/.notdef 20/.notdef mg/.notdef on/.notdef body/.notdef weight/.notdef was/.notdefsimilar/.notdefin/.notdefthe/.notdef3/.notdef RIO/.notdef studies/.notdef including/.notdefnon-diabetic/.notdef patients./.notdef A/.notdef mean/.notdef body/.notdef weight/.notdef loss/.notdef of/.notdef 6.3/.notdef to/.notdef 6.9/.notdef kg/.notdef from/.notdef baseline/.notdef was/.notdef observed/.notdef at/.notdef 1/.notdef year/.notdef in/.notdef the/.notdef ITT/.notdef population/.notdef (LOCF)./.notdef The/.notdef weight/.notdef reduction/.notdef in/.notdef the/.notdef placebo/.notdef groups/.notdef was/.notdef similar/.notdef across/.notdef these/.notdef 3/.notdef studies/.notdef with/.notdef body/.notdefweight/.notdefloss/.notdefof/.notdef1.5/.notdefto/.notdef1.8/.notdefkg./.notdefThe/.notdefmean/.notdefbody/.notdefweight/.notdefloss/.notdefdifference/.notdefof/.notdefthe/.notdef20/.notdefmg/.notdefdose/.notdefover/.notdefplacebo/.notdef ranged/.notdef from/.notdef 4.7/.notdef kg/.notdef in/.notdef RIO-North/.notdef America/.notdef and/.notdef RIO-Europe/.notdef to/.notdef 5.4/.notdef kg/.notdef in/.notdef RIO-Lipids/.notdef (p&lt;0.001)./.notdef In/.notdef RIODiabetes/.notdef the/.notdef body/.notdef weight/.notdef loss/.notdef from/.notdef baseline/.notdef was/.notdef slightly/.notdef lower/.notdef in/.notdef both/.notdef groups,/.notdef rimonabant/.notdef 20/.notdef mg/.notdef (-5.3/.notdefkg)/.notdefand/.notdefplacebo/.notdef(-1.4/.notdefkg),/.notdefbut/.notdefwith/.notdefa/.notdefsignificant/.notdefdifference/.notdefbetween/.notdefthe/.notdef2/.notdefgroups/.notdef(-3.9/.notdefkg,/.notdefp&lt;0.001)./.notdef (See/.notdefTable/.notdef6.)/.notdef

/.notdef

<!-- image -->

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

<!-- image -->

/.notdef

Medicinal product no longer authorised The/.notdefeffects/.notdefdemonstrated/.notdefby/.notdefthe/.notdef5/.notdefmg/.notdefdose/.notdefwere/.notdefconsistently/.notdeflower/.notdefthan/.notdefthe/.notdefeffect/.notdefof/.notdefthe/.notdef20/.notdefmg/.notdefdose/.notdefwith/.notdef a/.notdef mean/.notdef difference/.notdef of/.notdef -1.4/.notdef kg/.notdef (p&lt;0.01)/.notdef and/.notdef -0.8/.notdef kg/.notdef (p=0.013)/.notdef vs./.notdef placebo/.notdef in/.notdef non-diabetic/.notdef and/.notdef diabetic/.notdef patients,/.notdefrespectively./.notdef Table/.notdef6:/.notdefBody/.notdefweight/.notdefresults/.notdefin/.notdefthe/.notdeffour/.notdefpivotal/.notdefstudies,/.notdefchange/.notdefin/.notdefkg/.notdeffrom/.notdefbaseline/.notdefand/.notdefresponder/.notdefrates/.notdef The/.notdef ITT/.notdef analyses/.notdef were/.notdef supported/.notdef by/.notdef the/.notdef analyses/.notdef performed/.notdef on/.notdef patients/.notdef completing/.notdef treatment/.notdef where/.notdef weight/.notdefreduction/.notdefgenerally/.notdefappeared/.notdefsomewhat/.notdefmore/.notdefpronounced./.notdef The/.notdef weight/.notdef effects/.notdef over/.notdef time/.notdef were/.notdef very/.notdef similar/.notdef in/.notdef the/.notdef four/.notdef studies/.notdef and/.notdef are/.notdef presented/.notdef in/.notdef Figure/.notdef 1/.notdef below/.notdef with/.notdefthe/.notdefRIO-Europe/.notdefresults./.notdefThe/.notdefweight/.notdefreduction/.notdefreached/.notdefa/.notdefplateau/.notdefafter/.notdefapproximately/.notdef36/.notdefweeks./.notdef/.notdef Figure/.notdef1:/.notdefWeight/.notdefreduction/.notdefover/.notdeftime/.notdefin/.notdefthe/.notdefRIO-Europe/.notdefstudy/.notdef The/.notdefdecrease/.notdefin/.notdefthe/.notdefwaist/.notdefcircumference/.notdefin/.notdefthe/.notdefrimonabant/.notdeftreated/.notdefpatients/.notdefparalleled/.notdefthe/.notdefdecrease/.notdefin/.notdefbody/.notdef weight/.notdefwith/.notdefmean/.notdefdecreases/.notdef(relative/.notdefto/.notdefplacebo)/.notdefvarying/.notdefbetween/.notdef3.3/.notdefand/.notdef4.7/.notdefcm/.notdef(p&lt;0.001/.notdefin/.notdefall/.notdefstudies)/.notdef with/.notdefabsolute/.notdefdecreases/.notdeffrom/.notdefbaseline/.notdefbetween/.notdef5.2/.notdefand/.notdef7.1/.notdefcm./.notdef/.notdef

/.notdef

/.notdef

<!-- image -->

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

Medicinal product no longer authorised Body/.notdefcomposition/.notdefwas/.notdefmeasured/.notdefin/.notdefa/.notdefsubgroup/.notdefof/.notdefpatients/.notdefand/.notdefa/.notdefdecrease/.notdefin/.notdefthe/.notdeftotal/.notdefbody/.notdeffat/.notdefmass/.notdefwas/.notdef demonstrated/.notdefin/.notdefthe/.notdef20/.notdefmg/.notdefgroup. /.notdef The/.notdef effects/.notdef on/.notdef body/.notdef weight/.notdef and/.notdef related/.notdef criteria/.notdef appeared/.notdef to/.notdefbe/.notdefconsistent/.notdefamong/.notdefmen/.notdefand/.notdefwomen/.notdef(mean/.notdef weight/.notdef reductions/.notdef 5.1/.notdef and/.notdef 4.8/.notdef kg,/.notdef respectively),/.notdef in/.notdef different/.notdef geographic/.notdef regions,/.notdef in/.notdef different/.notdef age/.notdef groups/.notdef and/.notdefamong/.notdefsmokers/non-smokers./.notdef The/.notdef effects/.notdef also/.notdef appeared/.notdef essentially/.notdef consistent/.notdef in/.notdef the/.notdef subgroup/.notdef of/.notdef patients/.notdef with/.notdef severe/.notdef obesities/.notdef (BMI/.notdef GLYPH&lt;1&gt; 40/.notdef kg/m²),/.notdef as/.notdef in/.notdef those/.notdef not/.notdef losing/.notdef significant/.notdef body/.notdef weight/.notdef with/.notdef diet/.notdef and/.notdef exercise/.notdefalone/.notdefduring/.notdefthe/.notdefinitial/.notdef one/.notdef month/.notdefrun-in./.notdefHowever,/.notdefin/.notdefthe/.notdeflimited/.notdefnumber/.notdefof/.notdefAfro-American/.notdefpatients/.notdefin/.notdefthe/.notdefRIO/.notdefstudies/.notdef(74/.notdefand/.notdef 169/.notdef patients/.notdef randomised/.notdef to/.notdef placebo/.notdef and/.notdef rimonabant/.notdef 20/.notdef mg/.notdef groups,/.notdef respectively)/.notdef weight/.notdef loss/.notdef was/.notdef less/.notdef pronounced/.notdef(mean/.notdefdifference/.notdefas/.notdefcompared/.notdefto/.notdefplacebo/.notdefwas/.notdef-2.9/.notdefkg). /.notdef/.notdef Effect/.notdefof/.notdefrimonabant/.notdefon/.notdefdyslipidaemia/.notdef The/.notdef patients/.notdef included/.notdefin/.notdefthe/.notdeffour/.notdefstudies/.notdefcould/.notdefbe/.notdefconsidered/.notdefto/.notdefbe/.notdefrepresentative/.notdeffor/.notdefa/.notdefbroad/.notdefpopulation/.notdef of/.notdef obese/.notdefpatients/.notdefwith/.notdefconcurrent/.notdeftreated/.notdefor/.notdefuntreated/.notdefdyslipidaemia/.notdefof/.notdefthe/.notdefkind/.notdeftypically/.notdefassociated/.notdefwith/.notdef overweight/.notdef(low/.notdefHDL-C/.notdefand/.notdefelevated/.notdeftriglycerides/.notdef[TG])./.notdef/.notdef Mean/.notdef HDL-C/.notdef levels/.notdef increased/.notdef in/.notdef all/.notdef treatment/.notdef groups,/.notdef but/.notdef in/.notdef all/.notdef studies/.notdef the/.notdef increase/.notdef was/.notdef greater/.notdef in/.notdef the/.notdef rimonabant/.notdef20/.notdef mg/.notdef group/.notdef (mean/.notdef differences/.notdef 7.2/.notdef -/.notdef 8.4%/.notdef at/.notdef one/.notdef year,/.notdef p&lt;0.001)/.notdef than/.notdef in/.notdef the/.notdef placebo/.notdef group./.notdef The/.notdef differences/.notdef between/.notdef treatment/.notdef groups/.notdef were/.notdef consistent/.notdef in/.notdef men/.notdef and/.notdef women./.notdef There/.notdef was,/.notdef however,/.notdef a/.notdef significantly/.notdefless/.notdefpronounced/.notdefmean/.notdefincrease/.notdefin/.notdefAfro-Americans./.notdef In/.notdef the/.notdef 4/.notdef RIO/.notdef studies,/.notdef the/.notdef absolute/.notdef TG/.notdef levels/.notdef decreased/.notdefin/.notdef the/.notdef 20mg/.notdef rimonabant/.notdefgroup/.notdefby/.notdef-5.3/.notdefto/.notdef-12.6%./.notdef In/.notdefthe/.notdefplacebo/.notdefgroups/.notdefthe/.notdefmean/.notdeftriglyceride/.notdeflevels/.notdefincreased/.notdef(by/.notdef7.3-8.3%/.notdefin/.notdefthe/.notdefRIO-Europe,/.notdefRio-NA/.notdefand/.notdef Rio-Diabetes/.notdef studies)/.notdef or/.notdef remained/.notdef stable/.notdef (-0.2%/.notdef in/.notdef the/.notdef RIO-lipids/.notdef study)./.notdef The/.notdef decreases/.notdef in/.notdef the/.notdef 20/.notdef mg/.notdef group,/.notdef when/.notdef compared/.notdef with/.notdef placebo,/.notdef were/.notdef similar/.notdef across/.notdef the/.notdef studies,/.notdef with/.notdef differences/.notdef being/.notdef 12.4/.notdef to/.notdef 15.1%/.notdef in/.notdef non-diabetic/.notdef patients/.notdef in/.notdef the/.notdef ITT/.notdef population/.notdef (LOCF)/.notdef (p&lt;0.001)./.notdef In/.notdef diabetic/.notdef patients/.notdef the/.notdef difference,/.notdef compared/.notdef with/.notdef placebo,/.notdef was/.notdef 16.4%./.notdef The/.notdef results/.notdef were/.notdef consistent/.notdef in/.notdef patients/.notdef with/.notdef elevated/.notdef or/.notdef normal/.notdefTG/.notdefat/.notdefbaseline./.notdefGenerally/.notdefthe/.notdefeffects/.notdefof/.notdefrimonabant/.notdefon/.notdefHDL-C/.notdefand/.notdeftriglycerides/.notdefreached/.notdefa/.notdefplateau/.notdef after/.notdefapproximately/.notdef36/.notdefweek's/.notdefof/.notdeftreatment./.notdef /.notdef The/.notdef total-C/.notdef and/.notdef LDL-C/.notdef remained/.notdef unchanged/.notdef in/.notdef all/.notdef groups/.notdef in/.notdef the/.notdef RIO/.notdef studies,/.notdef taking/.notdef into/.notdef account/.notdef the/.notdef initial/.notdef small/.notdef drop/.notdef in/.notdef LDL-C/.notdef observed/.notdef during/.notdef the/.notdef run-in/.notdef period./.notdef In/.notdef RIO-Lipids/.notdef LDL/.notdef particle/.notdef size/.notdef was/.notdef evaluated/.notdefand/.notdefa/.notdefshift/.notdeftowards/.notdeflarger/.notdefparticles/.notdefwas/.notdefnoted./.notdef /.notdef The/.notdefeffects/.notdefof/.notdefrimonabant/.notdefon/.notdefglucose/insulin/.notdefhomeostasis/.notdef In/.notdef the/.notdef overall/.notdef type/.notdef 2/.notdef diabetes/.notdef obese/.notdef population/.notdef (RIO-diabetes),/.notdef with/.notdef a/.notdef mean/.notdef HbA1c/.notdefof/.notdef7.3%/.notdefat/.notdefbaseline,/.notdef the/.notdef HbA1c/.notdefdecreased/.notdefin/.notdefthe/.notdefrimonabant/.notdef20/.notdefmg/.notdefgroup/.notdefby/.notdef0.6%/.notdefcompared/.notdefwith/.notdefan/.notdefincrease/.notdefof/.notdef0.1%/.notdefin/.notdefthe/.notdef placebo/.notdef group,/.notdef resulting/.notdef in/.notdef 0.7%/.notdef improvement/.notdef (p&lt;0.01)./.notdef The/.notdef effects/.notdef were/.notdef similar/.notdef in/.notdef the/.notdef metformin/.notdef or/.notdef sulfonylurea/.notdef treated/.notdef patients./.notdef A/.notdef majority/.notdef of/.notdef patients/.notdef were/.notdef inadequately/.notdef controlled/.notdef at/.notdef baseline./.notdef The/.notdef 5/.notdef mg/.notdef dose/.notdefdecreased/.notdefHbA1c/.notdefto/.notdefa/.notdefless/.notdefpronounced/.notdefextent./.notdefFasting/.notdefglucose/.notdefwas/.notdefdecreased/.notdefby/.notdefrimonabant/.notdef20/.notdefmg/.notdef compared/.notdef with/.notdef placebo/.notdef (mean/.notdef difference/.notdef -0.97/.notdef mmol/L;/.notdef 95%/.notdef CI;/.notdef -1.30,/.notdef -0.64)./.notdef Insulin/.notdef resistance/.notdef as/.notdef measured/.notdef by/.notdef HOMA/.notdef (homeostasis/.notdef model/.notdef assessment,/.notdef calculated/.notdef from/.notdef fasting/.notdef glucose/.notdef and/.notdef insulin)/.notdef decreased/.notdefsignificantly/.notdefin/.notdefthe/.notdefrimonabant/.notdef20/.notdefmg/.notdefgroup/.notdefas/.notdefcompared/.notdefto/.notdefplacebo./.notdef/.notdef In/.notdef the/.notdef 3/.notdef studies/.notdef of/.notdef non-diabetic/.notdef patients/.notdef there/.notdef were/.notdef 774/.notdef patients/.notdef with/.notdef impaired/.notdef fasting/.notdef glycaemia,/.notdef i.e./.notdef fasting/.notdefglucose/.notdef(FG) GLYPH&lt;1&gt; 5.55/.notdefmmol/L/.notdefor/.notdefdiabetic/.notdefFG/.notdef(&gt;6.99/.notdefmmol/L)/.notdefat/.notdefbaseline./.notdefThe/.notdefmean/.notdefdifference/.notdefin/.notdefFG/.notdef between/.notdef the/.notdef pooled/.notdef 20/.notdef mg/.notdef treatment/.notdef groups/.notdef and/.notdef the/.notdef placebo/.notdef groups/.notdef was/.notdef -0.10/.notdef mmol/L/.notdef (95%/.notdef CI;/.notdef -0.22,/.notdef 0.03)./.notdef Fasting/.notdef insulin/.notdef was/.notdef higher/.notdef than/.notdef in/.notdef the/.notdef general/.notdef population/.notdef at/.notdef baseline/.notdef (around/.notdef 16/.notdef µ IU/mL)./.notdef There/.notdef was/.notdefno/.notdefchange/.notdefin/.notdefthe/.notdefplacebo/.notdefgroup/.notdefafter/.notdefone/.notdefyear,/.notdefwhereas/.notdefinsulin/.notdefdecreased/.notdefby/.notdef3/.notdefµ IU/mL/.notdefin/.notdefthe/.notdefpooled/.notdef rimonabant/.notdef20/.notdefmg/.notdefgroup/.notdef(p/.notdef=/.notdef0.002/.notdefin/.notdefpooled/.notdefstudies)./.notdef/.notdef In/.notdef the/.notdef subgroup/.notdef of/.notdef 258/.notdef prediabetic/.notdef patients/.notdef identified/.notdef in/.notdef the/.notdef RIO-Europe/.notdef and/.notdef RIO-Lipids/.notdef studies/.notdef by/.notdef the/.notdef oral/.notdef glucose/.notdeftolerance/.notdeftest/.notdefthe/.notdefglucose/.notdeflevel/.notdefat/.notdef30/.notdefminutes/.notdefafter/.notdefthe/.notdefglucose/.notdefload/.notdefwas/.notdeflower/.notdefin/.notdefthe/.notdefpooled/.notdef rimonabant/.notdef20/.notdefmg/.notdefgroups/.notdefthan/.notdefin/.notdefthe/.notdefplacebo/.notdefgroups/.notdefat/.notdefone/.notdefyear/.notdef(mean/.notdefdifference/.notdef-0.89/.notdefmmol/L,/.notdef95%/.notdefCI;/.notdef -1.39,/.notdef-0.39,/.notdefp&lt;0.001)./.notdefNo/.notdefdifference/.notdefbetween/.notdefgroups/.notdefwas/.notdefseen/.notdefat/.notdef120/.notdefminutes./.notdefMean/.notdefinsulin/.notdeflevels/.notdefwere/.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

| no   |
|------|

/.notdef

/.notdef

Medicinal product no longer authorised lower/.notdef in/.notdef the/.notdef rimonabant/.notdef 20/.notdef mg/.notdef groups/.notdef at/.notdef 30/.notdef and/.notdef 120/.notdef minutes/.notdef after/.notdef the/.notdef glucose/.notdef load/.notdef compared/.notdef with/.notdef placebo./.notdef In/.notdef patients/.notdef with/.notdef normal/.notdef FG/.notdef at/.notdef baseline/.notdef no/.notdef significant/.notdef differences/.notdef in/.notdef FG/.notdef between/.notdef treatment/.notdef groups/.notdef were/.notdef found/.notdef at/.notdef one/.notdef year./.notdef However,/.notdef in/.notdef patients/.notdef with/.notdef normal/.notdef FG/.notdef both/.notdef fasting/.notdef insulin/.notdef levels/.notdef and/.notdef HOMA/.notdef levels/.notdef were/.notdefsignificantly/.notdefreduced/.notdefin/.notdefthe/.notdefpooled/.notdef20/.notdefmg/.notdefgroup/.notdefas/.notdefcompared/.notdefto/.notdefplacebo/.notdefafter/.notdefone/.notdefyear./.notdef Effect/.notdefof/.notdefrimonabant/.notdefon/.notdefblood/.notdefpressure/.notdef(BP)/.notdef In/.notdef the/.notdef subgroup/.notdef of/.notdef 555/.notdef patients/.notdef who/.notdef had/.notdef elevated/.notdef BP/.notdef at/.notdef baseline,/.notdef defined/.notdef as/.notdef either/.notdef SBP/.notdef GLYPH&lt;1&gt; 140/.notdef mmHg/.notdefor/.notdef DBP/.notdef GLYPH&lt;1&gt; 90/.notdef mmHg,/.notdef decreases/.notdef in/.notdef SBP/.notdef and/.notdef DBP/.notdef were/.notdef observed/.notdef at/.notdef one/.notdef year./.notdef Systolic/.notdef blood/.notdef pressure/.notdef decreased/.notdef by/.notdef 8.5/.notdef mmHg/.notdef in/.notdef the/.notdef rimonabant/.notdef group/.notdef and/.notdef 6.9/.notdef mmHg/.notdef in/.notdef the/.notdef placebo/.notdef group./.notdef The/.notdef decrease/.notdef in/.notdef DBP/.notdefwas/.notdef5.6/.notdefmmHg/.notdefin/.notdefthe/.notdefrimonabant/.notdef20/.notdefmg/.notdefgroup/.notdefversus/.notdef-3.5/.notdefmmHg/.notdefin/.notdefthe/.notdefplacebo/.notdefgroup/.notdef(p/.notdef=/.notdef0.009)./.notdef These/.notdefchanges/.notdefwere/.notdefconsistent/.notdefwith/.notdefthe/.notdefobserved/.notdefbody/.notdefweight/.notdefloss./.notdefIn/.notdefpatients/.notdeffollowed/.notdeffor/.notdeftwo/.notdefyears/.notdefno/.notdef significant/.notdefdifference/.notdefin/.notdefblood/.notdefpressure/.notdefwas/.notdefseen/.notdefbetween/.notdefthe/.notdefrimonabant/.notdefand/.notdefplacebo/.notdefgroups./.notdefIn/.notdefpatients/.notdef with/.notdefnormal/.notdefBP/.notdefat/.notdefbaseline,/.notdefrimonabant/.notdef20/.notdefmg/.notdefhad/.notdefno/.notdefsignificant/.notdefeffects/.notdefon/.notdefBP./.notdef/.notdef Effects/.notdefon/.notdefthe/.notdefpercentage/.notdefof/.notdefpatients/.notdefmeeting/.notdefthe/.notdefcriteria/.notdeffor/.notdefthe/.notdefmetabolic/.notdefsyndrome/.notdef In/.notdef the/.notdef 20/.notdef mg/.notdef groups,/.notdefthe/.notdefpercentages/.notdefof/.notdefpatients/.notdefhaving/.notdefmetabolic/.notdefsyndrome/.notdefat/.notdefendpoint/.notdefwere/.notdeflower/.notdefthan/.notdef in/.notdefthe/.notdefplacebo/.notdefgroups/.notdefin/.notdefthe/.notdef4/.notdefRIO/.notdefstudies,/.notdefsee/.notdeftable/.notdef7/.notdefbelow./.notdef Table/.notdef7:/.notdef%/.notdefof/.notdefpatients/.notdefmeeting/.notdefthe/.notdefcriteria/.notdeffor/.notdefmetabolic/.notdefsyndrome/.notdefat/.notdefbaseline/.notdefand/.notdefat/.notdefYear/.notdef1/.notdef Quality/.notdefof/.notdeflife/.notdefmeasurements/.notdef In/.notdef the/.notdef IWQOL-Lite/.notdef (Impact/.notdef on/.notdef Weight/.notdef on/.notdef Quality/.notdef of/.notdef Life-Lite)/.notdef instrument/.notdef significantly/.notdef higher/.notdef values/.notdef were/.notdef obtained/.notdef in/.notdef the/.notdef physical/.notdef functioning/.notdef and/.notdef self-esteem/.notdef domains/.notdef and/.notdef in/.notdef total/.notdef scores/.notdef in/.notdef the/.notdef 20/.notdef mg/.notdef rimonabant/.notdefgroups/.notdefas/.notdefcompared/.notdefto/.notdefplacebo./.notdefThere/.notdefwere/.notdefalso/.notdeftendencies/.notdeffor/.notdefimprovements/.notdefwhich/.notdefbecame/.notdef significant/.notdefas/.notdef compared/.notdef to/.notdef placebo/.notdef in/.notdef the/.notdef pooled/.notdef population/.notdef for/.notdef the/.notdef other/.notdef 3/.notdef domains/.notdef (Sexual/.notdef life,/.notdef Public/.notdef distress/.notdefand/.notdefWork)./.notdefIn/.notdefthe/.notdefSF-36/.notdefinstrument/.notdefsignificant/.notdefimprovements/.notdefin/.notdefphysical/.notdeffunctioning/.notdefand/.notdefgeneral/.notdef health/.notdef as/.notdef compared/.notdef to/.notdef placebo/.notdef were/.notdef observed./.notdef On/.notdef the/.notdef other/.notdef hand/.notdefa/.notdeftrend/.notdeffor/.notdefa/.notdefless/.notdeffavourable/.notdefemotional/.notdef health/.notdef and/.notdef a/.notdef significantly/.notdef worse/.notdef mental/.notdef health/.notdef situation/.notdef in/.notdef the/.notdef rimonabant/.notdef 20/.notdef mg/.notdef group,/.notdef as/.notdef compared/.notdef to/.notdef placebo,/.notdefwas/.notdefrecorded. /.notdef Relationship/.notdefbetween/.notdefbody/.notdefweight/.notdefloss/.notdefand/.notdefmetabolic/.notdefeffects/.notdefof/.notdefrimonabant/.notdef Four/.notdef different/.notdef methods/.notdef were/.notdef applied/.notdef to/.notdef investigate/.notdef the/.notdef relationship/.notdef between/.notdef metabolic/.notdef changes/.notdef and/.notdef weight/.notdef loss:/.notdef comparison/.notdef of/.notdef changes/.notdef in/.notdef metabolic/.notdef parameters/.notdef over/.notdef time/.notdef versus/.notdef changes/.notdef in/.notdef body/.notdef weight,/.notdef comparison/.notdef of/.notdef effects/.notdef of/.notdef rimonabant/.notdef on/.notdef metabolic/.notdef parameters/.notdef across/.notdef weight/.notdef change/.notdef categories,/.notdef assessment/.notdef of/.notdef metabolic/.notdef changes/.notdef in/.notdef the/.notdef population/.notdef from/.notdef the/.notdef STRATUS/.notdef development,/.notdef and/.notdef statistical/.notdef (regression)/.notdef analysis/.notdef of/.notdef the/.notdef relationship/.notdef between/.notdef body/.notdef weight/.notdef loss/.notdef and/.notdef metabolic/.notdef effects./.notdef It/.notdef is/.notdef estimated/.notdef that/.notdef approximately/.notdef half/.notdef of/.notdef the/.notdef mean/.notdef improvements/.notdef in/.notdef HbA1c,/.notdef HDL-C/.notdef and/.notdef triglycerides/.notdef in/.notdef patients/.notdef receiving/.notdef rimonabant/.notdef 20/.notdefmg/.notdef was/.notdef beyond/.notdef that/.notdef expected/.notdef from/.notdef weight/.notdef loss/.notdef alone./.notdef In/.notdef type/.notdef 2/.notdef diabetes/.notdef inadequately/.notdefcontrolled/.notdefat/.notdefbaseline/.notdefapproximately/.notdef50%/.notdefof/.notdefthe/.notdeftotal/.notdefreduction/.notdefin/.notdefHbA1c/.notdeflevels/.notdef(0.8%)/.notdefwas/.notdef estimated/.notdefto/.notdefbe/.notdefindependent/.notdefof/.notdefweight/.notdefreduction./.notdefThe/.notdefmagnitude/.notdefof/.notdefthe/.notdefestimated/.notdefindependent/.notdefeffects/.notdefon/.notdef lipids,/.notdefwas/.notdef3.6%/.notdefchange/.notdeffrom/.notdefbaseline/.notdefHDL-C/.notdef(1.22)/.notdefand/.notdef6.5%/.notdefchange/.notdeffrom/.notdefbaseline/.notdeftriglycerides. /.notdef

/.notdef

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

<!-- image -->

Medicinal product no longer authorised Efficacy/.notdefresults/.notdefat/.notdef2/.notdefyears/.notdef The/.notdef body/.notdef weight/.notdef loss/.notdef was/.notdef essentially/.notdef maintained/.notdef in/.notdef the/.notdef 2/.notdef studies/.notdef (RIO-Europe/.notdef and/.notdef RIO-North/.notdef America)/.notdef where/.notdefpatients/.notdefreceived/.notdefthe/.notdeftreatment/.notdeffor/.notdefup/.notdefto/.notdef2/.notdefyears./.notdef/.notdef In/.notdefRIO-North/.notdefAmerica/.notdefpatients/.notdefon/.notdefrimonabant/.notdef20/.notdefmg/.notdefwere/.notdefre-randomised/.notdefto/.notdefplacebo/.notdefor/.notdefrimonabant/.notdef20/.notdefmg/.notdef after/.notdefone/.notdefyear/.notdefand/.notdeffollowed/.notdeffor/.notdefan/.notdefadditional/.notdefyear./.notdefThe/.notdefbody/.notdefweight/.notdefincreased/.notdefon/.notdefaverage/.notdefto/.notdeflevels/.notdefsimilar/.notdef to/.notdefthose/.notdeftreated/.notdefwith/.notdefplacebo/placebo/.notdeffor/.notdeftwo/.notdefyears/.notdef(see/.notdefFigure/.notdef2/.notdefbelow)./.notdefAvailable/.notdefdata/.notdefdo/.notdefnot/.notdefindicate/.notdefa/.notdef rebound/.notdefphenomenon./.notdef /.notdef Figure/.notdef2/.notdefRIO-North/.notdefAmerica:/.notdefbody/.notdefweight/.notdefchange/.notdef(kg)/.notdefby/.notdefvisit/.notdefat/.notdef2/.notdefyears/.notdef/.notdef (mean/.notdef±/.notdefSEM)/.notdef-/.notdefITT/.notdefpopulation/.notdef SMOKING/.notdefCESSATION/.notdef One/.notdef phase/.notdef II/.notdef study/.notdef (ACT4389) ,/.notdef three/.notdef short-term/.notdef (10/.notdef weeks)/.notdef phase/.notdef III/.notdef studies/.notdef (STRATUS-US//.notdef STRATUS-EU//.notdef STRATUS-META),/.notdef and/.notdef one/.notdef long-term/.notdef (one/.notdef year)/.notdef phase/.notdef III/.notdef study/.notdef (STRATUS-WW)/.notdef were/.notdef carried/.notdef out/.notdef to/.notdef demonstrate/.notdef efficacy/.notdef and/.notdef safety/.notdef of/.notdef rimonabant/.notdef as/.notdef an/.notdef aid/.notdef to/.notdef smoking/.notdef cessation./.notdef (See/.notdef below/.notdefTable/.notdef8.)/.notdef

/.notdef

<!-- image -->

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

| Main/.notdefStudies/.notdef                                                                               | Design/.notdef                                                                                                                                                                                                                                                                                      | Treatment/.notdef(QD)/.notdef                                                                                                                                                                                                                                                                                                                                                                 | Duration/.notdef                                                                                      | Follow/.notdefup/.notdef off/.notdefdrug/.notdef                                                                      | Assessments/.notdef                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| STRATUS-US/.notdef US,/.notdef11/.notdefcentres/.notdef /.notdef                                          | Rd,/.notdefDb,/.notdefPl,/.notdefParallel/.notdefgroup/.notdef (3)/.notdefdesign/.notdef                                                                                                                                                                                                            | Placebo/.notdef Rimonabant/.notdef5/.notdefmg,/.notdef/.notdef Rimonabant/.notdef20/.notdefmg,/.notdef/.notdef                                                                                                                                                                                                                                                                                | 10/.notdefweeks/.notdef                                                                               | 40/.notdefweeks/.notdef                                                                                               | Primary :/.notdefAbstinence/.notdef during/.notdefthe/.notdeflast/.notdef4/.notdefweeks/.notdefof/.notdef treatment/.notdef(self-report)/.notdef Secondary :/.notdefweight/.notdefgain,/.notdef craving/.notdef                                                                                                                                              |
| STRATUS-EU/.notdef BE,/.notdefDK,/.notdefFR,/.notdefES,/.notdefSE,/.notdef SW,/.notdefUK/.notdef /.notdef | Rd,/.notdefDb,/.notdefPl,/.notdefParallel/.notdefgroup/.notdef (3)/.notdefdesign/.notdef                                                                                                                                                                                                            | Placebo/.notdef Rimonabant/.notdef5/.notdefmg,/.notdef/.notdef Rimonabant/.notdef20/.notdefmg,/.notdef/.notdef                                                                                                                                                                                                                                                                                | 10/.notdefweeks/.notdef                                                                               | 40/.notdefweeks/.notdef                                                                                               | Primary :/.notdefAbstinence/.notdef during/.notdefthe/.notdeflast/.notdef4/.notdefweeks/.notdefof/.notdef treatment/.notdef(self-report)/.notdef Secondary :/.notdefweight/.notdefgain,/.notdef craving/.notdef                                                                                                                                              |
| STRATUS-META/.notdef USA,/.notdef10/.notdefcentres/.notdef /.notdef                                       | Rd,/.notdefDb,/.notdefPl,/.notdefParallel/.notdefgroup/.notdef (2)/.notdefdesign/.notdef                                                                                                                                                                                                            | Placebo/.notdef Rimonabant/.notdef20/.notdefmg,/.notdef/.notdef                                                                                                                                                                                                                                                                                                                               | 10/.notdefweeks/.notdef                                                                               | /.notdef                                                                                                              | Primary:/.notdef Abstinence/.notdef during/.notdefthe/.notdeflast/.notdef4/.notdefweeks/.notdefof/.notdef treatment/.notdef(self-report)/.notdef Secondary :/.notdefweight/.notdefgain,/.notdef craving /.notdef                                                                                                                                             |
| Supportive/.notdefStudies/.notdef                                                                         | Design/.notdef                                                                                                                                                                                                                                                                                      | Treatment/.notdefarms/.notdef                                                                                                                                                                                                                                                                                                                                                                 | Duration/.notdef                                                                                      | Follow/.notdefup/.notdef                                                                                              | Assessments/.notdef                                                                                                                                                                                                                                                                                                                                          |
| STRATUS-WW/.notdef US,/.notdefCanada,/.notdefAustralia/.notdef /.notdef                                   | Rd,/.notdefDb,/.notdefParallel/.notdefgroup/.notdef(2)/.notdef design/.notdef /.notdef Re-randomization/.notdefof/.notdef responders/.notdef(abstinence)/.notdef at/.notdefweek/.notdef10,/.notdef /.notdef Db,/.notdefPl,/.notdefParallel/.notdefgroup/.notdef(5)/.notdef design /.notdef /.notdef | Rimonabant/.notdef5/.notdefmg,/.notdef/.notdef Rimonabant/.notdef20/.notdefmg,/.notdef/.notdef /.notdef /.notdef /.notdef /.notdef /.notdef Rimonabant/.notdef(20)/20/.notdefmg,/.notdef/.notdef Rimonabant/.notdef(20)/5/.notdefmg,/.notdef/.notdef Rimonabant/.notdef(20/.notdefmg)/Pl/.notdef/.notdef Rimonabant/.notdef(5)/5/.notdefmg/.notdef Rimonabant/.notdef(5/.notdefmg)/Pl/.notdef | 10/.notdefweeks/.notdef /.notdef /.notdef /.notdef /.notdef /.notdef /.notdef 42/.notdefweeks/.notdef | longer off/.notdefdrug/.notdef /.notdef /.notdef /.notdef /.notdef /.notdef /.notdef /.notdef 52/.notdefweeks/.notdef | Primary: /.notdefAbstinence/.notdef during/.notdefthe/.notdeflast/.notdef4/.notdefweeks/.notdefof/.notdef treatment/.notdef(self-report) /.notdef Secondary :/.notdefweight/.notdefgain,/.notdef craving /.notdef /.notdef /.notdef Primary:/.notdef Relapse/.notdefto/.notdef smoking/.notdefat/.notdefweek/.notdef32/.notdef(self/.notdef report) /.notdef |
| ACT4389/.notdef USA,/.notdef6/.notdefcentres/.notdef /.notdef                                             | Rd,/.notdefDb,/.notdefPl,/.notdefParallel/.notdefgroup/.notdef (2)/.notdefdesign,/.notdef/.notdef phase/.notdefII/.notdef                                                                                                                                                                           | Pl/.notdef Rimonabant/.notdef40/.notdefmg,/.notdef/.notdef                                                                                                                                                                                                                                                                                                                                    | 10/.notdefweeks/.notdef                                                                               | 4/.notdefweeks/.notdef                                                                                                | Primary :/.notdefAbstinence/.notdef during/.notdefthe/.notdeflast/.notdef4/.notdefweeks/.notdefof/.notdef treatment/.notdef(self-report)/.notdef                                                                                                                                                                                                             |

/.notdef

/.notdef

/.notdef

/.notdef

<!-- image -->

Medicinal product no longer authorised Table/.notdef8:/.notdefOverview/.notdefof/.notdefsubmitted/.notdefstudies/.notdefin/.notdefsmoking/.notdefcessation/.notdef Db,/.notdefdouble-blind;/.notdefPl,/.notdefplacebo-controlled;/.notdefRd,/.notdefrandomised/.notdef Dose-finding/.notdef studies/.notdef The/.notdefclinical/.notdefefficacy/.notdefof/.notdefrimonabant/.notdefin/.notdefsmoking/.notdefcessation/.notdefwas/.notdeffirst/.notdefstudied/.notdefin/.notdefa/.notdef10-week/.notdefstudy/.notdef(ACT/.notdef4389)/.notdef comparing/.notdef40/.notdefmg/.notdefto/.notdefplacebo/.notdefin/.notdef370/.notdefsubjects./.notdef116/186/.notdefin/.notdefthe/.notdefrimonabant/.notdefgroup/.notdefand/.notdef127/184/.notdefin/.notdefthe/.notdefplacebo/.notdef group/.notdefcompleted/.notdefthe/.notdef10-week/.notdeftreatment/.notdefperiod./.notdefThe/.notdefnumber/.notdefand/.notdefpercentage/.notdefof/.notdefpatients/.notdefwho/.notdefachieved/.notdefthe/.notdef primary/.notdefefficacy/.notdefendpoint/.notdef(prolonged/.notdefabstinence/.notdefduring/.notdefthe/.notdeflast/.notdef4/.notdefweeks/.notdefof/.notdeftreatment)/.notdefin/.notdefthe/.notdefrimonabant/.notdef 40/.notdef mg/.notdef group/.notdef was/.notdef significantly/.notdef higher/.notdef than/.notdef in/.notdef the/.notdef placebo/.notdef group/.notdef (23.5%/.notdef versus/.notdef 13.1%,/.notdef respectively;/.notdef p/.notdef =/.notdef 0.0146;/.notdefOR/.notdef =/.notdef 2.035,/.notdef 95%/.notdef CI:/.notdef 1.176/.notdef -/.notdef 3.522)./.notdef The/.notdef higher/.notdef incidence/.notdef of/.notdef treatment/.notdef discontinuations/.notdef due/.notdefto/.notdef adverse/.notdef events/.notdef (AEs)/.notdef observed/.notdef with/.notdef this/.notdef dose/.notdef compared/.notdef with/.notdef placebo/.notdef [38/.notdef patients/.notdef (20.8%)/.notdef versus/.notdef 10/.notdef (5.5%)],/.notdef essentially/.notdef due/.notdef to/.notdef gastrointestinal/.notdef (nausea),/.notdef central/.notdef and/.notdef peripheral/.notdef nervous/.notdef system/.notdef (tremor,/.notdef dizziness),/.notdef and/.notdef psychiatric/.notdef disorder/.notdef (anxiety,/.notdef nervousness,/.notdef depression)/.notdef adverse/.notdef events,/.notdef led/.notdef to/.notdef consideration/.notdefof/.notdeflower/.notdefdoses/.notdefin/.notdefthe/.notdeffollowing/.notdefstudies./.notdef Main/.notdefstudies/.notdef A/.notdef total/.notdef of/.notdef 7,164/.notdefpatients/.notdefwere/.notdefrandomised/.notdefin/.notdefthe/.notdefthree/.notdefshort/.notdefterm/.notdefstudies/.notdef(main/.notdefstudies:/.notdefSTRATUS-US,/.notdefEU/.notdef and/.notdef -META/.notdef studies)/.notdef and/.notdef one/.notdef long-term/.notdef study/.notdef (supportive/.notdef study:/.notdef STRATUS-WW):/.notdef the/.notdef programme/.notdef included/.notdef3,813/.notdefpatients/.notdeftreated/.notdefwith/.notdefrimonabant/.notdef20/.notdefmg,/.notdef2,534/.notdefpatients/.notdeftreated/.notdefwith/.notdef5/.notdefmg/.notdefand/.notdef789/.notdefpatients/.notdef in/.notdefthe/.notdefplacebo/.notdefgroup./.notdef(See/.notdefTable/.notdef8/.notdefabove/.notdeffor/.notdefmore/.notdefdetails.)/.notdef

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Medicinal product no longer authorised METHODS/.notdef /.notdef Study/.notdefparticipants,/.notdeftreatments/.notdef In/.notdefthe/.notdefshort-term/.notdefstudies/.notdefthe/.notdefmain/.notdefinclusion/.notdefcriteria/.notdefwere:/.notdefmale/.notdefand/.notdeffemale,/.notdefaged/.notdef18/.notdefyears/.notdefand/.notdefolder,/.notdefwho/.notdef had/.notdef smoked/.notdef a/.notdef mean/.notdef of/.notdef at/.notdef least/.notdef 10/.notdef cigarettes/day/.notdef for/.notdef a/.notdef minimum/.notdef of/.notdef at/.notdef least/.notdef 2/.notdef months/.notdef prior/.notdef to/.notdef treatment./.notdef They/.notdefneeded/.notdefto/.notdefbe/.notdefmotivated/.notdefto/.notdefquit/.notdef(score/.notdef&gt;6/.notdefon/.notdefa/.notdef10-point/.notdefvisual/.notdefanalogue/.notdefscale),/.notdefand/.notdefotherwise/.notdefhealthy/.notdef as/.notdefchecked/.notdefby/.notdefphysical/.notdefexamination,/.notdeflaboratory/.notdefevaluation/.notdefand/.notdefECG./.notdefSubjects/.notdefwere/.notdefexcluded/.notdefif/.notdefthey/.notdefwere/.notdef smoking/.notdefother/.notdefthan/.notdefregular/.notdefnicotine/.notdefcontaining/.notdefcigarettes/.notdefor/.notdefmarijuana/.notdefat/.notdefa/.notdefregular/.notdefbase,/.notdefif/.notdefsuffering/.notdeffrom/.notdef severe/.notdef psychiatric/.notdef illness/.notdef (e.g./.notdef psychosis,/.notdef depression,/.notdef anxiety,/.notdef alcohol/.notdef or/.notdef substance/.notdef abuse/dependency,/.notdef assessed/.notdefby/.notdefthe/.notdefMINI),/.notdefor/.notdefany/.notdefclinically/.notdefsignificant/.notdefacute/.notdefor/.notdefchronic/.notdefprogressive/.notdefsomatic/.notdefdisease,/.notdefor/.notdefeating/.notdef disorder./.notdefSubjects/.notdefwith/.notdefa/.notdefhistory/.notdefof/.notdefepilepsy,/.notdefas/.notdefwell/.notdefas/.notdefsubjects/.notdefat/.notdefhigh/.notdefcardiovascular/.notdefrisk/.notdef(uncontrolled/.notdef hypertension,/.notdef post-myocardial/.notdef infarction)/.notdef were/.notdef also/.notdef excluded./.notdef Female/.notdef subjects/.notdef were/.notdef excluded/.notdef when/.notdef pregnant/.notdefor/.notdef lactating./.notdef Subjects/.notdef were/.notdef also/.notdef excluded/.notdef when/.notdef they/.notdef had/.notdef used/.notdef NRT,/.notdef bupropion,/.notdef counselling,/.notdef or/.notdef antidepressant/.notdef therapy/.notdef for/.notdef more/.notdef than/.notdef 1/.notdef week,/.notdef within/.notdef 3/.notdef months/.notdef prior/.notdef to/.notdef randomization,/.notdef or/.notdef systemic/.notdef treatment/.notdefon/.notdefa/.notdefchronic/.notdefbase/.notdef(corticosteroids,/.notdefantihistamines,/.notdefor/.notdefanti-obesity/.notdefdrugs)./.notdef /.notdef In/.notdef the/.notdef STRATUS-WW/.notdef the/.notdef inclusion/.notdef and/.notdef exclusion/.notdef criteria/.notdef were/.notdef similar/.notdef to/.notdef those/.notdef in/.notdef the/.notdef main/.notdef short-term/.notdef studies./.notdef /.notdef In/.notdef the/.notdef short-term/.notdef studies/.notdef (STRATUS-US,/.notdef -EU/.notdef and/.notdef -META/.notdef studies)/.notdef the/.notdef patients/.notdef were/.notdef randomised/.notdef while/.notdef still/.notdef smoking/.notdef and/.notdef were/.notdef treated/.notdef for/.notdef two/.notdef weeks/.notdefprior/.notdefto/.notdefand/.notdefeight/.notdefweeks/.notdefafter/.notdefthe/.notdefTarget/.notdefQuit/.notdefDay/.notdef(TQD);/.notdef the/.notdef patients/.notdef were/.notdef followed/.notdef up/.notdef for/.notdef 40/.notdef weeks/.notdef off/.notdef drug./.notdef STRATUS-WW/.notdef was/.notdef a/.notdef long/.notdef term/.notdef follow-up/.notdef study:/.notdef after/.notdef ten/.notdef weeks/.notdef of/.notdef double-blind/.notdef treatment/.notdef with/.notdef rimonabant/.notdef 5/.notdef mg/day/.notdef (n=2016)/.notdef or/.notdef 20/.notdef mg/day/.notdef (n=3023),/.notdef patients/.notdef who/.notdef were/.notdef abstinent/.notdef were/.notdef re-randomised/.notdef to/.notdef the/.notdef active/.notdef treatment/.notdef or/.notdef placebo/.notdef for/.notdef 42/.notdef weeks/.notdef to/.notdef evaluate/.notdefmaintenance/.notdefof/.notdefabstinence./.notdefPatients/.notdefinitially/.notdefrandomised/.notdefto/.notdefthe/.notdef20/.notdefmg/.notdefarm/.notdefwere/.notdefre-randomised/.notdefto/.notdef 20/.notdef mg,/.notdef 5/.notdef mg,/.notdef or/.notdef placebo./.notdef Patients/.notdef initially/.notdef randomised/.notdef to/.notdef 5/.notdef mg/.notdef were/.notdef re-randomised/.notdef to/.notdef 5/.notdef mg/.notdef or/.notdef placebo./.notdef The/.notdefpatients/.notdefwere/.notdeffollowed/.notdefup/.notdeffor/.notdef52/.notdefweeks/.notdefoff/.notdefdrug./.notdef/.notdef /.notdef Outcomes//.notdefendpoints/.notdef /.notdef The/.notdef primary/.notdef efficacy/.notdefendpoint/.notdefin/.notdef the/.notdef three/.notdef short-term/.notdef studies/.notdef was/.notdefpercentage/.notdefof/.notdefsubjects/.notdefwith/.notdefprolonged/.notdef abstinence/.notdeffrom/.notdefsmoking/.notdef(not/.notdefeven/.notdefa/.notdefpuff)/.notdefat/.notdefevery/.notdefvisit/.notdefduring/.notdefthe/.notdeflast/.notdef4/.notdefweeks/.notdefof/.notdeftreatment/.notdef(week/.notdef7-10),/.notdef as/.notdef assessed/.notdef by/.notdef the/.notdef subject's/.notdef self-report/.notdef and/.notdef diary/.notdef consultation,/.notdef and/.notdef confirmed/.notdef by/.notdef a/.notdef CO/.notdef content/.notdef of/.notdef the/.notdef exhaled/.notdef breath/.notdef &lt;10/.notdef ppm,/.notdef and/.notdef plasma/.notdef cotinine/.notdef &lt;8/.notdef GLYPH&lt;4&gt; g/l/.notdef at/.notdef 2/.notdef time/.notdef points/.notdef measured/.notdef (week/.notdef 8/.notdef and/.notdef 10)./.notdef Main/.notdef secondary/.notdefendpoints/.notdefwere:/.notdefChange/.notdefin/.notdefbody-weight/.notdef[mean/.notdefchange/.notdeffrom/.notdefbaseline/.notdefin/.notdefbody-weight/.notdefat/.notdefthe/.notdefend/.notdef of/.notdef treatment/.notdef in/.notdef non-obese/.notdef (BMI&lt;30/.notdef kg/m2)/.notdef subjects,/.notdef categorized/.notdef as/.notdef decrease/no/.notdef change/increase/.notdef (decrease/increase/.notdef defined/.notdef as/.notdef &gt;5%/.notdef difference/.notdef from/.notdef baseline)],/.notdef and/.notdef Decrease/.notdef of/.notdef craving/.notdef [mean/.notdef change/.notdef from/.notdefbaseline/.notdefat/.notdefthe/.notdefend/.notdefof/.notdeftreatment/.notdefof/.notdefthe/.notdeftotal/.notdefscore/.notdefof/.notdefthe/.notdefQuestionnaire/.notdefof/.notdefSmoking/.notdefCessation/.notdefUrges/.notdef Brief/.notdefform/.notdef(QSU/.notdefBrief)]./.notdef /.notdef In/.notdefthe/.notdefSTRATUS-WW,/.notdefthe/.notdefprimary/.notdefefficacy/.notdefendpoint/.notdefwas/.notdeftime/.notdefto/.notdefsmoking/.notdefrelapse /.notdef from/.notdefweek/.notdef10/.notdefto/.notdefweek/.notdef 32/.notdef [relapse/.notdef was/.notdef defined/.notdef as:/.notdef any/.notdef 7/.notdef or/.notdef more/.notdef consecutive/.notdef days/.notdef of/.notdef smoking/.notdef (even/.notdef a/.notdef puff),/.notdef or/.notdef any/.notdef 2/.notdef consecutive/.notdef days/.notdef of/.notdef smoking/.notdef 5/.notdef or/.notdef more/.notdef cigarettes/.notdef per/.notdef day/.notdef (even/.notdef a/.notdef puff)]./.notdef Secondary/.notdef endpoints/.notdef included/.notdef abstinence/.notdef related/.notdef endpoints/.notdef (4-week/.notdef prolonged/.notdef abstinence,/.notdef continuous/.notdef abstinence,/.notdef weekly/.notdef point/.notdef prevalence/.notdefabstinence),/.notdefbody/.notdefweight,/.notdefcraving,/.notdefmetabolic/.notdefparameters./.notdefTime/.notdefto/.notdef relapse/.notdef was/.notdef also/.notdef measured/.notdef at/.notdefweek/.notdef52./.notdef/.notdef /.notdef RESULTS/.notdef /.notdef STRATUS-US,/.notdefSTRATUS-EU/.notdefand/.notdefSTRATUS-META/.notdefstudies/.notdef The/.notdef included/.notdef subjects/.notdef were/.notdef middle-aged,/.notdef with/.notdef equivalent/.notdef proportion/.notdef of/.notdef male/.notdef and/.notdef female/.notdef patients./.notdef Most/.notdef patients/.notdef were/.notdef Caucasian./.notdef Majority/.notdef of/.notdef the/.notdef participants/.notdef was/.notdef enrolled/.notdef in/.notdef North/.notdef America/.notdef (84%)./.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

<!-- image -->

| /.notdef/.notdef                                       | STRATUS/.notdefUS/.notdef       | STRATUS/.notdefUS/.notdef           | STRATUS/.notdefUS/.notdef            | STRATUS/.notdefEU/.notdef       | STRATUS/.notdefEU/.notdef           | STRATUS/.notdefMETA/.notdef          | STRATUS/.notdefMETA/.notdef     | STRATUS/.notdefMETA/.notdef          |
|--------------------------------------------------------|---------------------------------|-------------------------------------|--------------------------------------|---------------------------------|-------------------------------------|--------------------------------------|---------------------------------|--------------------------------------|
|                                                        | Placebo/.notdef (N=261)/.notdef | 5/.notdefmg/.notdef (N=262)/.notdef | 20/.notdefmg/.notdef (N=261)/.notdef | Placebo/.notdef (N=260)/.notdef | 5/.notdefmg/.notdef (N=256)/.notdef | 20/.notdefmg/.notdef (N=267)/.notdef | Placebo/.notdef (N=268)/.notdef | 20/.notdefmg/.notdef (N=262)/.notdef |
| Abstinent/.notdef                                      | 42/.notdef (16.1%)/.notdef      | 41/.notdef (15.6 %)/.notdef         | 72/.notdef (27.6%)/.notdef           | 51/.notdef (19.6%)/.notdef      | 62/.notdef (24.2%)/.notdef          | 66/.notdef (24.7%)/.notdef           | 25/.notdef (9.3%)/.notdef       | 36/.notdef (13.7%)/.notdef           |
| p/.notdef vs/.notdef placebo/.notdef [a]/.notdef       | /.notdef/.notdef                | 0.905/.notdef                       | 0.002/.notdef                        | /.notdef                        | 0.242/.notdef                       | 0.174/.notdef                        | /.notdef                        | 0.134/.notdef                        |
| Odds/.notdef ratios/.notdef vs/.notdef placebo/.notdef | /.notdef/.notdef                | 0.967/.notdef                       | 1.986/.notdef                        | /.notdef                        | 1.310/.notdef                       | 1.346/.notdef                        | /.notdef                        | 1.548/.notdef                        |
| 95%/.notdefCI/.notdef                                  | /.notdef/.notdef                | (0.605,/.notdef 1.546)/.notdef      | (1.296,/.notdef 3.046)/.notdef       | /.notdef                        | (0.861,/.notdef 1.991)/.notdef      | (0.890,/.notdef 2.035)/.notdef       | /.notdef                        | (0.901,/.notdef 2.661)/.notdef       |

/.notdef

/.notdef

/.notdef

<!-- image -->

Medicinal product no longer authorised Approximately/.notdef 25%/.notdef of/.notdef the/.notdef population/.notdef across/.notdef studies/.notdef was/.notdef obese/.notdef (BMI/.notdef ≥ 30/.notdefkg/m 2 )./.notdef Patients/.notdef had/.notdef been/.notdef smoking/.notdef regularly/.notdef for/.notdef about/.notdef 24/.notdef to/.notdef 27/.notdefyears,/.notdef and/.notdef smoked/.notdef an/.notdef average/.notdef of/.notdef 23/.notdefcigarettes/.notdef per/.notdef day./.notdef The/.notdef mean/.notdef number/.notdefof/.notdef previous/.notdef attempts/.notdef to/.notdef stop/.notdef smoking/.notdef ranged/.notdef from/.notdef approximately/.notdef3/.notdef in/.notdef STRATUS-EU/.notdefstudy/.notdefto/.notdef6/.notdef in/.notdef STRATUS-META/.notdef study./.notdef The/.notdef group/.notdef of/.notdef subjects/.notdef above/.notdef 64/.notdef years/.notdef was/.notdef small,/.notdef only/.notdef 55/.notdef subjects/.notdef in/.notdef the/.notdef STRATUS-US,/.notdef-EU/.notdefand/.notdefMETA/.notdeftogether./.notdefThe/.notdefgroup/.notdefof/.notdefAfro-American/.notdefsubjects/.notdefwas/.notdefalso/.notdefsmall/.notdef(6%)./.notdef The/.notdef efficacy/.notdefof/.notdefrimonabant/.notdefas/.notdefan/.notdefaid/.notdefto/.notdefsmoking/.notdefcessation/.notdefwas/.notdefobserved/.notdefin/.notdefSTRATUS-US,/.notdefbut/.notdefthe/.notdefother/.notdef two/.notdefshort-term/.notdefstudies/.notdeffailed/.notdefto/.notdefshow/.notdefsignificant/.notdefdifferences/.notdefbetween/.notdefrimonabant/.notdefand/.notdefplacebo/.notdef(see/.notdeftable/.notdef9/.notdef below)./.notdef/.notdef Table/.notdef9:/.notdefResults/.notdeffrom/.notdefSTRATUS-US,/.notdef-EU/.notdefand/.notdef-META-studies/.notdef [a]/.notdefp-values/.notdefcome/.notdeffrom/.notdefFisher's/.notdefexact/.notdeftest/.notdef The/.notdef prespecified/.notdef pooled/.notdef analysis/.notdef of/.notdef prolonged/.notdef abstinence/.notdef data/.notdef from/.notdef these/.notdef short-term/.notdef studies/.notdef suggested/.notdef that/.notdef rimonabant/.notdef 20/.notdefmg/.notdef was/.notdef associated/.notdef with/.notdef greater/.notdef efficacy/.notdef compared/.notdef with/.notdef placebo/.notdef (rimonabant/.notdef 20/.notdefmg:/.notdef 22.0%,/.notdef placebo:/.notdef 15.0%,/.notdef p/.notdef=/.notdef0.0003,/.notdef OR/.notdef=/.notdef1.610,/.notdef 95%/.notdef CI:/.notdef 1.241,/.notdef 2.088)./.notdef A/.notdef total/.notdef of/.notdef 47%/.notdef more/.notdef patients/.notdef achieved/.notdefabstinence/.notdefwith/.notdefrimonabant/.notdef20/.notdefmg/.notdefthan/.notdefwith/.notdefplacebo./.notdef/.notdef The/.notdefOR/.notdeffor/.notdefsmoking/.notdefcessation/.notdefwith/.notdefrimonabant/.notdefwas/.notdefbetween/.notdef1.4/.notdefand/.notdef1.6,/.notdefwhich/.notdefplaces/.notdefrimonabant/.notdefat/.notdefthe/.notdef lower/.notdefend/.notdefof/.notdefthe/.notdefefficacy/.notdefspectrum/.notdefcompared/.notdefwith/.notdefconventional/.notdeftreatment/.notdefmodalities./.notdef/.notdef During/.notdefthe/.notdefprocedure/.notdefthe/.notdefapplicant/.notdefsubmitted/.notdefresults/.notdefof/.notdefa/.notdeffollow-up/.notdefof/.notdefabout/.notdefone/.notdefyear/.notdefof/.notdefsubjects/.notdeffrom/.notdefthe/.notdef short/.notdefterm/.notdefstudies./.notdefThe/.notdefSTRATUS-US/.notdefstudy/.notdefpatients/.notdeftreated/.notdefwith/.notdefrimonabant/.notdef20/.notdefmg/.notdefduring/.notdefthe/.notdefinitial/.notdef10/.notdef weeks/.notdef continued/.notdef to/.notdef show/.notdef a/.notdef statistically/.notdef significant/.notdef improvement/.notdef in/.notdef abstinence/.notdef at/.notdef 1/.notdef year/.notdef (p=0.021);/.notdef similarly,/.notdef the/.notdef STRATUS-EU/.notdef results/.notdef at/.notdef 1-year/.notdef remained/.notdef consistent/.notdef with/.notdef those/.notdef observed/.notdef at/.notdef 10/.notdef weeks,/.notdef i.e./.notdef not/.notdefsignificant./.notdef(See/.notdefTables/.notdef10/.notdefand/.notdef11/.notdefbelow.)/.notdef/.notdef Table/.notdef 10:/.notdef Point/.notdef prevalence/.notdef abstinence/.notdef at/.notdef end-of-treatment/.notdef visit/.notdef (day/.notdef 70)/.notdef and/.notdef end-of-study/.notdef visit/.notdef (day/.notdef 350),/.notdef in/.notdef the/.notdefSTRATUS-US-study/.notdef

/.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

<!-- image -->

Medicinal product no longer authorised Table/.notdef 11:/.notdef Point/.notdef prevalence/.notdef abstinence/.notdef at/.notdef end-of-treatment/.notdef visit/.notdef (day/.notdef 70)/.notdef and/.notdef end-of-study/.notdef visit/.notdef (day/.notdef 350),/.notdef in/.notdef the/.notdefSTRATUS-EU-study/.notdef Thus,/.notdef the/.notdef short/.notdef term/.notdef effects/.notdef seen/.notdef in/.notdef the/.notdef -US/.notdef study/.notdef were/.notdef relatively/.notdefwell/.notdefmaintained/.notdefover/.notdefone/.notdefyear,/.notdefwith/.notdefa/.notdef difference/.notdef of/.notdef 10.3%/.notdef after/.notdef 10/.notdef weeks/.notdef compared/.notdef to/.notdef a/.notdef difference/.notdef of/.notdef 7.7%/.notdef after/.notdef the/.notdef additional/.notdef 40/.notdef weeks/.notdef of/.notdef follow/.notdefup./.notdef/.notdef STRATUS-WW/.notdefstudy/.notdef The/.notdef mean/.notdef age/.notdef of/.notdef patients/.notdef in/.notdef STRATUS-WW-study/.notdefwas/.notdef44/.notdef(SD/.notdef 11)/.notdef years,/.notdef the/.notdef study/.notdef included/.notdef equivalent/.notdef proportion/.notdefof/.notdefmales/.notdefand/.notdeffemales,/.notdefmajority/.notdefof/.notdefthe/.notdefpatients/.notdefwere/.notdefCaucasian,/.notdefthe/.notdefmean/.notdefBMI/.notdefwas/.notdef28/.notdefkg//.notdefm 2 ,/.notdef the/.notdefpatients/.notdefhad/.notdefbeen/.notdefsmoking/.notdeffor/.notdef26/.notdef(mean)/.notdefyears,/.notdefand/.notdefsmoked/.notdefan/.notdefaverage/.notdefof/.notdef23/.notdefcigarettes/.notdefper/.notdefday./.notdef The/.notdefresults/.notdeffrom/.notdefSTRATUS-WW-study/.notdefare/.notdefpresented/.notdefin/.notdefFigure/.notdef3/.notdefand/.notdefTable/.notdef12/.notdefbelow./.notdef Figure/.notdef3:/.notdefA/.notdefsummary/.notdefof/.notdefprimary/.notdefendpoint/.notdeftime/.notdefto/.notdefrelapse/.notdeffor/.notdefthe/.notdef20/.notdefmg/.notdefdose/.notdefrimonabant. Time/.notdefto/.notdefrelapse/.notdef(week) Time/.notdefto/.notdefrelapse/.notdef(week)

/.notdef

/.notdef

<!-- image -->

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised Table/.notdef 12:/.notdef Non-relapse/.notdef rates/.notdef at/.notdef Week/.notdef 32/.notdef (primary/.notdef efficacy/.notdef endpoint)/.notdef and/.notdef Week/.notdef 52/.notdef (secondary/.notdef efficacy/.notdef endpoint)/.notdefin/.notdefthe/.notdefSTRATUS-WW-study/.notdef[N/.notdef(%)],/.notdefstratum/.notdef20/.notdefmg/.notdef A/.notdef 10%/.notdefdifference/.notdefin/.notdeffavour/.notdefof/.notdefrimonabant/.notdefwas/.notdefobserved/.notdeffor/.notdefmaintenance/.notdefat/.notdefWeek/.notdef32/.notdefand/.notdefWeek/.notdef52,/.notdefboth/.notdef for/.notdefthe/.notdef5/.notdefmg/.notdefdose/.notdefand/.notdefthe/.notdef20/.notdefmg/.notdefdose/.notdefversus/.notdefplacebo,/.notdefin/.notdefpatients/.notdefinitially/.notdeftreated/.notdefwith/.notdefrimonabant/.notdef20/.notdefmg./.notdef This/.notdef corresponds/.notdef for/.notdef the/.notdef 20/.notdef mg/.notdef dose/.notdef to/.notdef a/.notdef reduction/.notdef in/.notdef odds/.notdef of/.notdef relapse/.notdef by/.notdef approximately/.notdef 30%./.notdef Both/.notdef rimonabant/.notdef20/.notdef mg/.notdef and/.notdef 5/.notdef mg/.notdef showed/.notdef similar/.notdef effects/.notdef regarding/.notdef maintenance/.notdef of/.notdef abstinence/.notdef versus/.notdef placebo/.notdef in/.notdefpatients/.notdefwho/.notdefinitially/.notdefstopped/.notdefsmoking/.notdefwith/.notdefthe/.notdef20/.notdefmg/.notdefdose./.notdef In/.notdefaddition,/.notdefresults/.notdefafter/.notdef102/.notdefweeks/.notdef(off/.notdefdrug)/.notdefare/.notdefgiven/.notdefin/.notdefTable/.notdef13./.notdef/.notdef Table/.notdef13:/.notdefNon-relapse/.notdefrates/.notdefat/.notdefWeek/.notdef102/.notdefin/.notdefthe/.notdefSTRATUS-WW-study/.notdef[N/.notdef(%)],/.notdefstratum/.notdef20/.notdefmg · Discussion/.notdefon/.notdefclinical/.notdefefficacy/.notdef OBESITY/.notdef The/.notdef demonstrated/.notdef body/.notdef weight/.notdef reduction/.notdef in/.notdef overweight/.notdef patients/.notdef with/.notdef additional/.notdef cardiovascular/.notdef risk/.notdef factors/.notdefand/.notdefin/.notdefobese/.notdefpatients/.notdefand/.notdefthe/.notdefeffects/.notdefon/.notdefbody/.notdefweight/.notdefrelated/.notdefparameters/.notdefobtained/.notdefwith/.notdefrimonabant/.notdef 20/.notdef mg/.notdef were/.notdef clinically/.notdef relevant/.notdef and/.notdef maintained/.notdef over/.notdef time./.notdef Obese/.notdef patients/.notdef with/.notdef type/.notdef 2/.notdef diabetes/.notdef and/.notdef dyslipidaemia/.notdefwere/.notdefspecifically/.notdefstudied/.notdefin/.notdefseparate/.notdefstudies/.notdefand/.notdefclinically/.notdefrelevant/.notdefweight/.notdefreductions/.notdefwere/.notdef demonstrated/.notdefalso/.notdefin/.notdefthese/.notdefpatient/.notdefgroups./.notdef The/.notdefCHMP/.notdefdoes/.notdefnot/.notdefcurrently/.notdefaccept/.notdefmetabolic/.notdefsyndrome/.notdefas/.notdefan/.notdefinstrument/.notdefto/.notdefidentify/.notdefa/.notdeftarget/.notdefpopulation/.notdef for/.notdef pharmacological/.notdef therapy./.notdef No/.notdef generally/.notdef accepted/.notdef definition/.notdef of/.notdef the/.notdef metabolic/.notdef syndrome/.notdef exists./.notdef No/.notdef proper/.notdefbenefit/risk/.notdefevaluation/.notdefcould/.notdefbe/.notdefmade/.notdeffor/.notdefthe/.notdeflong-term/.notdefrimonabant/.notdeftreatment/.notdefof/.notdefpatients/.notdefwith/.notdefthe/.notdef proposed/.notdefrisk/.notdeffactor/.notdefcomplex,/.notdefas/.notdefno/.notdefoutcome/.notdefdata/.notdefwith/.notdefregard/.notdefto/.notdefclinically/.notdefrelevant/.notdefevents/.notdefexisted./.notdefThus,/.notdef the/.notdef claim/.notdef for/.notdef pharmacological/.notdef intervention/.notdef based/.notdef on/.notdef a/.notdef demonstrated/.notdef reduction/.notdef of/.notdef the/.notdef incidence/.notdef of/.notdef the/.notdef metabolic/.notdefsyndrome/.notdef(or/.notdefof/.notdefa/.notdefgeneral/.notdefreduction/.notdefof/.notdefthe/.notdefincidence/.notdefof/.notdefthe/.notdefindividual/.notdefrisk/.notdeffactor/.notdefcomponents)/.notdef could/.notdefnot/.notdefbe/.notdefaccepted/.notdefwith/.notdefcurrent/.notdefknowledge./.notdef/.notdef The/.notdefeffects/.notdefof/.notdefrimonabant/.notdefon/.notdefHDL-C,/.notdefits/.notdefsubfractions/.notdefand/.notdefon/.notdeftriglycerides/.notdefwere/.notdefinteresting/.notdefand/.notdefthey/.notdefmay/.notdef indicate/.notdefthat/.notdefrimonabant/.notdefcould/.notdefreduce/.notdefthe/.notdefrisk/.notdeffor/.notdefcardiovascular/.notdefcomplications,/.notdefwhich,/.notdefhowever,/.notdefremains/.notdef

/.notdef

<!-- image -->

| /.notdef Non-relapse/.notdefrates/.notdef                                    | 20/.notdefmg/PLB/.notdef (N=342)/.notdef   | no 20/.notdefmg/5/.notdefmg/.notdef (N=335)/.notdef   | 20/.notdefmg/20/.notdefmg/.notdef (N=340)/.notdef   |
|------------------------------------------------------------------------------|--------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|
| Follow-up/.notdefoff-drug/.notdefup/.notdefto/.notdefWeek/.notdef102/.notdef | 81/.notdef(23.7%)/.notdef                  | 97/.notdef(29.0%)/.notdef                             | 106/.notdef(31.2%)/.notdef                          |
| Odds/.notdefratio/.notdef                                                    | /.notdef                                   | 1.313/.notdef                                         | 1.460/.notdef                                       |
| 95%/.notdefCI/.notdef                                                        | /.notdef                                   | (0.932,/.notdef1.851)/.notdef                         | (1.040,/.notdef2.048)/.notdef                       |
| p/.notdefvalue/.notdefversus/.notdefplacebo/.notdef                          | /.notdef                                   | 0.018/.notdef                                         | 0.005/.notdef                                       |

/.notdef

<!-- image -->

/.notdef

<div style=\"page-break-after: always\"></div>

Medicinal product no longer authorised to/.notdef be/.notdef shown,/.notdef as/.notdef outcome/.notdef data/.notdef demonstrating/.notdef a/.notdef reduction/.notdef of/.notdef clinically/.notdef relevant/.notdef events/.notdef were/.notdef lacking./.notdef Furthermore,/.notdef no/.notdef comparative/.notdef data/.notdef with/.notdef an/.notdef active/.notdef comparator/.notdef product/.notdef were/.notdef available./.notdef Thus,/.notdef a/.notdef specific/.notdef claim/.notdef for/.notdef treatment/.notdef of/.notdef dyslipidaemia/.notdef could/.notdef not/.notdef be/.notdef accepted;/.notdef these/.notdef effects/.notdef were,/.notdef however,/.notdef considered/.notdef of/.notdef importance/.notdefand/.notdefare/.notdefthus/.notdefdescribed/.notdefin/.notdefthe/.notdefSPC/.notdef(5.1)./.notdef /.notdef The/.notdefindication/.notdefas/.notdefan/.notdefadjunct/.notdeftreatment/.notdefto/.notdefdiet/.notdefand/.notdefexercise/.notdefto/.notdefimprove/.notdefglycaemic/.notdefcontrol/.notdefin/.notdeftreated/.notdeftype/.notdef2/.notdef diabetes/.notdefpatients/.notdefsuggested/.notdefthat/.notdefin/.notdefthese/.notdefpatients/.notdefwith/.notdefoverweight/.notdefthere/.notdefwas/.notdefmore/.notdefto/.notdefgain/.notdefthan/.notdefweight/.notdefloss/.notdef only,/.notdef i.e./.notdef substantial/.notdef glycaemic/.notdef control./.notdef The/.notdef total/.notdef reduction/.notdef of/.notdef HbA1c/.notdef in/.notdef type/.notdef 2/.notdef diabetes/.notdef already/.notdef treated/.notdef with/.notdefan/.notdeforal/.notdefanti-diabetic/.notdefwas/.notdef0.7%/.notdefwith/.notdefrimonabant/.notdef(as/.notdefcompared/.notdefto/.notdefplacebo),/.notdefwhich/.notdefwas/.notdefjudged/.notdefto/.notdefbe/.notdefa/.notdef clinically/.notdefrelevant/.notdefreduction./.notdefHowever,/.notdefthe/.notdefsignificant/.notdefinteraction/.notdefbetween/.notdefweight/.notdefloss/.notdefand/.notdeftreatment/.notdefwith/.notdef respect/.notdef to/.notdef HbA1c/.notdef (%)/.notdef allowed/.notdef no/.notdef straight/.notdef forward/.notdef interpretation/.notdef of/.notdef the/.notdef main/.notdef effect,/.notdef i.e./.notdef reduction/.notdef of/.notdef HbA1c(%)/.notdef corrected/.notdef for/.notdef weight/.notdef loss;/.notdef hence/.notdef the/.notdef independent/.notdef effect/.notdef of/.notdef rimonabant/.notdef on/.notdef HbA1c/.notdef was/.notdef questioned/.notdef by/.notdef the/.notdef CHMP./.notdef Therefore/.notdef the/.notdef applicant/.notdef carried/.notdef out/.notdef extensive/.notdef analyses,/.notdef which/.notdef demonstrated/.notdef that/.notdefthere/.notdefwas,/.notdefindeed,/.notdefan/.notdefeffect/.notdefon/.notdefHbA1c/.notdefthat/.notdefwas/.notdefindependent/.notdefof/.notdefweight/.notdefloss./.notdefIt/.notdefwas/.notdefdifficult/.notdefto/.notdefexactly/.notdef define/.notdefthe/.notdefsize/.notdefof/.notdefthis/.notdefeffect/.notdef(and/.notdefwill/.notdefbe/.notdefthe/.notdefsame/.notdefalso/.notdefin/.notdeflarger/.notdefstudies),/.notdefbut/.notdefit/.notdefwas/.notdefagreed/.notdefthat/.notdefthe/.notdefoverall/.notdef HbA1c/.notdef reducing/.notdef effect/.notdef was/.notdef the/.notdef most/.notdef relevant/.notdef effect/.notdef from/.notdef clinical/.notdef perspective./.notdef Overall,/.notdef the/.notdef beneficial/.notdef effects/.notdef of/.notdef combined/.notdef weight/.notdef reduction/.notdef and/.notdef improved/.notdef glucose/.notdef regulation/.notdef (which/.notdef is/.notdef difficult/.notdef to/.notdef achieve/.notdef in/.notdef patients/.notdeffailing/.notdefon/.notdefmetformin/.notdeftreatment/.notdefwith/.notdefthe/.notdeftreatment/.notdefalternatives/.notdefavailable/.notdeftoday)/.notdefcould/.notdefbe/.notdefexpected/.notdef to/.notdefbe/.notdefgreater/.notdefin/.notdeftype/.notdef2/.notdefdiabetes/.notdefpatients/.notdefthan/.notdefin/.notdefa/.notdefgeneral/.notdefoverweight/.notdefpopulation./.notdefHowever,/.notdefno/.notdefprospective/.notdef confirmatory/.notdef trial/.notdef focusing/.notdef on/.notdef patients/.notdef failing/.notdef on/.notdef OAD/.notdef was/.notdef performed./.notdef Also,/.notdef no/.notdef study/.notdef on/.notdef rimonabant/.notdef monotherapy/.notdefin/.notdeftype/.notdef2/.notdefdiabetes/.notdefpatients/.notdefwas/.notdefcarried/.notdefout./.notdefThus,/.notdefa/.notdefseparate/.notdefindication/.notdeffor/.notdeftreatment/.notdefof/.notdeftype/.notdef 2/.notdef diabetes/.notdef was/.notdef not/.notdef currently/.notdef justified./.notdef Furthermore,/.notdef treatment/.notdef of/.notdef overweight/.notdef in/.notdef patients/.notdef with/.notdef type/.notdef 2/.notdef diabetes/.notdef was/.notdef already/.notdef included/.notdef in/.notdef an/.notdef indication/.notdef for/.notdef treatment/.notdef of/.notdef overweight/.notdef patients/.notdef with/.notdef additional/.notdef risk/.notdef factors./.notdef It/.notdef was/.notdef agreed/.notdef with/.notdef the/.notdef applicant/.notdef that/.notdef rimonabant/.notdef could/.notdef not/.notdef be/.notdef directly/.notdef compared/.notdef with/.notdef classical/.notdef OAD/.notdefagents./.notdefA/.notdefshort/.notdefdescription/.notdefof/.notdefthe/.notdefRIO-diabetes/.notdefstudy/.notdefresults/.notdefare/.notdefdescribed/.notdefin/.notdefthe/.notdefSPC/.notdef(5.1)./.notdef/.notdef Further,/.notdef in/.notdef the/.notdef major/.notdef dose-finding/.notdef study/.notdef the/.notdef high/.notdef withdrawal/.notdef rate/.notdef in/.notdef combination/.notdef with/.notdef the/.notdef rather/.notdef small/.notdef efficacy/.notdefdifference/.notdefbetween/.notdefthe/.notdef10/.notdefand/.notdef20/.notdefmg/.notdefgroups,/.notdeftogether/.notdefwith/.notdefa/.notdeftendency/.notdeffor/.notdefa/.notdefhigher/.notdefincidence/.notdefof/.notdef adverse/.notdef reactions/.notdef in/.notdef the/.notdef 20/.notdef mg/.notdef group/.notdef (nausea,/.notdef diarrhoea,/.notdef dizziness),/.notdef resulted/.notdef in/.notdef remaining/.notdef uncertainty/.notdef whether/.notdef 20/.notdef mg/.notdef is/.notdef the/.notdef most/.notdef optimal/.notdef dose./.notdef The/.notdef Applicant/.notdef committed/.notdef to/.notdef further/.notdef investigate/.notdef (as/.notdef a/.notdef postapproval/.notdeffollow-up/.notdefmeasure)/.notdefthe/.notdefefficacy/.notdefand/.notdefsafety/.notdefof/.notdefa/.notdef10/.notdefmg/.notdefdose/.notdefin/.notdefpatients/.notdefnot/.notdeftolerating/.notdef20/.notdefmg/.notdefdue/.notdef to/.notdefside/.notdefeffects/.notdefor/.notdefas/.notdefa/.notdeflong-term/.notdeftreatment/.notdefto/.notdefmaintain/.notdefthe/.notdefeffects/.notdefinitially/.notdefobtained/.notdefwith/.notdefa/.notdef20/.notdefmg/.notdefdose./.notdef /.notdef SMOKING/.notdefCESSATION/.notdef /.notdef The/.notdef selection/.notdef of/.notdef doses/.notdef (5,/.notdef 20,/.notdef and/.notdef 40mg/day/.notdef of/.notdef rimonabant)/.notdef for/.notdef the/.notdef different/.notdefsmoking/.notdefstudies/.notdefwas/.notdefbased/.notdef on/.notdef pharmacokinetic,/.notdef safety/.notdef and/.notdef tolerability/.notdef data/.notdef of/.notdef rimonabant/.notdef in/.notdef healthy/.notdef volunteers./.notdef The/.notdef maximal/.notdef tolerated/.notdef dose/.notdef in/.notdef those/.notdef studies/.notdef was/.notdef 60/.notdef mg/day/.notdef of/.notdef rimonabant./.notdef Subsequently,/.notdef the/.notdef dose/.notdef of/.notdef 40/.notdef mg/day/.notdef of/.notdef rimonabant/.notdef was/.notdef chosen/.notdef for/.notdef the/.notdef phase/.notdef II/.notdef smoking/.notdef cessation/.notdef study/.notdef (ACT4389)./.notdef No/.notdef other/.notdef doses/.notdef were/.notdef included/.notdefin/.notdef the/.notdef phase/.notdef II/.notdef study,/.notdef indicating/.notdef that/.notdef no/.notdef formal/.notdef phase/.notdefII/.notdef dose-finding/.notdefstudies/.notdefwere/.notdefperformed/.notdefin/.notdef the/.notdef target/.notdef population./.notdef Subsequently,/.notdef based/.notdef on/.notdef efficacy/.notdef and/.notdef tolerability/.notdef of/.notdef rimonabant/.notdef 40/.notdef mg/day/.notdef in/.notdef the/.notdef ACT4389/.notdefstudy,/.notdef and/.notdef experience/.notdef with/.notdef the/.notdef 20/.notdef mg/day/.notdef dose/.notdef in/.notdef the/.notdef obesity/.notdef studies,/.notdef the/.notdef 5/.notdef and/.notdef 20/.notdef mg/.notdef doses/.notdef were/.notdefselected/.notdeffor/.notdefthe/.notdefconfirmatory/.notdefphase/.notdefIII/.notdeftrials./.notdef /.notdef Only/.notdef one/.notdef of/.notdef the/.notdef three/.notdef short-term/.notdef phase/.notdef III/.notdef studies/.notdef (STRATUS-US)/.notdef was/.notdef positive/.notdef on/.notdef all/.notdef conditions,/.notdef i.e./.notdef prolonged/.notdefabstinence/.notdefafter/.notdef10/.notdefweeks/.notdeftreatment,/.notdefand/.notdefsustained/.notdefabstinence/.notdefat/.notdef1/.notdefyear/.notdefoff/.notdefdrug./.notdefThe/.notdefother/.notdeftwo/.notdef studies/.notdef were/.notdef negative/.notdef and/.notdef thereby/.notdef raised/.notdef the/.notdef question/.notdef which/.notdef study(ies)/.notdef should/.notdef be/.notdef regarded/.notdef as/.notdef outlier(s)./.notdef The/.notdef pooled/.notdef analysis/.notdef of/.notdef the/.notdef short-term/.notdef studies,/.notdef as/.notdef well/.notdef as/.notdef data/.notdef from/.notdef the/.notdef study/.notdef with/.notdef 40/.notdef mg/.notdef dose/.notdef provided/.notdef evidence/.notdef that/.notdef rimonabant/.notdef had,/.notdef indeed,/.notdef positive/.notdef effect/.notdef in/.notdef smoking/.notdef cessation./.notdef The/.notdef randomized/.notdef withdrawal/.notdef study/.notdef was/.notdef also/.notdef positive/.notdef with/.notdef regard/.notdef to/.notdef maintenance/.notdef treatment;/.notdef however,/.notdef the/.notdef data/.notdef could/.notdef be/.notdef regarded/.notdef only/.notdef as/.notdef supportive./.notdefOverall,/.notdefbased/.notdefon/.notdefthe/.notdeftotality/.notdefof/.notdefdata/.notdefit/.notdefwas/.notdefconcluded/.notdefthat/.notdefan/.notdefeffect/.notdefon/.notdefsmoking/.notdefcessation/.notdef had/.notdef been/.notdef demonstrated./.notdef The/.notdef magnitude/.notdef of/.notdef the/.notdef effect/.notdef on/.notdef smoking/.notdef cessation/.notdef was,/.notdef however,/.notdef difficult/.notdef to/.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

<!-- image -->

| /.notdef                                                                                                                                                                                                                   | N/.notdefstudies/.notdef                                   | N/.notdef exposed/.notdef rimonabant/.notdef                           | to/.notdef Dose/.notdefof/.notdefrimonabant/.notdef                                                                                                            | Duration/.notdef                                                                                                                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase/.notdef1/.notdefstudies/.notdef Single/.notdefdose/.notdefstudies/.notdef Repeated/.notdefdose/.notdefstudies/.notdef Sub-total/.notdef/.notdef                                                                      | /.notdef 21/.notdef 15/.notdef 36/.notdef                  | /.notdef 579/.notdef 449/.notdef 1028/.notdef                          | /.notdef 1/.notdefto/.notdef300/.notdefmg/.notdef 1/.notdefto/.notdef90/.notdefmg/.notdef /.notdef                                                             | /.notdef -/.notdef Up/.notdefto/.notdef4/.notdefweeks/.notdef /.notdef                                                                               |
| Phase/.notdefII/.notdefstudies/.notdef Obesity/energy/.notdefexpenditure/.notdef Aid/.notdefto/.notdefsmoking/.notdefcessation/.notdef Relapse/.notdefin/.notdefalcoholism/.notdef Schizophrenia/.notdef Sub-total/.notdef | /.notdef 2/.notdef 1/.notdef 1/.notdef 1/.notdef 5/.notdef | no /.notdef 227/.notdef 183/.notdef 131/.notdef 72/.notdef 613/.notdef | /.notdef 5,/.notdef10,/.notdef20/.notdefor/.notdef40/.notdefmg/.notdef 40/.notdefmg/.notdef 20/.notdefmg/.notdef 20/.notdefmg/.notdef /.notdef                 | /.notdef Up/.notdefto/.notdef16/.notdefweeks/.notdef 10/.notdefweeks/.notdef 12/.notdefweeks/.notdef 6/.notdefweeks/.notdef                          |
| product Phase/.notdefIII/.notdefstudies/.notdef RIO/.notdefstudies/.notdef STRATUS/.notdefstudies/.notdef(short-term)/.notdef STRATUS/.notdefstudy/.notdef /.notdef(medium-term)/.notdef Sub-total/.notdef                 | /.notdef 4/.notdef 3/.notdef 1/.notdef 8/.notdef           | /.notdef 5023/.notdef 1308/.notdef 5039/.notdef                        | /.notdef 5/.notdefmg/.notdefor/.notdef20/.notdefmg/.notdef 5/.notdefmg/.notdefor/.notdef20/.notdefmg/.notdef 5/.notdefmg/.notdefor/.notdef20/.notdefmg/.notdef | /.notdef /.notdef Up/.notdefto/.notdef2/.notdefyears/.notdef Up/.notdefto/.notdef10/.notdefweeks/.notdef Up/.notdefto/.notdef52/.notdefweeks/.notdef |
| Total/.notdef                                                                                                                                                                                                              | 49/.notdef                                                 | 11370/.notdef 13011/.notdef                                            | /.notdef /.notdef                                                                                                                                              | /.notdef /.notdef                                                                                                                                    |

/.notdef

/.notdef

<!-- image -->

Medicinal product no longer authorised estimate./.notdef The/.notdef variability/.notdef in/.notdef the/.notdef results/.notdef from/.notdef the/.notdef short-term/.notdef studies/.notdef indicated/.notdef that/.notdef the/.notdef effect/.notdef size/.notdef may/.notdef be/.notdef marginal./.notdef Furthermore,/.notdef there/.notdef were/.notdef remaining/.notdef uncertainties/.notdef regarding/.notdef the/.notdef optimal/.notdef dose,/.notdef duration/.notdef of/.notdef treatment/.notdefand/.notdefwhether/.notdefthe/.notdefdose/.notdefcould/.notdefbe/.notdefdecreased/.notdefafter/.notdefan/.notdefinitial/.notdeftreatment/.notdefperiod/.notdefin/.notdefcases/.notdefwhere/.notdeflonger/.notdef treatment/.notdefis/.notdefconsidered/.notdefjustified./.notdef Clinical/.notdefsafety/.notdef · Patient/.notdefexposure/.notdef The/.notdefrimonabant/.notdefclinical/.notdefdevelopment/.notdefprogram/.notdefincluded/.notdef49/.notdefcompleted/.notdefclinical/.notdefstudies,/.notdefinvolving/.notdefa/.notdeftotal/.notdefof/.notdef 16,120/.notdefsubjects/.notdefor/.notdefpatients./.notdefThere/.notdefwere/.notdef36/.notdefphase/.notdefI /.notdef studies/.notdefand/.notdeffive/.notdefphase/.notdefII/.notdefstudies,/.notdefin/.notdefaddition/.notdefto/.notdefa/.notdeflarge/.notdef phase/.notdefIII/.notdefprogram,/.notdefcomposed/.notdefof/.notdeftwo/.notdefmajor/.notdefsets/.notdefof/.notdefstudies/.notdef(four/.notdefRIO/.notdefstudies/.notdefand/.notdeffour/.notdefSTRATUS/.notdefstudies),/.notdef which/.notdef was/.notdef carried/.notdef out/.notdef in/.notdef the/.notdef indications/.notdef of/.notdef body/.notdef weight/.notdef management/.notdef and/.notdef related/.notdef metabolic/.notdef disorders/.notdef (6,625/.notdef patients),/.notdef and/.notdef aid/.notdef to/.notdef and/.notdef maintenance/.notdef of/.notdef smoking/.notdef cessation/.notdef (7,136/.notdef patients),/.notdef respectively/.notdef (see/.notdef Table/.notdef 14/.notdef below)./.notdef These/.notdef studies/.notdef were/.notdef designed/.notdef for/.notdef assessing/.notdef drug/.notdef safety,/.notdef i.e.,/.notdef randomised,/.notdef double-blind,/.notdef placebo-controlled/.notdef and/.notdef parallel/.notdef group/.notdef studies,/.notdef and/.notdef a/.notdef substantial/.notdef number/.notdef of/.notdef rimonabant-treated/.notdef patients/.notdef were/.notdefexposed/.notdefto/.notdefeither/.notdefrimonabant/.notdef5/.notdefmg/.notdefor/.notdef20/.notdefmg/.notdeffor/.notdefone/.notdefyear/.notdefor/.notdefup/.notdefto/.notdeftwo/.notdefyears/.notdef(in/.notdefRIO/.notdefstudies)/.notdefor/.notdeffor/.notdef ten/.notdef weeks/.notdef or/.notdef up/.notdef to/.notdef 32/.notdef weeks/.notdef (in/.notdef STRATUS/.notdef studies;/.notdef safety/.notdef data/.notdef between/.notdef week/.notdef 33/.notdef and/.notdef week/.notdef 52/.notdef were/.notdef submitted/.notdefduring/.notdefthe/.notdefprocedure)./.notdef/.notdef Table/.notdef14:/.notdefSafety/.notdefpopulation/.notdefexposed/.notdefto/.notdefrimonabant/.notdef · Adverse/.notdefevents/.notdef/.notdef The/.notdef overall/.notdef safety/.notdef review/.notdef of/.notdef the/.notdef combined/.notdef phase/.notdef III/.notdef RIO/.notdef +/.notdef STRATUS/.notdef programs/.notdef showed/.notdef that/.notdef treatment/.notdef emergent/.notdef adverse/.notdef events/.notdef (TEAEs)/.notdef were/.notdef comparably/.notdef reported/.notdef across/.notdef the/.notdef three/.notdef treatment/.notdef groups/.notdef (rimonabant/.notdef 5mg,/.notdef rimonabant/.notdef 20mg,/.notdef placebo)./.notdef TEAEs/.notdef commonly/.notdef reported/.notdef ( GLYPH&lt;1&gt; 2%/.notdef of/.notdef patients)/.notdef during/.notdef rimonabant/.notdef administration/.notdef were/.notdef mostly/.notdef of/.notdef gastrointestinal/.notdef (nausea,/.notdef diarrhoea,/.notdef vomiting,/.notdef loose/.notdef stools),/.notdef nervous/.notdefsystem/.notdef(dizziness,/.notdefdisturbance/.notdefin/.notdefattention,/.notdefsomnolence)/.notdefor/.notdefpsychiatric/.notdeforigin/.notdef(insomnia,/.notdefanxiety,/.notdef depressive/.notdefdisorders,/.notdefmood/.notdefalterations,/.notdefirritability)./.notdef/.notdef The/.notdeffollowing/.notdefTable/.notdef15/.notdefshows/.notdefall/.notdeftreatment-emergent/.notdefadverse/.notdefreactions/.notdeffrom/.notdefthe/.notdeffour/.notdefplacebo-controlled/.notdef studies/.notdefin/.notdefpatients/.notdeftreated/.notdeffor/.notdefweight/.notdefloss/.notdefand/.notdefrelated/.notdefmetabolic/.notdefdisorders/.notdefthat/.notdefoccurred/.notdefat/.notdefa/.notdefrate/.notdefof/.notdef ≥ /.notdef1%,/.notdef when/.notdef these/.notdef incidences/.notdef were/.notdef statistically/.notdef significantly/.notdef greater/.notdef than/.notdef the/.notdef corresponding/.notdef placebo/.notdef rate/.notdef or/.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

| /.notdef                                                                            | Year/.notdef1/.notdef(4/.notdefstudies)/.notdef                                                                   | Year/.notdef1/.notdef(4/.notdefstudies)/.notdef                                               | Year/.notdef2/.notdef(2/.notdefstudies)/.notdef                                                                   | Year/.notdef2/.notdef(2/.notdefstudies)/.notdef                                              |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| SYSTEM/.notdef ORGAN/.notdef CLASS/.notdef Adverse/.notdefevents/.notdef            | ZIMULTI/.notdef/.notdef 20/.notdefmg/.notdef %/.notdefof/.notdefpatients/.notdef (N/.notdef=/.notdef2503)/.notdef | Placebo/.notdef %/.notdefof/.notdefpatients/.notdef /.notdef (N/.notdef=/.notdef1602)/.notdef | ZIMULTI /.notdef/.notdef 20/.notdefmg/.notdef %/.notdefof/.notdefpatients/.notdef (N/.notdef=/.notdef688)/.notdef | Placebo/.notdef %/.notdefof/.notdefpatients/.notdef /.notdef (N/.notdef=/.notdef466)/.notdef |
| INFECTIONS/.notdefAND/.notdefINFESTATIONS/.notdef                                   | INFECTIONS/.notdefAND/.notdefINFESTATIONS/.notdef                                                                 | INFECTIONS/.notdefAND/.notdefINFESTATIONS/.notdef                                             | INFECTIONS/.notdefAND/.notdefINFESTATIONS/.notdef                                                                 | INFECTIONS/.notdefAND/.notdefINFESTATIONS/.notdef                                            |
| Upper/.notdef Respiratory/.notdef tract/.notdef Infection/.notdef                   | 12.4/.notdef                                                                                                      | 11.4/.notdef                                                                                  | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Gastroenteritis/.notdefviral/.notdef                                                | 3.6/.notdef                                                                                                       | 2.9/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Nasopharyngitis/.notdef                                                             | -/.notdef                                                                                                         | -/.notdef                                                                                     | 10.3/.notdef                                                                                                      | 8.8/.notdef                                                                                  |
| Urinary/.notdeftract/.notdefinfection/.notdef                                       | -/.notdef                                                                                                         | -/.notdef                                                                                     | 2.8/.notdef                                                                                                       | 2.1/.notdef                                                                                  |
| Gastroenteritis/.notdef                                                             | -/.notdef                                                                                                         | -/.notdef                                                                                     | 2.5/.notdef                                                                                                       | 1.1/.notdef                                                                                  |
| longer PSYCHIATRIC/.notdefDISORDERS/.notdef                                         | longer PSYCHIATRIC/.notdefDISORDERS/.notdef                                                                       | longer PSYCHIATRIC/.notdefDISORDERS/.notdef                                                   | longer PSYCHIATRIC/.notdefDISORDERS/.notdef                                                                       | longer PSYCHIATRIC/.notdefDISORDERS/.notdef                                                  |
| Anxiety/.notdef                                                                     | 5.6/.notdef                                                                                                       | 2.4/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Insomnia/.notdef                                                                    | 5.4/.notdef                                                                                                       | 3.2/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Mood/.notdef alterations/.notdef with/.notdef depressive/.notdefsymptoms/.notdef    | 4.8/.notdef                                                                                                       | 3.1/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Depressive/.notdefdisorders/.notdef                                                 | 3.2/.notdef                                                                                                       | 1.6/.notdef                                                                                   | 1.6/.notdef                                                                                                       | 0.4/.notdef                                                                                  |
| Irritability/.notdef                                                                | 1.9/.notdef                                                                                                       | 0.6/.notdef                                                                                   | /.notdef                                                                                                          | /.notdef                                                                                     |
| Parasomnia/.notdef                                                                  | 1.5/.notdef                                                                                                       | 0.2/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Nervousness/.notdef                                                                 | 1.2/.notdef                                                                                                       | 0.2/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Sleep/.notdefdisorders/.notdef                                                      | 1.0/.notdef                                                                                                       | 0.4/.notdef                                                                                   | /.notdef                                                                                                          | /.notdef                                                                                     |
| no NERVOUS/.notdefSYSTEM/.notdefDISORDERS/.notdef                                   | no NERVOUS/.notdefSYSTEM/.notdefDISORDERS/.notdef                                                                 | no NERVOUS/.notdefSYSTEM/.notdefDISORDERS/.notdef                                             | no NERVOUS/.notdefSYSTEM/.notdefDISORDERS/.notdef                                                                 | no NERVOUS/.notdefSYSTEM/.notdefDISORDERS/.notdef                                            |
| Dizziness/.notdef                                                                   | 7.5/.notdef                                                                                                       | 4.9/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Memory/.notdefloss/.notdef                                                          | 1.6/.notdef                                                                                                       | 0.9/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Hypoesthesia/.notdef                                                                | 1.6/.notdef                                                                                                       | 0.6/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Sciatica/.notdef                                                                    | 1.0/.notdef                                                                                                       | 0.4/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| product VASCULAR/.notdefDISORDERS/.notdef                                           | product VASCULAR/.notdefDISORDERS/.notdef                                                                         | product VASCULAR/.notdefDISORDERS/.notdef                                                     | product VASCULAR/.notdefDISORDERS/.notdef                                                                         | product VASCULAR/.notdefDISORDERS/.notdef                                                    |
| Hot/.notdefflush/.notdef                                                            | 1.9/.notdef                                                                                                       | 0.7/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| GASTROINTESTINAL/.notdefDISORDERS/.notdef                                           | GASTROINTESTINAL/.notdefDISORDERS/.notdef                                                                         | GASTROINTESTINAL/.notdefDISORDERS/.notdef                                                     | GASTROINTESTINAL/.notdefDISORDERS/.notdef                                                                         | GASTROINTESTINAL/.notdefDISORDERS/.notdef                                                    |
| Nausea/.notdef                                                                      | 11.9/.notdef                                                                                                      | 4.9/.notdef                                                                                   | 2.8/.notdef                                                                                                       | 1.7/.notdef                                                                                  |
| Diarrhoea/.notdef                                                                   | 6.3/.notdef                                                                                                       | 4.8/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Vomiting/.notdef                                                                    | 4.0/.notdef                                                                                                       | 2.2/.notdef                                                                                   | 2.0/.notdef                                                                                                       | 1.3/.notdef                                                                                  |
| SKIN/.notdefAND/.notdefSUBCUTANEOUS/.notdefTISSUE/.notdefDISORDERS/.notdef          | SKIN/.notdefAND/.notdefSUBCUTANEOUS/.notdefTISSUE/.notdefDISORDERS/.notdef                                        | SKIN/.notdefAND/.notdefSUBCUTANEOUS/.notdefTISSUE/.notdefDISORDERS/.notdef                    | SKIN/.notdefAND/.notdefSUBCUTANEOUS/.notdefTISSUE/.notdefDISORDERS/.notdef                                        | SKIN/.notdefAND/.notdefSUBCUTANEOUS/.notdefTISSUE/.notdefDISORDERS/.notdef                   |
| Pruritus/.notdef                                                                    | 1.2/.notdef                                                                                                       | 0.5/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Hyperhydrosis/.notdef                                                               | 1.2/.notdef                                                                                                       | 0.5/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| MUSCULOSKELETAL/.notdefAND/.notdefCONNECTIVE/.notdefTISSUE/.notdefDISORDERS/.notdef | MUSCULOSKELETAL/.notdefAND/.notdefCONNECTIVE/.notdefTISSUE/.notdefDISORDERS/.notdef                               | MUSCULOSKELETAL/.notdefAND/.notdefCONNECTIVE/.notdefTISSUE/.notdefDISORDERS/.notdef           | MUSCULOSKELETAL/.notdefAND/.notdefCONNECTIVE/.notdefTISSUE/.notdefDISORDERS/.notdef                               | MUSCULOSKELETAL/.notdefAND/.notdefCONNECTIVE/.notdefTISSUE/.notdefDISORDERS/.notdef          |
| Tendonitis/.notdef                                                                  | 2.1/.notdef                                                                                                       | 1.0/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Muscle/.notdefcramp/.notdef                                                         | 1.4/.notdef                                                                                                       | 1.0/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Muscle/.notdefspasms/.notdef                                                        | 1.0/.notdef                                                                                                       | 0.5/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Back/.notdefpain/.notdef                                                            | -/.notdef                                                                                                         | -/.notdef                                                                                     | 7.3/.notdef                                                                                                       | 5.2/.notdef                                                                                  |
| GENERAL/.notdefDISORDERS/.notdef                                                    | GENERAL/.notdefDISORDERS/.notdef                                                                                  | GENERAL/.notdefDISORDERS/.notdef                                                              | GENERAL/.notdefDISORDERS/.notdef                                                                                  | GENERAL/.notdefDISORDERS/.notdef                                                             |
| Influenza/.notdef                                                                   | 8.9/.notdef                                                                                                       | 8.6/.notdef                                                                                   | 9.2/.notdef                                                                                                       | 7.5/.notdef                                                                                  |
| Asthenia/Fatigue/.notdef                                                            | 6.0/.notdef                                                                                                       | 5.0/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| INJURY,/.notdefPOISONING/.notdefAND/.notdefPROCEDURAL/.notdefCOMPLICATIONS/.notdef  | INJURY,/.notdefPOISONING/.notdefAND/.notdefPROCEDURAL/.notdefCOMPLICATIONS/.notdef                                | INJURY,/.notdefPOISONING/.notdefAND/.notdefPROCEDURAL/.notdefCOMPLICATIONS/.notdef            | INJURY,/.notdefPOISONING/.notdefAND/.notdefPROCEDURAL/.notdefCOMPLICATIONS/.notdef                                | INJURY,/.notdefPOISONING/.notdefAND/.notdefPROCEDURAL/.notdefCOMPLICATIONS/.notdef           |
| Joint/.notdefsprain/.notdef                                                         | 3.0/.notdef                                                                                                       | 2.1/.notdef                                                                                   | -/.notdef                                                                                                         | -/.notdef                                                                                    |
| Contusion/.notdef                                                                   | 2.2/.notdef                                                                                                       | 0.6/.notdef                                                                                   | 2.2/.notdef                                                                                                       | 0.6/.notdef                                                                                  |
| Fall/.notdef                                                                        | 1.9/.notdef                                                                                                       | 1.4/.notdef                                                                                   | /.notdef                                                                                                          | /.notdef                                                                                     |

/.notdef

Medicinal product no longer authorised considered/.notdef clinically/.notdef relevant./.notdef They/.notdef are/.notdef listed/.notdef by/.notdef treatment/.notdef group/.notdef and/.notdef by/.notdef first-/.notdef and/.notdef second-year/.notdef study/.notdef periods./.notdef Table/.notdef 15:/.notdef Adverse/.notdef Reactions/.notdef ≥ /.notdef1%/.notdef from/.notdef Four/.notdef Studies/.notdef that/.notdef Examined/.notdef ZIMULTI/.notdef 20/.notdefmg/.notdef in/.notdef Overweight/.notdef and/.notdef Obese/.notdefPatients./.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised Depressive/.notdefdisorders/.notdefreported/.notdefwith/.notdefrimonabant/.notdef20/.notdefmg/.notdefwere/.notdefusually/.notdefmild/.notdefor/.notdefmoderate/.notdefin/.notdefseverity./.notdefMost/.notdefof/.notdef the/.notdef cases/.notdef resolved/.notdef with/.notdef the/.notdef corrective/.notdef measures/.notdef undertaken,/.notdef either/.notdef discontinuation/.notdef or/.notdef anti-depressant/.notdef treatment./.notdef Overall,/.notdef psychiatric/.notdef adverse/.notdef events/.notdef or/.notdef adverse/.notdef symptoms/.notdef from/.notdef the/.notdef CNS/.notdef were/.notdef more/.notdef common/.notdef among/.notdef rimonabant/.notdef treated/.notdef patients/.notdef than/.notdef among/.notdef placebo/.notdef treated./.notdef These/.notdef adverse/.notdef events/.notdef were/.notdef dose/.notdef dependent,/.notdefwhere/.notdefthe/.notdef5/.notdefmg/.notdefdose/.notdefshowed/.notdefadverse/.notdefevent/.notdeffrequencies/.notdefcomparable/.notdefto/.notdefplacebo,/.notdefbut/.notdefthe/.notdef20/.notdefmg/.notdef and/.notdef40/.notdefmg/.notdefdose/.notdefshowing/.notdefa/.notdefconsiderably/.notdefhigher/.notdeffrequency./.notdef/.notdef TEAEs/.notdef related/.notdef to/.notdef cognitive/.notdef impairment/.notdef such/.notdef as/.notdef sedation,/.notdef somnolence/.notdef and/.notdef disturbance/.notdef in/.notdef attention/.notdef were/.notdef reported/.notdefand/.notdefwere/.notdefcomparable/.notdefacross/.notdefthe/.notdef3/.notdeftreatment/.notdefgroups/.notdef(rimonabant/.notdef5/.notdefmg,/.notdef20/.notdefmg/.notdefand/.notdefplacebo)/.notdefin/.notdefthe/.notdef 1-year/.notdef pooled/.notdef RIO/.notdef data/.notdef and/.notdef in/.notdef the/.notdef 2-year/.notdef pooled/.notdef RIO/.notdef data./.notdef In/.notdef the/.notdef placebo-controlled/.notdef period/.notdef of/.notdef the/.notdef STRATUS/.notdefprogram/.notdef(10-week/.notdefpooled/.notdefdata/.notdefand/.notdefSTRATUS-WW/.notdefweek/.notdef11/.notdefto/.notdefweek/.notdef32)/.notdefthere/.notdefwere/.notdefno/.notdefsigns/.notdef of/.notdefsedative/.notdefeffects./.notdef In/.notdef clinical/.notdef studies/.notdef on/.notdef smoking/.notdef cessation,/.notdef also/.notdef the/.notdef following/.notdef adverse/.notdef reactions/.notdef were/.notdef commonly/.notdef reported:/.notdef sinusitis/upper/.notdef respiratory/.notdef tract/.notdef infection,/.notdef decreased/.notdef appetite,/.notdef anorexia,/.notdef asthenia/fatigue,/.notdef dizziness,/.notdef disturbance/.notdefin/.notdefattention,/.notdefanxiety,/.notdefinsomnia,/.notdefnervousness,/.notdefnausea/vomiting,/.notdefdiarrhoea,/.notdefdry/.notdefmouth,/.notdefstomach/.notdef discomfort./.notdef · Serious/.notdefadverse/.notdefevent//.notdefdeaths//.notdefother/.notdefsignificant/.notdefevents/.notdef Deaths/.notdef A/.notdef total/.notdef of/.notdef 13/.notdef deaths/.notdef were/.notdef reported/.notdef out/.notdef of/.notdef the/.notdef 16/.notdef 120/.notdef subjects/.notdef or/.notdef patients/.notdef involved/.notdef in/.notdef the/.notdef 49/.notdef completed/.notdef studies:/.notdef 11/.notdef in/.notdef the/.notdef RIO/.notdef program,/.notdef equally/.notdef distributed/.notdef across/.notdef groups/.notdef (four/.notdef in/.notdef the/.notdef rimonabant/.notdef 20/.notdef mg/.notdef group,/.notdef three/.notdef in/.notdef the/.notdef rimonabant/.notdef 5/.notdef mg/.notdef group/.notdef and/.notdef four/.notdef in/.notdef the/.notdef placebo/.notdef group),/.notdef and/.notdef two/.notdef in/.notdef the/.notdef STRATUS/.notdef program/.notdef (both/.notdefin/.notdefthe/.notdefrimonabant/.notdef20/.notdefmg/.notdefgroup)./.notdefFatal/.notdefevents/.notdefwere/.notdefmostly/.notdefof/.notdefan/.notdefintercurrent/.notdeforigin/.notdef(seven/.notdefcases)/.notdefor/.notdef of/.notdef a/.notdef cardiac/.notdef origin/.notdef in/.notdef patients/.notdef with/.notdef heavy/.notdef cardiovascular/.notdef risk/.notdef factors/.notdef (four/.notdef cases)./.notdef The/.notdef origin/.notdef of/.notdef the/.notdef two/.notdef remaining/.notdef cases/.notdef remained/.notdef doubtful:/.notdef a/.notdef completed/.notdef suicide/.notdef in/.notdef unclear/.notdef circumstances/.notdef and/.notdef a/.notdef cardiac/.notdef arrest,/.notdef with/.notdefno/.notdefcardiac/.notdeflesions/.notdefon/.notdefautopsy,/.notdefpossibly/.notdeflinked/.notdefto/.notdefa/.notdeflong/.notdefQT/.notdefsyndrome,/.notdefpre-existing/.notdefprior/.notdefto/.notdefany/.notdefstudy/.notdef drug/.notdefintake./.notdefIn/.notdefaddition,/.notdefthere/.notdefwas/.notdefa/.notdefcardiac/.notdefrelated/.notdefdeath,/.notdefoccurring/.notdefthree/.notdefweeks/.notdefpost-completion/.notdefof/.notdefstudy/.notdef treatment/.notdef(10/.notdefweek/.notdefof/.notdefrimonabant/.notdef5/.notdefmg/.notdefthen/.notdef42/.notdefweeks/.notdefof/.notdefplacebo)/.notdefin/.notdefthe/.notdef1-year/.notdefdata/.notdefof/.notdefSTRATUS-WW./.notdef Obesity/.notdef In/.notdef the/.notdef RIO/.notdef program,/.notdef serious/.notdef adverse/.notdef events/.notdef (SAEs)/.notdef were/.notdef reported/.notdef with/.notdef similar/.notdef incidence/.notdef in/.notdef the/.notdef placebo/.notdef group/.notdef and/.notdef rimonabant/.notdef groups:/.notdef 5.9%/.notdef in/.notdef the/.notdef rimonabant/.notdef 20mg/.notdef group,/.notdef 5.4%/.notdef in/.notdef the/.notdef rimonabant/.notdef 5mg/.notdef group/.notdef and/.notdef 4.2%/.notdef in/.notdef the/.notdef placebo/.notdef group./.notdef In/.notdef each/.notdef treatment/.notdef group,/.notdef similar/.notdef SAEs/.notdef in/.notdef similar/.notdef System/.notdef Organ/.notdef Classes/.notdef (SOCs)/.notdefwere/.notdefreported./.notdef The/.notdef following/.notdef SAEs/.notdef were/.notdef more/.notdef frequently/.notdef reported/.notdef in/.notdef the/.notdef rimonabant/.notdef 20/.notdef mg/.notdef group/.notdef than/.notdef in/.notdef the/.notdef placebo/.notdef group:/.notdef · 12/.notdef cases/.notdef of/.notdef psychiatric/.notdef disorders/.notdef (6/.notdef serious/.notdef depressive/.notdef disorder)/.notdef in/.notdef the/.notdef rimonabant/.notdef 20/.notdef mg/.notdef group/.notdef (0.5%),/.notdefversus/.notdef2/.notdefcases/.notdefin/.notdefthe/.notdefplacebo/.notdefgroup/.notdef(0.1%);/.notdef · 12/.notdef cases/.notdef of/.notdef cardiac/.notdef disorders/.notdef in/.notdef the/.notdef rimonabant/.notdef 20/.notdef mg/.notdef group/.notdef (0.5%)/.notdef versus/.notdef 4/.notdef cases/.notdef in/.notdef the/.notdef placebo/.notdef group/.notdef(0.2%);/.notdef2/.notdefcases/.notdefresulted/.notdefin/.notdefdeath;/.notdef · 9/.notdef cases/.notdef of/.notdef urinary/.notdef disorders/.notdef in/.notdef the/.notdef rimonabant/.notdef 20/.notdef mg/.notdef group/.notdef (0.4%)/.notdef versus/.notdef 2/.notdef cases/.notdef in/.notdef the/.notdef placebo/.notdef group/.notdef(0.1%)/.notdef · 6/.notdef cases/.notdef of/.notdef road/.notdef traffic/.notdef accident/.notdef in/.notdef the/.notdef rimonabant/.notdef 20/.notdef mg/.notdef group/.notdef versus/.notdef zero/.notdef in/.notdef the/.notdef placebo/.notdef group;/.notdef 2/.notdef cases/.notdefoccurred/.notdefin/.notdefthe/.notdefcontext/.notdefof/.notdefsleepiness./.notdef · 4/.notdefcases/.notdefof/.notdeffall/.notdefin/.notdefthe/.notdefrimonabant/.notdef20/.notdefmg/.notdefgroup./.notdef In/.notdef the/.notdef 2-year/.notdef pooled/.notdef data,/.notdef new/.notdef SAEs/.notdef during/.notdef the/.notdef second-year/.notdef exposure/.notdef were/.notdef occasionally/.notdef reported/.notdef in/.notdef the/.notdef rimonabant/.notdef20/.notdefmg/.notdefgroup/.notdef(1/.notdefor/.notdef2/.notdefpatients/.notdefeach)/.notdefand/.notdefwere/.notdefless/.notdefor/.notdefcomparably/.notdefreported/.notdefthan/.notdefduring/.notdefYear/.notdef1;/.notdef two/.notdefcases/.notdefhad/.notdefa/.notdeffatal/.notdefoutcome./.notdef

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

<!-- image -->

Medicinal product no longer authorised Smoking/.notdefcessation/.notdef Only/.notdef few/.notdef serious/.notdef TEAEs/.notdef were/.notdef observed/.notdef throughout/.notdef the/.notdef short-term/.notdef STRATUS/.notdef studies/.notdef (pooled/.notdef data),/.notdef percentages/.notdef being/.notdef 2.2%/.notdef for/.notdef the/.notdef placebo/.notdef group,/.notdef 1.2%/.notdef for/.notdef the/.notdef rimonabant/.notdef 5/.notdef mg/.notdef group,/.notdef and/.notdef 2.0%/.notdef for/.notdef the/.notdef rimonabant/.notdef 20/.notdef mg/.notdef group./.notdef No/.notdef serious/.notdef events/.notdef were/.notdef of/.notdef cardiovascular/.notdef origin/.notdef in/.notdef the/.notdef rimonabant/.notdef treatment/.notdef arms/.notdef (high/.notdef risk/.notdef subjects/.notdef were/.notdef excluded/.notdef from/.notdef participation)./.notdef The/.notdef cases/.notdef that/.notdef were/.notdef considered/.notdef of/.notdef clinical/.notdef relevance/.notdefand/.notdefrelated/.notdefto/.notdefthe/.notdefstudy-drug/.notdefwere/.notdefsevere/.notdeffatigue,/.notdefmajor/.notdefdepression/.notdefand/.notdefgastroenteritis./.notdef/.notdef · Laboratory/.notdeffindings/.notdef In/.notdef the/.notdef combined/.notdef RIO/.notdef +/.notdef STRATUS/.notdef data,/.notdef no/.notdef laboratory/.notdef safety/.notdef concerns/.notdef were/.notdef detected/.notdef in/.notdef the/.notdef main/.notdef biological/.notdef functions/.notdef (liver,/.notdef renal,/.notdef hematology,/.notdef electrolytes,/.notdef metabolism)/.notdef over/.notdef time/.notdef during/.notdef the/.notdef whole/.notdef rimonabant/.notdeftreatment/.notdefperiod/.notdef(up/.notdefto/.notdeftwo/.notdefyears),/.notdefand/.notdefwere/.notdefcomparable/.notdefwith/.notdefplacebo./.notdef/.notdef Effects/.notdefon/.notdefECG/.notdef PKD/.notdef5237 /.notdef was/.notdefa/.notdefsingle-centre,/.notdefrandomised,/.notdefdouble-dummy,/.notdefplacebo/.notdefcontrolled,/.notdeffour/.notdefparallel/.notdefgroup/.notdefstudy/.notdef in/.notdef 128/.notdef male/.notdef or/.notdef female/.notdef subjects/.notdef assessing/.notdef the/.notdef effect/.notdef on/.notdef ECG/.notdef parameters/.notdef of/.notdefrimonabant/.notdef20/.notdefmg/.notdefand/.notdef60/.notdefmg/.notdef compared/.notdef to/.notdef placebo/.notdef and/.notdef with/.notdef moxifloxacin/.notdef 400/.notdef mg/.notdef as/.notdef a/.notdef positive/.notdef control./.notdef Moxifloxacin/.notdef produced/.notdef clear/.notdef and/.notdef consistent/.notdefQT/QTc/.notdefinterval/.notdefincreases/.notdefcompared/.notdefwith/.notdefplacebo./.notdefThere/.notdefwas/.notdefno/.notdefevidence/.notdeffor/.notdefa/.notdefpotential/.notdef of/.notdefrimonabant/.notdefto/.notdefprolong/.notdefventricular/.notdefrepolarisation./.notdefThere/.notdefwas/.notdefno/.notdefsignificant/.notdefrelationship/.notdefbetween/.notdefthe/.notdefQT/.notdef changes/.notdeffrom/.notdefbaseline/.notdefas/.notdefmeasured/.notdefby/.notdefthe/.notdefHolter/.notdefmethod/.notdefor/.notdeffrom/.notdefextracted/.notdefECGs/.notdef(with/.notdefBazett,/.notdefFridericia,/.notdef or/.notdefpopulation-specific/.notdefcorrection)/.notdefand/.notdefrimonabant/.notdefplasma/.notdefconcentrations./.notdefThere/.notdefwas/.notdefsome/.notdefsuggestion/.notdefthat/.notdef the/.notdef60/.notdefmg/.notdefdose/.notdefmay/.notdefbe/.notdefassociated/.notdefwith/.notdefa/.notdefslight/.notdefincrease/.notdef(+6/.notdefbpm)/.notdefin/.notdefheart/.notdefrate/.notdef(HR),/.notdefin/.notdefhealthy/.notdefsubjects./.notdef /.notdef Vital/.notdefsigns/.notdef The/.notdef review/.notdef of/.notdef vital/.notdef signs,/.notdef including/.notdef supine/.notdef blood/.notdef pressure/.notdef (BP)/.notdef and/.notdef HR/.notdef from/.notdef phase/.notdef I/.notdef and/.notdef II/.notdef studies/.notdef did/.notdef not/.notdefreveal/.notdefany/.notdefsafety/.notdefissues./.notdefWhen/.notdefcombining/.notdefall/.notdefphase/.notdefIII/.notdefstudies,/.notdefthere/.notdefwas/.notdefa/.notdeftrend/.notdeftowards/.notdefa/.notdefdecrease/.notdefin/.notdef supine/.notdefBP/.notdefin/.notdefthe/.notdefrimonabant/.notdef20/.notdefmg/.notdefgroup/.notdefcompared/.notdefwith/.notdefplacebo./.notdef/.notdef · Safety/.notdefin/.notdefspecial/.notdefpopulations/.notdef No/.notdefmarked/.notdefdifferences/.notdefin/.notdefterms/.notdefof/.notdefclinical/.notdefsafety/.notdefwere/.notdefobserved/.notdeffor/.notdefelderly/.notdefcompared/.notdefto/.notdefyounger/.notdefpatients,/.notdef but/.notdef elderly/.notdef obese/.notdef patients/.notdef appeared/.notdef to/.notdef be/.notdef more/.notdef prone/.notdef to/.notdef develop/.notdef dizziness/.notdef or/.notdef diarrhoea/.notdef compared/.notdef with/.notdef either/.notdefyoung/.notdefor/.notdefmiddle-aged/.notdefobese/.notdefpatients/.notdefin/.notdefthe/.notdefrimonabant/.notdef20/.notdefmg/.notdefgroup./.notdef/.notdef There/.notdef were/.notdef no/.notdef marked/.notdef differences/.notdef in/.notdef terms/.notdef of/.notdef safety/.notdef between/.notdef the/.notdef two/.notdef prominent/.notdef ethnic/.notdef sub-groups/.notdef (Caucasian/.notdefand/.notdefAfro-American/.notdefpatients),/.notdefapart/.notdeffrom/.notdefa/.notdeflower/.notdefincidence/.notdefof/.notdefnausea/.notdefor/.notdefsomnolence/.notdefobserved/.notdef in/.notdefAfro-American/.notdefpatients./.notdef/.notdef · Discontinuation/.notdefdue/.notdefto/.notdefadverse/.notdefevents/.notdef The/.notdefoverall/.notdefsafety/.notdefreview/.notdefof/.notdefthe/.notdefcombined/.notdefphase/.notdefIII/.notdefRIO/.notdef+/.notdefSTRATUS/.notdefprograms/.notdefshowed/.notdefthat/.notdefthere/.notdefwas/.notdefa/.notdef higher/.notdefrate/.notdefof/.notdeftreatment/.notdefdiscontinuations/.notdefdue/.notdefto/.notdefAE/.notdefin/.notdefthe/.notdefrimonabant/.notdef20/.notdefmg/.notdefgroup/.notdef(15.7%)/.notdefcompared/.notdefto/.notdef placebo/.notdef(7.8%)/.notdef(also/.notdefobserved/.notdefin/.notdefthe/.notdefindividual/.notdefRIO/.notdefand/.notdefSTRATUS/.notdefprograms)./.notdefIn/.notdefthe/.notdefRIO/.notdef1-year/.notdefpooled/.notdef data,/.notdefthe/.notdefmain/.notdefTEAEs/.notdefleading/.notdefto/.notdefdiscontinuations/.notdefin/.notdefthe/.notdefrimonabant/.notdef20/.notdefmg/.notdeftreated/.notdefpatients,/.notdefreported/.notdefin/.notdefat/.notdef least/.notdef 0.5%,/.notdef were:/.notdef nausea,/.notdef mood/.notdef alterations/.notdef with/.notdef depressive/.notdef symptoms,/.notdefirritability,/.notdefanxiety,/.notdefinsomnia/.notdefand/.notdef dizziness/.notdef(see/.notdefTable/.notdef16/.notdefbelow)./.notdef/.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

<!-- image -->

Medicinal product no longer authorised Table/.notdef 16:/.notdef Percentage/.notdef of/.notdef patients/.notdef with/.notdef TEAE/.notdef leading/.notdef to/.notdef permanent/.notdef treatment/.notdef discontinuation/.notdef -/.notdef randomised/.notdef and/.notdefexposed/.notdefpatients/.notdef-/.notdef1-year/.notdefpooled/.notdefRIO/.notdefdata/.notdef · Discussion/.notdefon/.notdefclinical/.notdefsafety/.notdef The/.notdef main/.notdef safety/.notdef issue/.notdef was/.notdef the/.notdef psychiatric/.notdef AEs,/.notdef which/.notdef caused/.notdef concerns,/.notdef especially/.notdef since/.notdef patients/.notdef with/.notdef current/.notdefdepressions/.notdefwere/.notdefexcluded/.notdeffrom/.notdefthe/.notdefclinical/.notdefstudies./.notdefThe/.notdefsafety/.notdefdata/.notdefin/.notdefTable/.notdef16/.notdefabove/.notdefshows/.notdefthat/.notdef there/.notdef was/.notdef a/.notdef dose-response/.notdef relation/.notdef between/.notdef the/.notdef frequency/.notdef of/.notdef certain/.notdef psychiatric/.notdef adverse/.notdef events/.notdef and/.notdef the/.notdef dose/.notdefof/.notdefrimonabant./.notdef The/.notdeffindings/.notdeffrom/.notdefthe/.notdefRIO-programme/.notdefshowed/.notdefthat/.notdefhalf/.notdefof/.notdefdepressive/.notdefdisorders/.notdefwere/.notdefreported/.notdefduring/.notdefthe/.notdef first/.notdef3/.notdefmonths/.notdefof/.notdefthe/.notdefstudies,/.notdefwhen/.notdefweight/.notdefloss/.notdefwas/.notdefmaximum./.notdefThe/.notdefnumber/.notdefof/.notdefevents/.notdefwas/.notdefincreased/.notdefin/.notdefthe/.notdef body/.notdef weight/.notdef responder/.notdef patients/.notdef compared/.notdef to/.notdef the/.notdef non-responders./.notdef In/.notdef the/.notdef STRATUS/.notdef program/.notdef (10-week/.notdef pooled/.notdefdata),/.notdef the/.notdef probability/.notdef of/.notdefoccurrence/.notdefof/.notdefe.g./.notdefanxiety/.notdefpeaked/.notdefafter/.notdefthe/.notdeftarget/.notdefquit/.notdefday;/.notdefhowever,/.notdefthis/.notdef could/.notdef be/.notdef expected/.notdef in/.notdef the/.notdef context/.notdef of/.notdef the/.notdef nicotine/.notdef withdrawal./.notdef The/.notdef SPC/.notdef contains/.notdef warnings/.notdef (4.4)/.notdef related/.notdefto/.notdef use/.notdef in/.notdef patients/.notdef with/.notdef uncontrolled/.notdef serious/.notdef psychiatric/.notdef illness/.notdef such/.notdef as/.notdef a/.notdef major/.notdef depression,/.notdef and/.notdef in/.notdef patients/.notdef with/.notdef ongoing/.notdef antidepressant/.notdef treatment./.notdef The/.notdef effects/.notdef on/.notdef the/.notdef central/.notdef nervous/.notdef system,/.notdef including/.notdef psychiatric/.notdef events,/.notdefare/.notdefalso/.notdefone/.notdefof/.notdefthe/.notdefmain/.notdefissues/.notdefin/.notdefthe/.notdefrisk/.notdefmanagement/.notdefplan./.notdef/.notdef 5./.notdef Pharmacovigilance/.notdef/.notdef Detailed/.notdefdescription/.notdefof/.notdefthe/.notdefPharmacovigilance/.notdefsystem/.notdef The/.notdef CHMP/.notdef considered/.notdef that/.notdef the/.notdef Pharmacovigilance/.notdef system/.notdef as/.notdef described/.notdef by/.notdef the/.notdef applicant/.notdef fulfils/.notdef the/.notdef legislative/.notdefrequirements./.notdef Risk/.notdefManagement/.notdefPlan/.notdef The/.notdefapplicant/.notdefsubmitted/.notdefa/.notdefrisk/.notdefmanagement/.notdefplan/.notdef(see/.notdefTable/.notdef17/.notdefbelow)./.notdef

/.notdef

| /.notdef/.notdef                                                              | Placebo/.notdef   | Rimonabant/.notdef                   | Rimonabant/.notdef                    |
|-------------------------------------------------------------------------------|-------------------|--------------------------------------|---------------------------------------|
| /.notdef                                                                      | (N=1602)/.notdef  | 5/.notdefmg/.notdef (N=2520)/.notdef | 20/.notdefmg/.notdef (N=2503)/.notdef |
| Any/.notdefevent /.notdef                                                     | 7.2% /.notdef     | 8.8% /.notdef                        | 13.8% /.notdef                        |
| Depressive/.notdefdisorders/.notdef                                           | 0.8%/.notdef      | 1.0%/.notdef                         | 1.9%/.notdef                          |
| Nausea/.notdef                                                                | 0.1%/.notdef      | 0.2%/.notdef                         | 1.4%/.notdef                          |
| Mood/.notdefalterations/.notdefwith/.notdefdepressive/.notdefsymptoms/.notdef | 0.6%/.notdef      | 0.9%/.notdef                         | 1.0%/.notdef                          |
| Anxiety/.notdef                                                               | 0.3%/.notdef      | 0.3%/.notdef                         | 1.0%/.notdef                          |
| Dizziness/.notdef                                                             | <0.1%/.notdef     | 0.2%/.notdef                         | 0.7%/.notdef                          |

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

| Safety/.notdefissue/.notdef                                                                                                                                   | Proposed/.notdefpharmacovigilance/.notdefactivities/.notdef /.notdef                                                                                                                                                                              | Proposed/.notdefrisk/.notdefminimization/.notdefactivities/.notdef                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing/.notdefor/.notdeflimited/.notdefinformation/.notdef                                                                                                   | Missing/.notdefor/.notdeflimited/.notdefinformation/.notdef                                                                                                                                                                                       | Missing/.notdefor/.notdeflimited/.notdefinformation/.notdef                                                                                                                                                                                                                                                                                                                                                                      |
| /.notdef Children/.notdefunder/.notdefthe/.notdefage/.notdef of/.notdef18/.notdef /.notdef                                                                    | Monitoring/.notdefof/.notdefrimonabant/.notdefprescriptions/.notdef                                                                                                                                                                               | authorised SPC/.notdef 4.2:/.notdef Not/.notdef recommended/.notdeffor/.notdef those/.notdef <18/.notdef years/.notdef of/.notdef age./.notdef Customer/.notdefcare/.notdefprogram/.notdef                                                                                                                                                                                                                                       |
| Pregnancy/.notdef                                                                                                                                             | /.notdef                                                                                                                                                                                                                                          | SPC/.notdef4.6:/.notdefUse/.notdefin/.notdefpregnancy/.notdefnot/.notdefrecommended./.notdefNon- clinical/.notdeffindings/.notdefdescribed/.notdefin/.notdef5.3./.notdef Customer/.notdefcare/.notdefprogram/.notdef                                                                                                                                                                                                             |
| Lactation/.notdef                                                                                                                                             | /.notdef                                                                                                                                                                                                                                          | SPC/.notdef 4.3/.notdef and/.notdef 4.6:/.notdef Contraindication/.notdef in/.notdef lactation./.notdef Non-clinical/.notdeffindings/.notdefdescribed/.notdefin/.notdef5.3./.notdef Customer/.notdefcare/.notdefprogram/.notdef                                                                                                                                                                                                  |
| Elderly/.notdefpatients/.notdef                                                                                                                               | THIN/.notdefand/.notdefARIC/.notdefdatabases,/.notdefdisease/.notdefregistry/.notdef Further/.notdef clinical/.notdef trials,/.notdef Monitoring/.notdef of/.notdef rimonabant/.notdefprescriptions/.notdef                                       | longer SPC/.notdef 4.2,/.notdef 4.4:/.notdef Use/.notdef with/.notdef caution/.notdef in/.notdef those/.notdef >75/.notdef years/.notdef of/.notdefage./.notdefMentioned/.notdefalso/.notdefin/.notdef5.1-5.2./.notdef Customer/.notdefcare/.notdefprogram/.notdef                                                                                                                                                               |
| Black,/.notdef Afro- Americans/.notdefand/.notdefAsiatic/.notdef patients/.notdef /.notdef                                                                    | ARIC/.notdefdatabases,/.notdef/.notdef Further/.notdefclinical/.notdeftrials/.notdef/.notdef                                                                                                                                                      | SPC/.notdef4.4:/.notdefWarning/.notdefof/.notdeflower/.notdefexposure/.notdefin/.notdefblacks./.notdef5.1- 5.2:/.notdef Description/.notdef of/.notdef PK/PD-effects/.notdef in/.notdef blacks/.notdef and/.notdef Japanese./.notdef                                                                                                                                                                                             |
| Patients/.notdef with/.notdef hepatic/.notdef impairment/.notdef                                                                                              | no /.notdef                                                                                                                                                                                                                                       | Customer/.notdefcare/.notdefprogram/.notdef SPC/.notdef 4.2,/.notdef 4.4:/.notdef Caution/.notdef of/.notdef use/.notdef in/.notdef patients/.notdef with/.notdef moderate/.notdef hepatic/.notdef impairment;/.notdefuse/.notdef in/.notdef severe/.notdef hepatic/.notdef impairment/.notdefnot/.notdefrecommended./.notdefPK-data/.notdefdescribed/.notdefin/.notdef 5.2./.notdef Customer/.notdefcare/.notdefprogram/.notdef |
| Patients/.notdef with/.notdef renal/.notdef impairment/.notdef                                                                                                | Further/.notdefclinical/.notdeftrial/.notdef/.notdef                                                                                                                                                                                              | SPC/.notdef 4.2,/.notdef 4.4:/.notdef Use/.notdef in/.notdef severe/.notdef renal/.notdef impairment/.notdef not/.notdef recommended./.notdefPK-data/.notdefdescribed/.notdefin/.notdef5.2./.notdef Customer/.notdefcare/.notdefprogram/.notdef                                                                                                                                                                                  |
| Use/.notdef of/.notdef concomitant/.notdef medications:/.notdef antidepressants/.notdef and/.notdef potent/.notdef CYP/.notdef 3A4/.notdef inhibitors/.notdef | product /.notdefMonitoring/.notdefof/.notdefrimonabant/.notdefprescriptions/.notdef                                                                                                                                                               | SPC/.notdef 4.4,/.notdef 4.5:/.notdef Warning/.notdef of/.notdef use/.notdef with/.notdef CYP/.notdef 3A4- inhibitors/.notdefand/.notdefwith/.notdefanti-depressants./.notdef Customer/.notdefcare/.notdefprogram/.notdef                                                                                                                                                                                                        |
| Potential/.notdefand/.notdefidentified/.notdefrisks /.notdef                                                                                                  | Potential/.notdefand/.notdefidentified/.notdefrisks /.notdef                                                                                                                                                                                      | Potential/.notdefand/.notdefidentified/.notdefrisks /.notdef                                                                                                                                                                                                                                                                                                                                                                     |
| Depressive/.notdefdisorders/.notdef                                                                                                                           | Specific/.notdefreporting/.notdefforms/.notdef THIN/.notdefand/.notdefARIC/.notdefdatabases,/.notdefdisease/.notdefregistry/.notdef Further/.notdefclinical/.notdeftrials/.notdef/.notdef Special/.notdefreporting/.notdefin/.notdefPSURs/.notdef | SPC:/.notdefDescribed/.notdefas/.notdefan/.notdefadverse/.notdefeffect/.notdefin/.notdef4.8./.notdef Customer/.notdefcare/.notdefprogram/.notdef                                                                                                                                                                                                                                                                                 |
| Convulsions/.notdef                                                                                                                                           | Specific/.notdefreporting/.notdefforms,/.notdefdisease/.notdefregistry/.notdef Further/.notdefclinical/.notdeftrials/.notdef/.notdef                                                                                                              | SPC/.notdef 4.4:/.notdef Warning/.notdef of/.notdef use/.notdef in/.notdef patients/.notdef treated/.notdef for/.notdef epilepsy./.notdefNon-clinical/.notdeffindings/.notdefdescribed/.notdefin/.notdef5.3./.notdef/.notdef Customer/.notdefcare/.notdefprogram/.notdef                                                                                                                                                         |
| Medicinal Anxiety/.notdef                                                                                                                                     | THIN/.notdefand/.notdefARIC/.notdefdatabases,/.notdefdisease/.notdefregistry/.notdef Further/.notdefclinical/.notdeftrials/.notdef Special/.notdefreporting/.notdefin/.notdefPSURs/.notdef                                                        | SPC:/.notdefDescribed/.notdefas/.notdefan/.notdefadverse/.notdefeffect/.notdefin/.notdef4.8./.notdef Customer/.notdefcare/.notdefprogram/.notdef                                                                                                                                                                                                                                                                                 |

<!-- image -->

/.notdef

<div style=\"page-break-after: always\"></div>

| Insomnia/.notdef                                                               | Further/.notdefclinical/.notdeftrials/.notdef                                                                                                                    | SPC:/.notdefDescribed/.notdefas/.notdefan/.notdefadverse/.notdefeffect/.notdefin/.notdef4.8./.notdef Customer/.notdefcare/.notdefprogram/.notdef   |
|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Dizziness/.notdef                                                              | Further/.notdefclinical/.notdeftrials/.notdef                                                                                                                    | SPC:/.notdefDescribed/.notdefas/.notdefan/.notdefadverse/.notdefeffect/.notdefin/.notdef4.8./.notdef Customer/.notdefcare/.notdefprogram/.notdef   |
| Neurological/.notdef sensory/.notdef disturbance/.notdefof/.notdefskin/.notdef | Further/.notdefclinical/.notdeftrials/.notdef                                                                                                                    | SPC:/.notdefDescribed/.notdefas/.notdefan/.notdefadverse/.notdefeffect/.notdefin/.notdef4.8./.notdef Customer/.notdefcare/.notdefprogram/.notdef   |
| Withdrawal/.notdefsyndrome/.notdef                                             | Further/.notdefclinical/.notdeftrials/.notdef/.notdef                                                                                                            | /.notdef                                                                                                                                           |
| Off-label/.notdefuse/.notdef                                                   | THIN/.notdefand/.notdefARIC/.notdefdatabases,/.notdefdisease/.notdefregistry/.notdef Monitoring/.notdefof/.notdefrimonabant/.notdefprescriptions/.notdef/.notdef | Customer/.notdefcare/.notdefprogram/.notdef                                                                                                        |

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised THIN/.notdef and/.notdef ARIC/.notdef databases,/.notdef disease/.notdef registry:/.notdef THIN/.notdef (The/.notdef Health/.notdef Improvement/.notdef Network/.notdef Database)/.notdef is/.notdef a/.notdef computerised/.notdef database/.notdef of/.notdef medical/.notdef records/.notdef from/.notdef general/.notdef practices/.notdef in/.notdef the/.notdef UK;/.notdef it/.notdef will/.notdef be/.notdef used/.notdef to/.notdef evaluate/.notdef incidence/.notdefrates/.notdefof/.notdefe.g./.notdefcardiovascular/.notdefdiseases/.notdefand/.notdefdepression,/.notdefand/.notdefto/.notdefaddress/.notdefany/.notdefnew/.notdefsafety/.notdefissues./.notdefThe/.notdef applicant/.notdef also/.notdef committed/.notdef to/.notdef perform/.notdef a/.notdef full/.notdef periodic/.notdef follow-up/.notdef study/.notdef of/.notdef the/.notdef outcomes/.notdef of/.notdef rimonabant/.notdef exposed/.notdef and/.notdef non-exposed/.notdef patients./.notdef ARIC/.notdef (Atherosclerosis/.notdef Risk/.notdef in/.notdef Communities/.notdef database)/.notdef is/.notdef a/.notdef prospective/.notdefcohort/.notdefstudy/.notdefof/.notdefatherosclerosis/.notdefand/.notdefcardiovascular/.notdefdisease/.notdefconducted/.notdefin/.notdef4/.notdefUS/.notdefcommunities;/.notdefit/.notdef will/.notdef be/.notdef used/.notdef to/.notdef evaluate/.notdef e.g./.notdef cardiovascular/.notdef diseases/.notdef and/.notdef depression./.notdef Disease/.notdef registry:/.notdef the/.notdef applicant/.notdef will/.notdef establish/.notdef a/.notdef disease/.notdef registry/.notdef in/.notdef the/.notdef US/.notdef population/.notdef to/.notdef assess/.notdef e.g./.notdef background/.notdef incidence/.notdef rates/.notdef of/.notdef adverse/.notdef events,/.notdef to/.notdef describe/.notdef concomitant/.notdef drug/.notdef use//.notdef co-morbidities,/.notdef and/.notdef to/.notdef compare/.notdef adverse/.notdef events/.notdef among/.notdef rimonabant/.notdefusers/.notdefand/.notdefnon-users./.notdef Customer/.notdefCare/.notdefprogram:/.notdefTo/.notdefencourage/.notdefthat/.notdefrimonabant/.notdefis/.notdefused/.notdefin/.notdefpatients/.notdefat/.notdefrisk/.notdeffor/.notdef health /.notdefreason/.notdefwhile/.notdef avoiding/.notdefuse/.notdeffor/.notdef cosmetic /.notdef reasons:/.notdefa/.notdefspecific/.notdeftraining/.notdeffor/.notdefcompany/.notdefrepresentatives/.notdefwill/.notdefbe/.notdefimplemented/.notdefin/.notdef order/.notdef to/.notdef provide/.notdef healthcare/.notdef professionals/.notdef with/.notdef the/.notdef appropriate/.notdef information/.notdef (e.g./.notdef by/.notdef offering/.notdef physicians/.notdef simple/.notdef ways/.notdef to/.notdef educate/.notdef patients/.notdef on/.notdef the/.notdef clinical/.notdef benefits/.notdef of/.notdef therapy/.notdef while/.notdef setting/.notdef treatment/.notdef expectations;/.notdef providing/.notdef physicians/.notdef and/.notdef other/.notdef healthcare/.notdef professionals/.notdef with/.notdef regular,/.notdef ongoing/.notdef educational/.notdef support/.notdef tools/.notdef that/.notdefcan/.notdefassist/.notdeftheir/.notdefpatients/.notdefin/.notdefreaching/.notdefthe/.notdefgoals/.notdefthey/.notdefhave/.notdefestablished/.notdeffor/.notdefthem;/.notdefintegrating/.notdefpractical/.notdefdiet/.notdef and/.notdef exercise/.notdef information/.notdef and/.notdef programmes/.notdef for/.notdef healthcare/.notdef professionals/.notdef and/.notdef their/.notdef patients/.notdef for/.notdef when/.notdef they/.notdef prescribe/.notdefrimonabant,/.notdefthat/.notdefis/.notdefconsistent/.notdefwith/.notdeflocal/.notdeftreatment/.notdefguidelines)./.notdefThis/.notdefcustomer/.notdefcare/.notdefprogram/.notdefwill/.notdef include/.notdef education/.notdef for/.notdef example/.notdef on/.notdef the/.notdef use/.notdef of/.notdef rimonabant/.notdef in/.notdef pregnancy,/.notdef lactation,/.notdef elderly,/.notdef blacks,/.notdef AfroAmericans,/.notdef Asiatic,/.notdef patients/.notdef with/.notdef hepatic/.notdef or/.notdef renal/.notdef impairment,/.notdef and/.notdef with/.notdef concomitant/.notdef antidepressants/.notdef or/.notdef potent/.notdefCYP3A4/.notdefinhibitors;/.notdefeducation/.notdefwill/.notdefbe/.notdefprovided/.notdefalso/.notdefon/.notdefdepressive/.notdefdisorders,/.notdefconvulsions,/.notdefanxiety,/.notdef insomnia,/.notdefdizziness/.notdefand/.notdefneurological/.notdefsensory/.notdefdisturbances/.notdefof/.notdefthe/.notdefskin. /.notdef Monitoring/.notdef rimonabant/.notdef prescriptions:/.notdef Specific/.notdef surveys/.notdef will/.notdef be/.notdef put/.notdef in/.notdef place/.notdef in/.notdef order/.notdef to/.notdef monitor/.notdef the/.notdef prescriptions/.notdefof/.notdefrimonabant/.notdefespecially/.notdefto/.notdefdetect/.notdefany/.notdefmisuse/.notdef//.notdefoff-label/.notdefuse/.notdefof/.notdefthe/.notdefdrug,/.notdefby/.notdefanalyzing/.notdefdata/.notdef such/.notdef as/.notdef drug/.notdef prescriptions,/.notdef diagnosis/.notdef information,/.notdef demographic/.notdef parameters/.notdef (weight,/.notdef height,/.notdef waist/.notdef circumference,/.notdefmedical/.notdefhistory)./.notdef Further/.notdef clinical/.notdef trials:/.notdef These/.notdef will/.notdef be/.notdef carried/.notdef out/.notdef as/.notdef part/.notdef of/.notdef the/.notdef large/.notdef life-cycle/.notdef management/.notdef clinical/.notdef trial/.notdef programme/.notdef of/.notdef rimonabant./.notdef Special/.notdef focus/.notdef will/.notdef be/.notdef given/.notdef on/.notdef neurological/.notdef and/.notdef psychiatric/.notdef adverse/.notdef events/.notdef through/.notdef scripted/.notdef neuropsychiatric/.notdefquestions/.notdefobtained/.notdefat/.notdef every/.notdef visit/.notdefor/.notdefintermediate/.notdefphone/.notdefcalls./.notdefSeparate/.notdef studies/.notdef will/.notdef be/.notdef carried/.notdef out/.notdef in/.notdef patients/.notdef with/.notdef severe/.notdef renal/.notdef impairment/.notdef and/.notdef some/.notdef other/.notdef ethnic/.notdef groups/.notdef than/.notdef blacks./.notdef Special/.notdef reporting/.notdef in/.notdef PSURs:/.notdef Post-marketing/.notdef cases/.notdef of/.notdef depression/.notdef and/.notdef anxiety/.notdef in/.notdef patients/.notdef concomitantly/.notdef using/.notdefantidepressants/.notdefwill/.notdefbe/.notdefpresented/.notdefseparately/.notdefin/.notdefPSURs./.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

Medicinal product no longer authorised The/.notdefCHMP,/.notdefhaving/.notdefconsidered/.notdefthe/.notdefdata/.notdefsubmitted/.notdefin/.notdefthe/.notdefapplication/.notdefis/.notdefof/.notdefthe/.notdefopinion/.notdefthat/.notdefsome/.notdefadditional/.notdef pharmacovigilance/.notdef activities/.notdef are/.notdef needed/.notdef apart/.notdef from/.notdef routine/.notdef pharmacovigilance/.notdef activities/.notdef (see/.notdef table/.notdef 17/.notdef above)./.notdef/.notdef 6./.notdef Overall/.notdefconclusions,/.notdefrisk/benefit/.notdefassessment/.notdefand/.notdefrecommendation/.notdef Quality/.notdef Quality/.notdef aspects/.notdef are/.notdef satisfactory./.notdef There/.notdef are/.notdef no/.notdef unresolved/.notdef quality/.notdef issues/.notdef which/.notdef could/.notdef have/.notdef a/.notdef negative/.notdef impact/.notdefon/.notdefthe/.notdefbenefit/risk/.notdefbalance/.notdefof/.notdefthe/.notdefproduct./.notdef Non-clinical/.notdefpharmacology/.notdefand/.notdeftoxicology/.notdef Rimonabant/.notdef is/.notdef a/.notdef selective/.notdef CB1/.notdef antagonist./.notdef It/.notdef showed/.notdef activity/.notdef in/.notdef several/.notdef animal/.notdef models/.notdef for/.notdef obesity/.notdef and/.notdef nicotine/.notdef addiction./.notdef The/.notdef safety/.notdef pharmacology/.notdef studies/.notdef identified/.notdef CNS/.notdef (sedation,/.notdef decreased/.notdef muscle/.notdef tone,/.notdef a/.notdef proconvulsant/.notdef potential/.notdef when/.notdef combined/.notdef with/.notdef physical/.notdef or/.notdef chemical/.notdef seizure/.notdef inducers,/.notdef or/.notdef with/.notdef stressful/.notdef conditions)/.notdefas/.notdefa/.notdefpossible/.notdeftarget/.notdeffor/.notdefrimonabant./.notdef/.notdef The/.notdefresults/.notdefof/.notdefthe/.notdefpharmacokinetic/.notdefstudies/.notdefrevealed/.notdefa/.notdefconsistent/.notdefpicture/.notdefacross/.notdefthe/.notdefspecies/.notdefwith/.notdefrapid/.notdeforal/.notdef absorption,/.notdef a/.notdef low/.notdef to/.notdef moderate/.notdef bioavailability,/.notdef wide/.notdef distribution,/.notdef high/.notdef protein/.notdef binding,/.notdef extensive/.notdef metabolism,/.notdef long/.notdef terminal/.notdef half-life/.notdef with/.notdef bile//.notdef faeces/.notdef as/.notdef the/.notdef major/.notdef excretory/.notdef pathway./.notdef One/.notdef of/.notdef the/.notdef major/.notdef metabolic/.notdef pathways/.notdef was/.notdef hydrolysis/.notdef of/.notdef the/.notdef amide/.notdef bond/.notdef that/.notdef binds/.notdef the/.notdef piperidine/.notdef ring/.notdef to/.notdef the/.notdef rest/.notdef of/.notdef the/.notdef rimonabant/.notdefmolecule,/.notdefproducing/.notdefa/.notdefmetabolite/.notdefSR141715,/.notdefwhich/.notdefcould,/.notdeftheoretically,/.notdefrelease/.notdefthe/.notdefpiperidyl/.notdef radical/.notdef as/.notdef N-aminopiperidine/.notdef (NAP);/.notdef this/.notdef compound/.notdef is/.notdef mutagenic/.notdef in/.notdef bacteria/.notdef and/.notdef may/.notdef have/.notdef other/.notdef genotoxic/.notdef properties./.notdef Precise/.notdef estimate/.notdef of/.notdef the/.notdef risk/.notdef for/.notdef humans/.notdef could/.notdef not/.notdef be/.notdef made/.notdef but/.notdef the/.notdef risk/.notdef was/.notdef most/.notdef likely/.notdefvery/.notdeflow;/.notdefthe/.notdefapplicant/.notdefcommitted/.notdefto/.notdefprovide/.notdefadditional/.notdefdata/.notdefon/.notdefthe/.notdefissue/.notdefas/.notdefa/.notdefpost-approval/.notdeffollowup/.notdef measure./.notdef No/.notdef signs/.notdef of/.notdef genotoxicity/.notdef were/.notdef observed/.notdef in/.notdef a/.notdef standard/.notdef in/.notdef vitro /.notdef package/.notdef or/.notdef in/.notdef a/.notdef mouse/.notdef micronucleus/.notdeftest./.notdef The/.notdef results/.notdef of/.notdef the/.notdef toxicology/.notdef studies/.notdef were/.notdef consistent/.notdef across/.notdef species,/.notdef with/.notdef reduced/.notdef weight/.notdef gain,/.notdef weight/.notdef loss,/.notdef and/or/.notdef decreased/.notdef food/.notdef consumption./.notdef CNS-effects/.notdef including/.notdef clonic/.notdef convulsions/.notdef were/.notdef seen/.notdef at/.notdef higher/.notdef doses;/.notdef these/.notdef symptoms/.notdef prompted/.notdef a/.notdef reduction/.notdef of/.notdef the/.notdef dose/.notdef levels/.notdef in/.notdef the/.notdef later/.notdef studies./.notdef There/.notdef were/.notdef signs/.notdef of/.notdef involvement/.notdef of/.notdef the/.notdef liver,/.notdef kidneys/.notdef and/.notdef bone/.notdef marrow,/.notdef but/.notdef none/.notdef of/.notdef these/.notdef provided/.notdef clear-cut/.notdef evidence/.notdef of/.notdef a/.notdef direct/.notdeftoxicity/.notdefof/.notdefrimonabant./.notdefThe/.notdeftumour/.notdeffindings/.notdefin/.notdefthe/.notdefliver/.notdefand/.notdeffemale/.notdefgenital/.notdeftract/.notdeffound/.notdefin/.notdefthe/.notdeflongterm/.notdef rat/.notdef study/.notdef were/.notdef considered/.notdef to/.notdef be/.notdef species/.notdef specific/.notdef and/.notdef due/.notdef to/.notdef enzyme/.notdef induction/.notdef and/.notdef a/.notdef chronic/.notdef hormonal/.notdef imbalance/.notdef with/.notdef oestrogen/.notdef stimulation,/.notdef respectively./.notdef The/.notdef finding/.notdef of/.notdef neuropil/.notdef vacuolation/.notdef and/.notdef increased/.notdef GFAP/.notdef staining/.notdef in/.notdef rimonabant/.notdef treated/.notdef mice,/.notdef which/.notdef could/.notdef be/.notdef a/.notdef signal/.notdef of/.notdef underlying/.notdef neuropathology,/.notdefwas/.notdefdiminished/.notdefby/.notdefthe/.notdeflack/.notdefof/.notdefother/.notdefsigns/.notdefof/.notdefneuropathology./.notdef The/.notdeftoxic/.notdefprofile/.notdefof/.notdefrimonabant/.notdefwas/.notdefnot/.notdeffully/.notdefcharacterised/.notdefas/.notdefthe/.notdefhighest/.notdefexposures/.notdefto/.notdefrimonabant/.notdefin/.notdefthe/.notdef non-clinical/.notdef safety/.notdef studies/.notdef were/.notdef similar/.notdef to/.notdef the/.notdef expected/.notdef exposure/.notdef in/.notdef humans/.notdef after/.notdef the/.notdef therapeutic/.notdef dose./.notdef Thus,/.notdefthe/.notdefnon-clinical/.notdefstudies/.notdefcould/.notdefprovide/.notdefno/.notdefreassurance/.notdefregarding/.notdefmargins/.notdefto/.notdefthe/.notdefclinical/.notdefexposure/.notdefat/.notdef present./.notdefConsequently,/.notdefthe/.notdefsafe/.notdefuse/.notdefof/.notdefrimonabant/.notdefhas/.notdefto/.notdefrely/.notdefmore/.notdefon/.notdefthe/.notdefclinical/.notdefsafety/.notdefdata/.notdefand/.notdefon/.notdefthe/.notdef post-approval/.notdefpharmacovigilance/.notdefprogramme./.notdef/.notdef The/.notdefmost/.notdefremarkable/.notdefeffects/.notdefin/.notdefthe/.notdefreproductive/.notdeftoxicity/.notdefpackage/.notdefwere/.notdefdecreased/.notdefviability/.notdefindex/.notdefand/.notdefpup/.notdef growth/.notdef pre-weaning./.notdef There/.notdef were/.notdef malformations/.notdef in/.notdef the/.notdef rabbit/.notdef embryo-foetal/.notdef development/.notdef studies/.notdef (omphalocele/.notdefand/.notdefvarious/.notdefCNS-malformations)/.notdefthat/.notdefcould/.notdefbe/.notdefdue/.notdefto/.notdefrimonabant./.notdefThese/.notdeffindings/.notdefresulted/.notdef in/.notdefa/.notdefwarning/.notdefagainst/.notdefthe/.notdefuse/.notdefof/.notdefrimonabant/.notdefduring/.notdefpregnancy,/.notdefand/.notdefin/.notdefa/.notdefcontraindication/.notdefduring/.notdeflactation./.notdef/.notdef Finally,/.notdef the/.notdef environmental/.notdef impact/.notdef of/.notdef rimonabant/.notdef needed/.notdef further/.notdef evaluation/.notdef and/.notdef additional/.notdef studies;/.notdef the/.notdef applicant/.notdefcommitted/.notdefto/.notdefcarry/.notdefout/.notdefsuch/.notdefstudies/.notdefas/.notdefa/.notdeffollow-up/.notdefmeasure./.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

<!-- image -->

Medicinal product no longer authorised Efficacy/.notdef Obesity/.notdef More/.notdefthan/.notdef6800/.notdefpatients/.notdefwere/.notdefincluded/.notdefin/.notdefthe/.notdefPhase/.notdefII/.notdefand/.notdefPhase/.notdefIII/.notdefclinical/.notdefstudies./.notdefThe/.notdefpatients/.notdefincluded/.notdef in/.notdef the/.notdef Phase/.notdef III/.notdef trials/.notdef followed/.notdef a/.notdef mildly/.notdef reduced/.notdef diet/.notdef during/.notdef the/.notdef trial/.notdef prescribed/.notdef by/.notdef a/.notdef dietician/.notdef and/.notdef they/.notdef were/.notdefadvised/.notdefto/.notdefincrease/.notdeftheir/.notdefphysical/.notdefactivity./.notdefSignificant/.notdefmean/.notdefweight/.notdefreductions/.notdeffrom/.notdefbaseline/.notdefto/.notdefone/.notdef year/.notdef for/.notdef rimonabant/.notdef 20/.notdef mg/.notdef versus/.notdef placebo/.notdef were/.notdef demonstrated/.notdef in/.notdef the/.notdef three/.notdef studies/.notdef conducted/.notdef in/.notdef nondiabetic/.notdefpatients,/.notdefand/.notdefin/.notdefone/.notdefstudy/.notdefwith/.notdeftype/.notdef2/.notdefdiabetics./.notdefRimonabant/.notdefwas/.notdefeffective/.notdefin/.notdefmaintaining/.notdefweight/.notdef loss/.notdeffor/.notdefup/.notdefto/.notdeftwo/.notdefyears./.notdefMost/.notdefof/.notdefthe/.notdefobserved/.notdefweight/.notdefreduction/.notdefwas/.notdefobtained/.notdefwithin/.notdefthe/.notdeffirst/.notdefnine/.notdefmonths/.notdef of/.notdef treatment./.notdef Rimonabant/.notdef reduced/.notdef the/.notdef risk/.notdef of/.notdef weight/.notdef regain./.notdef Treatment/.notdef with/.notdef rimonabant/.notdef was/.notdef associated/.notdef with/.notdef reductions/.notdef in/.notdef waist/.notdef circumference,/.notdef and/.notdef with/.notdef an/.notdef increase/.notdef in/.notdef HDL-C/.notdef and/.notdef decrease/.notdef in/.notdef triglycerides;/.notdef generally/.notdef no/.notdef significant/.notdef effect/.notdef on/.notdef Total-C/.notdef or/.notdef LDL-C/.notdef levels/.notdef were/.notdef seen./.notdef In/.notdef the/.notdef trial/.notdef in/.notdef type/.notdef 2/.notdef diabetic/.notdef patients/.notdefwho/.notdefwere/.notdefoverweight/.notdefor/.notdefobese/.notdeftreated/.notdefwith/.notdefmetformin/.notdefor/.notdefsulfonylurea/.notdefan/.notdefimprovement/.notdefin/.notdefHbA1c/.notdef was/.notdefobserved./.notdef/.notdef Smoking/.notdefcessation/.notdef One/.notdefof/.notdefthe/.notdefthree/.notdefshort-term/.notdefPhase/.notdefIII/.notdefstudies/.notdefwas/.notdefpositive/.notdefon/.notdefall/.notdefconditions,/.notdefi.e./.notdefprolonged/.notdefabstinence/.notdefafter/.notdef 10/.notdefweeks/.notdeftreatment,/.notdefand/.notdefsustained/.notdefabstinence/.notdefat/.notdef1/.notdefyear/.notdefoff/.notdefdrug./.notdefThe/.notdefother/.notdeftwo/.notdefstudies/.notdefwere/.notdefnegative./.notdefThe/.notdef pooled/.notdefanalysis/.notdefof/.notdef these/.notdef short-term/.notdef studies,/.notdef as/.notdef well/.notdefas/.notdefdata/.notdeffrom/.notdefthe/.notdefPhase/.notdefII/.notdefstudy/.notdefwith/.notdef40/.notdefmg/.notdefdose/.notdefand/.notdef the/.notdef randomized/.notdef withdrawal/.notdef study/.notdef on/.notdef maintenance/.notdef treatment/.notdef provided/.notdef evidence/.notdef that/.notdef rimonabant/.notdef had/.notdef positive/.notdefeffect/.notdefin/.notdefsmoking/.notdefcessation./.notdefOverall,/.notdefbased/.notdefon/.notdefthe/.notdeftotality/.notdefof/.notdefdata/.notdefit/.notdefwas/.notdefconcluded/.notdefthat/.notdefan/.notdefeffect/.notdef on/.notdef smoking/.notdef cessation/.notdef had/.notdef been/.notdef demonstrated;/.notdef however,/.notdef the/.notdef magnitude/.notdef of/.notdef this/.notdef effect/.notdef was/.notdef difficult/.notdef to/.notdef estimate,/.notdefand/.notdefpossibly/.notdefmarginal./.notdef /.notdef Safety/.notdef The/.notdefmain/.notdefsafety/.notdefissue/.notdefwas/.notdefthe/.notdefpsychiatric/.notdefAEs,/.notdefwhich/.notdefwere/.notdefconsidered/.notdefto/.notdefhave/.notdefimportant/.notdefimplications/.notdeffor/.notdef the/.notdef use/.notdef of/.notdef rimonabant,/.notdefespecially/.notdefsince/.notdefpatients/.notdefwith/.notdefcurrent/.notdefdepressions/.notdefwere/.notdefexcluded/.notdeffrom/.notdefthe/.notdefclinical/.notdef studies./.notdefThere/.notdefwas/.notdef a/.notdefdose-response/.notdefrelation/.notdefbetween/.notdefdifferent/.notdefdepressive/.notdefAEs/.notdefand/.notdefrimonabant/.notdeftreatment./.notdef Most/.notdef of/.notdef the/.notdef patients/.notdef with/.notdef various/.notdef kinds/.notdef of/.notdef depressive/.notdef symptoms/.notdef did/.notdef eventually/.notdef recover/.notdef with/.notdef or/.notdef without/.notdef anti-depressants/.notdefdrugs./.notdefAll/.notdefthis/.notdefis/.notdefaddressed/.notdefin/.notdefthe/.notdefSPC/.notdefand/.notdefrisk/.notdefmanagement/.notdefplan./.notdef The/.notdef most/.notdef common/.notdef side/.notdef effects/.notdef were/.notdef anxiety,/.notdef insomnia,/.notdef mood/.notdef alterations/.notdef with/.notdef depressive/.notdef symptoms,/.notdef depressive/.notdefdisorders,/.notdefdizziness/.notdefnausea,/.notdefdiarrhea,/.notdefvomiting,/.notdefasthenia//.notdeffatigue./.notdef Having/.notdef considered/.notdef the/.notdef safety/.notdef concerns/.notdef in/.notdef the/.notdef risk/.notdef management/.notdef plan,/.notdef the/.notdef CHMP/.notdef considered/.notdef that/.notdef the/.notdef proposed/.notdefactivities/.notdefdescribed/.notdefin/.notdefsection/.notdef3.5/.notdefadequately/.notdefaddressed/.notdefthese./.notdef · User/.notdefconsultation/.notdef The/.notdef applicant/.notdef provided/.notdef results/.notdef of/.notdef assessments/.notdef carried/.notdef out/.notdef in/.notdef cooperation/.notdef with/.notdef target/.notdef patient/.notdef groups/.notdef on/.notdef the/.notdef package/.notdefleaflet/.notdef('user/.notdefconsultation'),/.notdefand/.notdefthe/.notdefpackage/.notdefleaflet/.notdefwas/.notdefmodified/.notdefaccordingly./.notdef Risk-benefit/.notdefassessment/.notdef /.notdef Management/.notdefof/.notdefmultiple/.notdefcardiovascular/.notdefrisk/.notdeffactors/.notdefin/.notdefpatients/.notdefwith/.notdefmetabolic/.notdefsyndrome:/.notdef The/.notdef CHMP/.notdef does/.notdef not/.notdef currently/.notdef accept/.notdef the/.notdef metabolic/.notdef syndrome/.notdef as/.notdef an/.notdef instrument/.notdef to/.notdef identify/.notdef a/.notdef target/.notdef population/.notdef for/.notdef pharmacological/.notdef therapy./.notdef Even/.notdef if/.notdef diabetes,/.notdef hyperlipidaemia/.notdef and/.notdef hypertension/.notdef are/.notdef recognised/.notdef as/.notdef factors/.notdef that,/.notdef especially/.notdef in/.notdef patients/.notdef with/.notdef abdominal/.notdef obesity,/.notdef increase/.notdef the/.notdef risk/.notdef for/.notdef cardiovascular/.notdef diseases,/.notdef no/.notdef generally/.notdef accepted/.notdef definition/.notdef of/.notdef the/.notdef metabolic/.notdef syndrome/.notdef exists./.notdef A/.notdef claim/.notdef for/.notdef pharmacological/.notdefintervention/.notdefbased/.notdefon/.notdefa/.notdefdemonstrated/.notdefreduction/.notdefof/.notdefthe/.notdefincidence/.notdefof/.notdefindividual/.notdefrisk/.notdeffactor/.notdef components/.notdef commonly/.notdef included/.notdef in/.notdef different/.notdef definitions/.notdef of/.notdef the/.notdef metabolic/.notdef syndrome/.notdef cannot/.notdef be/.notdef accepted/.notdef with/.notdefcurrent/.notdefknowledge./.notdefThere/.notdefare/.notdefseveral/.notdefeffective/.notdefoptions/.notdeffor/.notdefthe/.notdeftreatment/.notdefof/.notdefdiabetes,/.notdefhyperlipidaemia/.notdef and/.notdef hypertension/.notdef available/.notdef today;/.notdef therefore/.notdef the/.notdef existence/.notdef of/.notdef an/.notdef unmet/.notdef medical/.notdef need/.notdef is/.notdef questioned./.notdef On/.notdef

/.notdef

<!-- image -->

<div style=\"page-break-after: always\"></div>

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

/.notdef

<!-- image -->

Medicinal product no longer authorised these/.notdef grounds/.notdef the/.notdef benefit-risk/.notdef assessment/.notdef regarding/.notdef an/.notdef indication/.notdef of/.notdef 'Management/.notdef of/.notdef multiple/.notdef cardiovascular/.notdefrisk/.notdeffactors/.notdefin/.notdefpatients/.notdefwith/.notdefmetabolic/.notdefsyndrome'/.notdefis/.notdefnegative./.notdef Weight/.notdefreduction/.notdefin/.notdefobesity//.notdefoverweight:/.notdef The/.notdef demonstrated/.notdefbody/.notdefweight/.notdefreduction/.notdefin/.notdefoverweight/.notdefpatients/.notdefwith/.notdefadditional/.notdefrisk/.notdeffactors/.notdefand/.notdefin/.notdefobese/.notdef patients/.notdef has/.notdef been/.notdef sufficiently/.notdef demonstrated/.notdef and/.notdef the/.notdef magnitude/.notdef of/.notdef these/.notdef effects/.notdef is/.notdef clinically/.notdef relevant/.notdef and/.notdef appears/.notdef to/.notdef be/.notdef maintained/.notdef over/.notdef time./.notdef The/.notdef benefit-risk/.notdef assessment/.notdef for/.notdef this/.notdef indication/.notdef in/.notdef overweight/obese/.notdef patients/.notdef is/.notdef positive,/.notdef also/.notdef in/.notdef light/.notdef of/.notdef the/.notdef psychiatric/.notdef AEs/.notdef that/.notdef may/.notdef develop/.notdef over/.notdef time/.notdef and/.notdef the/.notdef pre-clinical/.notdef uncertainties/.notdefthat/.notdefstill/.notdefexist./.notdef/.notdef Type/.notdef2/.notdefdiabetes:/.notdef Extensive/.notdef analyses/.notdef performed/.notdef by/.notdef the/.notdef applicant/.notdef demonstrated/.notdef that/.notdef rimonabant/.notdef had/.notdef an/.notdef effect/.notdef on/.notdef HbA1c/.notdef independent/.notdefof/.notdefweight/.notdefloss./.notdefThe/.notdefsize/.notdefof/.notdefthis/.notdefeffect/.notdefremained/.notdefuncertain,/.notdefalthough/.notdefit/.notdefwas/.notdeflarge/.notdefenough/.notdefto/.notdefbe/.notdef clinically/.notdef relevant./.notdef The/.notdef beneficial/.notdef effects/.notdef of/.notdef a/.notdef combined/.notdef weight/.notdef reduction/.notdef and/.notdef improved/.notdef glucose/.notdef regulation/.notdef could/.notdef be/.notdef expected/.notdef to/.notdef be/.notdef greater/.notdef in/.notdef patients/.notdef with/.notdef type/.notdef 2/.notdef diabetes/.notdef than/.notdef in/.notdef a/.notdef general/.notdef overweight/.notdef population./.notdefThe/.notdeftreatment/.notdefalternatives/.notdefin/.notdefoverweight/.notdeftype/.notdef2/.notdefdiabetes/.notdefpatients/.notdeffailing/.notdefon/.notdeforal/.notdefanti-diabetics/.notdef are/.notdef limited/.notdef and/.notdef the/.notdef weight/.notdef gain/.notdef that/.notdef almost/.notdef inevitably/.notdef occurs/.notdef when/.notdef these/.notdef patients/.notdef are/.notdef given/.notdef insulin/.notdef is/.notdef a/.notdef common/.notdef and/.notdef important/.notdef clinical/.notdef problem./.notdef However,/.notdef it/.notdef is/.notdef recognised/.notdef that/.notdef a/.notdef prospective/.notdef confirmatory/.notdef trial/.notdef with/.notdef rimonabant/.notdef focusing/.notdef on/.notdef patients/.notdef failing/.notdef on/.notdef oral/.notdef anti-diabetics/.notdef is/.notdef lacking./.notdef Also,/.notdef no/.notdef study/.notdef on/.notdef rimonabant/.notdef monotherapy/.notdef in/.notdef type/.notdef 2/.notdef diabetes/.notdef was/.notdef performed./.notdef Therefore,/.notdef the/.notdef benefit-risk/.notdef assessment/.notdef was/.notdef currently/.notdefnegative/.notdeffor/.notdefdiabetes/.notdeftype/.notdef2-indication./.notdefHowever,/.notdefthese/.notdefeffects/.notdefare/.notdefdescribed/.notdefin/.notdef5.1/.notdefof/.notdefthe/.notdefSPC./.notdef Dyslipidaemia:/.notdef The/.notdef effects/.notdef of/.notdef rimonabant/.notdef on/.notdef HDL-C,/.notdef its/.notdef subfractions/.notdef and/.notdef on/.notdef triglycerides/.notdef are/.notdef interesting/.notdef and/.notdef they/.notdef may/.notdef indicate/.notdefthat/.notdefrimonabant/.notdefcould/.notdefreduce/.notdefthe/.notdefrisk/.notdeffor/.notdefcardiovascular/.notdefcomplications,/.notdefwhich,/.notdefhowever,/.notdefhas/.notdefnot/.notdef been/.notdef shown/.notdef (no/.notdef outcome/.notdef data/.notdef available)./.notdef Furthermore,/.notdefno/.notdefcomparative/.notdefdata/.notdefwith/.notdefan/.notdefactive/.notdefproduct/.notdefwere/.notdef available./.notdefTherefore,/.notdefthe/.notdefbenefit-risk/.notdefassessment/.notdeffor/.notdefthe/.notdeftreatment/.notdefof/.notdefdyslipidaemia/.notdefis/.notdefnegative./.notdefHowever,/.notdef these/.notdefeffects/.notdefare/.notdefdescribed/.notdefin/.notdef5.1/.notdefof/.notdefthe/.notdefSPC./.notdef Smoking/.notdefcessation:/.notdef An/.notdef effect/.notdef on/.notdef smoking/.notdef cessation/.notdef of/.notdef rimonabant/.notdef has/.notdef been/.notdef demonstrated,/.notdef but/.notdef based/.notdef on/.notdef current/.notdef data/.notdef the/.notdef magnitude/.notdefof/.notdefthis/.notdef effect/.notdefis/.notdefdifficult/.notdefto/.notdefassess./.notdefIn/.notdefaddition,/.notdefuncertainties/.notdefin/.notdefrelation/.notdefto/.notdefposology/.notdefremained;/.notdef in/.notdef light/.notdef of/.notdef the/.notdef psychiatric/.notdef AEs/.notdef that/.notdef may/.notdef develop/.notdef with/.notdef time/.notdef and/.notdef the/.notdef pre-clinical/.notdef uncertainties,/.notdef it/.notdef is/.notdef important/.notdefto/.notdefestablish/.notdefthe/.notdefoptimal/.notdefduration/.notdefof/.notdeftreatment/.notdefand/.notdefoptimal/.notdefdose./.notdefIn/.notdefconclusion,/.notdefthe/.notdefuncertainties/.notdef regarding/.notdef the/.notdef magnitude/.notdef of/.notdef the/.notdef effect/.notdef and/.notdef posology/.notdef result/.notdef in/.notdef a/.notdef negative/.notdef benefit/risk/.notdef assessment/.notdef for/.notdef this/.notdef indication./.notdef Additional/.notdef efficacy/.notdef data,/.notdef in/.notdef particular/.notdef during/.notdef short-term/.notdef treatment,/.notdef would/.notdef be/.notdef needed/.notdef to/.notdef establish/.notdef a/.notdef positive/.notdef benefit-risk/.notdef ratio./.notdef The/.notdef Applicant/.notdef withdrew/.notdef the/.notdef claim/.notdef for/.notdef a/.notdef smoking/.notdef cessation/.notdef indication/.notdefbefore/.notdefthe/.notdeforal/.notdefexplanation./.notdef Risk/.notdefmanagement/.notdefplan:/.notdef A/.notdef risk/.notdef management/.notdef plan/.notdef was/.notdef submitted./.notdef The/.notdef CHMP,/.notdef having/.notdef considered/.notdef the/.notdef data/.notdef submitted,/.notdef was/.notdef of/.notdef the/.notdef opinion/.notdefthat/.notdefsome/.notdeffurther/.notdefpharmacovigilance/.notdefactivities/.notdefin/.notdefaddition/.notdefto/.notdefthe/.notdefuse/.notdefof/.notdefroutine/.notdefpharmacovigilance/.notdef were/.notdefneeded/.notdefto/.notdefinvestigate/.notdeffurther/.notdefsome/.notdefof/.notdefthe/.notdefsafety/.notdefconcerns/.notdef(see/.notdef3.5)./.notdef /.notdef Recommendation/.notdef Based/.notdef on/.notdef the/.notdef CHMP/.notdef review/.notdef of/.notdef data/.notdef on/.notdef quality,/.notdef safety/.notdef and/.notdef efficacy,/.notdef the/.notdef CHMP/.notdef considered/.notdef by/.notdef consensus/.notdef that/.notdef the/.notdef risk-benefit/.notdef balance/.notdef of/.notdef ZIMULTI/.notdef 'as/.notdef an/.notdef adjunct/.notdef to/.notdef diet/.notdef and/.notdef exercise/.notdef for/.notdef the/.notdef treatment/.notdef of/.notdef obese/.notdef patients/.notdef(BMI/.notdef ≥ /.notdef30/.notdef kg/m 2 ),/.notdef or/.notdef overweight/.notdef patients/.notdef (BMI/.notdef &gt;/.notdef27/.notdef kg/m 2 )/.notdef with/.notdef associated/.notdefrisk/.notdeffactor(s),/.notdefsuch/.notdef

/.notdef

<div style=\"page-break-after: always\"></div>

<!-- image -->

/.notdef